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Hypothesis: 
This thesis set out to test the hypothesis, first propsed by Baker et al (1995), that Vascular 
Endothelial Growth Factor (VEGF) may be involved in the alteration i  endothelial function that is 
observed in the disease of pre-eclampsia. 
Aims: 
9 To investigate concentrations of VEGF in plasma from non-pregnant, and normal pregnant 
women and women with pre-eclampsia. 
" 
To investigate uterine and placental expression of VEGF in non-pregnant and normal 
pregnant women and women with pre-eclampsia. 
0 To investigate some of the vascular adaptations that occur in pregnancy and pre-eclampsia 
Within the uterine and systemic irculations. 
" 
To investigate he effect of plasma from women with PE and VEGF on 
i) An in vitro endothelial cell culture model. 
ii) An in vitro isolated vessel model. 
9 To characterise the mechanism whereby VEGF causes any alteration i  vascular function. 
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Chapter One: Introduction: 
1.1: General Introduction: 
1.1.1: Pre-eclampsia: 
1.1.1.1: Incidence: 
Pre-eclampsia complicates approximately 7-10 % of pregnancies in the United Kingdom (HMSO, 
1952-1984) and places the mother and fetus at risk, increasing both mortality and morbidity rates. 
However, despite vast amounts of research its cause remains an enigma of modem medicine. 
Therefore an increased understanding of the pathophysiology may well enhance our treatment 
modalities. 
1.1.1.2: Definition and Classification: 
The unknown aetiology of pre-eclampsia h s made its' definition difficult and led to the clinical 
signs being used not merely for diagnosing but also for defining the condition. Hypertension is the 
classical clinical sign associated with pre-eclampsia. However, pre-eclampsia is more than just 
hypertension i  pregnancy, it is a syndrome with a combination of abnormal signs. The second 
clinical sign that has been accepted by most authors as defining pre-eclampsia is proteinuria 
(Davey and MacGillivary, 1988). 
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Despite these controversies there is a need for provisional definitions to allow different 
investigators to compare their experiences. Davey and MacGillivray devised one of the most 
commonly used systems of classification a d it is their definition that is used in this thesis. 
It is that clinical syndrome in which a previously normotensive woman, with no pre- 
existing cardiovascular or renal disease, after the twentieth week of pregnancy, develops a blood 
pressure of at least 140/90 mmHg on two or more occasions (separated by greater than four 
hours) in the presence of proteinuria of at least 500mg (or 300mg/I) in a 24 hour collection of 
urine, in the absence of urinary tract infection. Blood pressure and proteinuria must have returned 
to normal levels by the sixth postpartum week" (Davey and MacGillivary, 1988). 
1.1.2: The pathogenesis ofDre"eciamnsia: 
Numerous hypotheses concerning the pathogenesis of pre-eclampsia have been proposed. 
These include, an alteration in the circulating prostaglandins, analtered response to angiotensin 
and an overstimulation f the sympathetic nervous ystem. These hypothesies have been fully 
reviewed previously (de Jong et al., 1991) (Broughton Pipkin and Rubin, 1994) (Higgins and 
Brennecke, 1998) (Dekker and Sibal, 1998) (Diet!, 2000) and therefore these will not be discussed 
further in this thesis. However, none of these hypotheses fully explain the observed 
pathophysiology. It has been suggested that an alteration in endothelial cell function accounts for 
its diverse clinical presentations (Roberts et al., 1989a). This is an attractive hypothesis as all 
blood vessels are lined by the endothelium and the association ofthe disease with an alteration In 
vascular function Is well documented. Whether such changes are primary or secondary emain to 
be determined. 
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The endothelial hypothesis proposed by Roberts et al (1989) suggests that a genetic 
predisposition leads to an immunologically-mediated failure of trophoblast invasion into the 
maternal decidua, resulting in poor placentation and hypoxia. Placental hypoxia then causes an 
upregulation of a factor(s) which are released into the maternal circulation and these dramatically 
alter vascular endothelial function (Roberts et al., 1989). This thesis was undertaken to examine 
the aetiology of this observed alteration in endothelial function and this literature review will 
assess and critically analyse the evidence for each component of this in turn. However, it does 
not attempt to address other hypotheses concerning the pathogenesis of pre-eclampsia. 
1.1.2.1 Uteroplacental function and pre-eclampsia: 
1.1.2.1.1: Placenta: 
The pivotal role of the placenta has been established by several clinical observations. The first 
was the recognition that the fetus is not a disease pre-requisite, as it occurs with hydatiform ole 
where the fetus is absent (Scott and Beer, 1976). The second was that resolution of the disease 
occurs on removal of the placenta (Newman and Eddy, 1988). Further grounds for accepting a
key role for the placenta come from the observation that the disease incidence increases with 
pregnancies that are associated with hyperplacentosis: multiple pregnancy, diabetes and 
hydatiform ole (Chesley, 1978) (Brittain and Bayliss, 1995) (Nugent et al., 1996) (Joffe et al., 
1998) (Ros et al., 1998) (Malone et al., 1998). 
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1.1.2.1.2: Trophoblasf: 
The placenta consists primarily of trophoblast cells. These can be divided into two distinct 
morphological cell types- the villous-trophoblast nd the semi-allogenic, extra-villous trophoblast 
(Pijnenborg, 1988) (Bulmer, 1992). The extra-villous trophoblast isinvasive in nature, lining both 
the inter-villous space and spiral arterioles of the uterus, and their semi-allogenic status with 
respect to their host is an obvious target for the HLA cell mediated immune system. 
Studies examining the expression of HLA molecules on trophoblast cells have shown that HLA 
expression is limited to HLA-C (King, 1996) and the pregnancy-specific HLA class I molecule, 
HLA-G (Ellis et at., 1990) (Kovats et al., 1990). Kovats et al noted that HLA-G expression was 
subject to gestational shift, with predominance occurring in the first trimester (Kovats et al., 1990). 
These observations led both Ellis and Kovats to postulate that HLA-G was important in mediating 
the lowered immune susceptibility of trophoblastic ssue. McMaster t at (1995) investigated the 
expression of HLA-G by human trophoblast in both the in vivo and in vitro situation, utilising 
immunohistochemical techniques they demonstrated that HLA-G expression was limited to the 
invasive cytotrophoblast (McMaster et al., 1995). In keeping with this is the observation that 
isolated first trimester t ophoblasts, which develop an invasive pattern in culture, increased their 
expression of HLA-G antigen during this transformation (McMaster et at., 1995). Two studies 
have demonstrated that HLA-G confers resistance to natural killer cell (NK) lysis (Chumbley et al., 
1994) (Rouas-Freiss N (1997). The evidence cited above both indirectly and directly confirms the 
hypothesis that HLA-G antigen bestows an immunological shield on the invading trophoblast in 
normal pregnancy(Rouas-Freiss et at., 1997). However, the role of HLA-G in pre-eclampsia has 
yet to be elucidated. 
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1.1.2.1.3: Myometrium: 
Spiral arteries run through the myometrium and during pregnancy supply the intervillous space. 
Normal placentation is characterised by trophoblast invasion into these arteries which causes, 
through structural changes, their diameter to increase by some 6-fold relative to the non-pregnant 
state (Robertson et al., 1973) (Robertson and Warner, 1974) (Sheppard and Bonnar, 1974) 
(Brosens et al., 1978). These vascular changes extend from the intervillous space up to the inner 
third of the myometrium and lead to a dramatic increase in the blood supply to this junction 
(Brosens et al., 1972) (Pijnenborg et al., 1991). Trophoblast invasion occurs in two phases, the 
first at six weeks gestation and the second at sixteen to eighteen weeks. During this process the 
endothelium and internal elastic lamina are replaced by trophoblast and an amorphous matrix that 
consists of fibrin deposits (Brosens et al., 1967) (De Wolf et al., 1975) (Pijnenborg et al., 1980). 
As an alteration in spiral artery function appears to be crucial for normal placental development, it 
has been postulated that abnormalities in this process may lead to pre-eclampsia. Several 
studies have demonstrated that in women who develop pre-eclampsia there is histological 
evidence of shallow endovascular trophoblast invasion, with the second invading phase failing to 
reach the myometrial segments of the spiral arteries (Brosens and Renaer, 1972) (Brosens et al., 
1977) (Khong et al., 1986) (Pijnenborg et al., 1991). Interestingly Robertson et al (1975) noted 
that this was not an effect specific to pre-eclampsia. They observed that the spiral arteries of 
chronic hypertensive women without proteinuria exhibited similar changes (Robertson et al., 
1975). Since this observation, several other groups have examined this finding with conflicting 
results. Brosens et al (1977) demonstrated that in chronic hypertensive subjects the invasion of 
the spiral arteries was normal, whereas Sheppard et al (1981); Frusca et al (1989) reported the 
absence of physiological changes (Brosens et al., 1977) (Brosens, 1977) (Sheppard and Bonnar, 
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1981) (Frusca et al., 1989). One explanation for the discrepancy in these results, is that there was 
no universal definition of the hypertensive disorders of pregnancy prior to Davey et al (1989) 
(Davey and MacGillivary, 1988). Both Sheppard et al and Frusca et at included patients who 
would now not be defined as having pre-eclampsia. Meekins et at (1994) using the definitions of 
Davey et at (1989) re-examined this question and demonstrated using immunohistochemical 
techniques that there was both a spectrum of trophoblast invasion, and that spiral arteries 
displaying no physiological changes had evidence of invasion. Their overall conclusion was that 
pregnancies complicated by pre-eclampsia had significantly less spiral artery invasion than normal 
pregnancies (Meekins et al., 1994). 
An alteration in spiral artery function may also manifest itself as acute atherosis of the spiral 
arteries. This is characterised by the appearance oflipid-laden foam cells consisting of damaged 
intimal smooth muscle cells and infiltrating macrophages and has been considered virtually 
pathognomonic of pre-eclampsia (Robertson et al., 1975). This view has been refuted by 
Sheppard et at (1974) who were able to demonstrate similar lesions in the spiral arteries of 
normotensive women with intra-uterine f tal growth restriction (Sheppard and Bonnar, 1974). 
This coupled with the demonstration that failure of adequate invasion is also apparent with intra- 
uterine growth restriction has led to the suggestion that inter-uterine growth restriction and pre- 
eclampsia lie within a spectrum of the same disease (Gerretsen et al., 1981), 
Although a uniform definition of pre-eclampsia w s not accepted until the late 1980s, it is apparent 
from the literature that pre-eclampsia involves hallow endovascular invasion of the spiral arteries 
by 
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1.1.3.1: Alteration of endothelial cell function in the pathogenesis of 
pre-eclampsia: 
All blood vessels within the vasculature are lined by a monolayer of flattened, rhomboid-shaped 
cells termed the endothelium. For many years these cells were considered to be a passive barrier 
between blood and the underlying vasculature. However, in 1980 Furchgott et at demonstrated 
that aorta denuded of endothelium was resistant to vasorelaxation initialted by acetlycholine, but 
was capable of relaxation to other agents (Furchgott and Zawadski, 1980). This observation led 
to the hypothesis that the endothelium was a prerequsite for some types of vasorelaxation. This 
relationship has subsequently been confirmed in other smaller blood vessels and other 
vasodilators (Furchgott RF, 1983). 
These observations and the development of techniques for cell culture (Booyse t al., 1975) (Elgjo 
et al., 1975) have led to much research in the field of endothelial cell biology (Luscher and Barton, 
1997) (Kirkpatrick et al., 1997). Endothelial cells offer a unique interface between the intra- and 
extra-vascular environment and have a diverse function in normal physiology and pathology, 
including the regulation of angiogenesis, immune responses and inflammation, as well as in the 
maintenance of vascular tone. Since the vascular endothelium has been shown to have such a 
diverse function in haemostasis, t has been hypothesised that it is central to the pathogenesis of 
pre-eclampsia (Roberts et at., 1989). The prominent and defining clinical features of pre- 
eclampsia; elevated blood pressure, glomerular capillary leakage leading to proteinuria, and 
oedema, are also consistent with an abnormality ofthe endothelium (Roberts et al., 1991). 
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1.1.3.1.1 In vivo evidence: 
There is much evidence for an altered endothelial state in the pathogenesis of pre-eclampsia. In 
vivo evidence for a loss of endothelial function comes from the study of Campbell et al who 
established that Evans blue labelled albumin exhibited an increased ispersion rate from the 
vascular compartment i  women with pre-eclampsia when compared to normotensive controls 
(Campbell and Campbell, 1983). 
Further evidence for endothelial involvement comes from histological assessment of renal 
biopsies and necropsies, which have revealed that the glomerular endothelial cells exhibit a 
characteristic engorged appearance with intracellular inclusions, termed glomerular endotheliosis 
(Sheehan, 1980) (Kincaid-Smith, 1991). However, it should be noted that few other vessels have 
been histologically examined for endothelial cell injury in women with pre-eclampsia. Umbilical 
cord arteries have been studied and reports have confirmed endothelial cell disruption (Gilabert et 
al., 1999). This serves to confirm the hypothesis of endothelial dysfunction and demonstrates that 
vascular changes in the fetus may parallel the vascular changes observed in the mother. 
Many studies have investigated circulating plasma and serum levels of endothelial products in 
women with pre-eclampsia and compared these to normotensive controls. Freidman et al 
demonstrated that plasma concentrations of fibronectin, von Willebrand factor, tissue plasminogen 
activator and plasminogen activator inhibitor-1 were increased in women with pre-eclampsia. 
Although all of these substances are synthesised by a large number of cells, they concluded that 
there was evidence of an alteration of endothelial cell function (Friedman et al., 1995). 
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Endothelial cells produce surface adhesion molecules upon cellular activation; these serve to 
enhance cell-cell binding to circulating immune cells such as neutrophils and platelets. This has 
led several groups to hypothesise that these would increase In pre-eclampsia. The cell adhesion 
molecules are a complex group consisting of vascular cell adhesion molecule (VCAM), 
intracellular adhesion molecule (ICAM), E-selectin, and P-selectin. Several studies have 
established circulating levels of ICAM in pregnancies complicated by pre-eclampsia nd have 
shown a significant increase in compromised pregnancies when compared to controls (Austguten 
et al., 1997) (Krauss et al., 1997). In contrast, Lyall et al and Djuovic et al were unable to show 
similar results in their populations (Lyall et al., 1995) (Djurovic et al., 1997). These differences 
may be explained by the fact that ICAM is not specific for endothelial cells and an increase may 
represent general cellular activation. E-Selectin and VCAM-1 show greater specificity for 
endothelial cells, although, measurement of these levels have still produced inconclusive results. 
All studies that have determined the less specific VCAM-1 levels have noted an increase in 
pregnancies complicated by pre-eclampsia (Lyall et al., 1994) (Budak et al., 1998) (Higgins et al., 
1998). The highly specific E-selectin show differing results, with several groups demonstrating an 
increase (Heyl et al., 1999) (Austgulen et al., 1997) (Krauss et al., 1997) and another group 
unable to determine any difference (Lyall et al., 1994). However, the concentration of E-selectin 
in peripheral blood has been shown to be very dependent on the assay utilised and this may 
explain the discrepancies within the literature. 
26 
1.1.3.1.2 In vitro evidence: 
McCarthy et at (1993) provided the first ex vivo evidence of altered endothelial function in women 
with pre-eclampsia. Utilising subcutaneous resistance vessels and the technique of wire 
myography, they showed that endothelial dependent relaxation to actelycholine was impaired in 
women with pre-eclampsia when compared to controls (McCarthy et at., 1993a). Knock and 
Poston, using the same system, have also show a similar diminished relaxation to bradykinin in 
subcutaneous resistance vessels (Knock and Poston, 1996). Ashworth et at, (1997) have 
indicated that is may be a more global effect by demonstrating that resistance vessels obtained 
from the myometrium exhibit an inhibition to relaxation with bradykinin in women with pre- 
eclampsia. 
The above evidence implicates the endothelium as pivotal to the pathogenesis of pre-eclampsia. 
The observations that the placenta ppears to be crucial have led to the hypothesis that it 
produces a factor(s) that are released into the maternal circulation initiating these alterations in 
endothelial function. The advent of endothelial cell culture has allowed this hypothesis to be 
tested further. 
1.1.4.1 Circulating factors in the pathogenesis of pre-eclampsia: 
1.1.4.1.1 Cell culture studies: 
The circulating factor hypothesis has been primarily investigated ina number of in vitro studies. 
These have compared the effects of serum or plasma samples taken from women with pre- 
eclampsia nd normal pregnant controls, on cultured endothelial cell function. 
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Rodgers et at first presented evidence of a circulating factor in 1988 (Rodgers et al., 1988). They 
established that 10% sera from women with pre-eclampsia exhibited agreater cytotoxic effect on 
human umbilical vein endothelial cells (HUVEC) than control plasma, assessed via the release of 
intracellular chromium 51, This led to the hypothesis that there was a short-lived cytotoxic factor, 
which was produced by the placenta nd released into the maternal circulation. However, other 
studies have failed to reproduce these findings (Kupferminc et al., 1996) (Endresen et al., 1995). 
Indeed, Roberts et at re-examined this question and demonstrated that the serum of women with 
pre-eclampsia did not cause endothelial cell membrane leakage or alteration i  morphology. Thus 
they modified their original description of vascular endothelial cytotoxicity to'activation'(Roberts et 
al., 1992). Other groups have demonstrated that endothelial cells cultured in the serum of women 
with pre-eclampsia exhibited a greater mitogenic effect and that any metabolic hanges noted 
were almost completely reversed within 24 hours by replacing the pathological sera with standard 
culture medium (Lorentzen et al., 1991). 
Many studies of plasma characterisation have utilised human umbilical vein endothelial cells 
(HUVEC) which are potentially misleading as pre-eclampsia is a disease of microvascular nd not 
macrovascular cells. HUVEC are derived from the fetal macrovasculature and as such their 
response to plasma from women with pre-eclampsia may not represent what happens at the 
maternal microvascular level. Other studies have opted for bovine microvascular endothelial cells 
(B88), and one may question for similar easons to HUVEC, the use of these in the determination 
of possible hypotheses regarding the pathopysiology of pre-eclampsia. To date no study has tried 
to rationalise the use of various endothelia( cell lines in the investigation of pre-eclampsia. 
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1.1.4.1.2 Myometrial vessel model 
Recently, Asworth, et al have utilised an ex vivo model to negate the problem of cultured 
endothelial cells (Ashworth et al., 1998). They examined bradykinin-mediated relaxation of 
myometrial resistance arteries after in vitro incubation with either plasma from women with pre- 
eclampsia or normotensive controls, demonstrating that there was impaired relaxation in the 
vessels that were exposed to the plasma from women with pre-eclampsia. The group of normal 
vessels exposed to plasma from women with pre-eclampsia mimicked vessels taken from women 
with pre-eclampsia (Ashworth et al., 1998). It would be of interest to examine whether plasma 
factors such as VEGF, which have been hypothesised to be integral to pathogenesis of pre- 
eclampsia produce the same effect in this vessel model system. 
Thus, there is a body of evidence to suggest that a circulating factor(s) exists in the blood of 
women with pre-eclampsia that causes endothelial cells to alter their behaviour. 
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1.2 Vascular reactivity: 
1.2.1 General: 
1.2.1.1 Vascular reactivity and the role of the endothelium: 
Blood flow and pressure are regulated in the periphery by a diverse set of vessels termed the 
'resistance arteries'. These vessels must achieve a compromise between the often-conflicting 
demands of the body and individual organs. Adjustments in resistance are achieved by a change 
in the luminal diameter. 
Formerly resistance vessels were considered to be arterioles, defined as those vessels that have 
no more than one layer of smooth muscle cells. These are arteries that have a diameter of 
between 30-50µm. It is now clear from functional evidence that this is not the case with 
approximately one half of resistance vessels lying proximal to arterioles. Bloom and Fawcett give 
an anatomical definition stating that pre-arteriolar vessels with a diameter of 5 500µm are 
resistance vessels (Bloom and Fawcett, 1968) and this is consistent with the functional definition 
of resistance vessels (Baumbach and Heistad, 1983) (Chilian et al, 1986) (Faraci and Heistad, 
1990). 
Under physiological conditions, the primary function of the smooth muscle is to generate force. 
Normal vascular smooth muscle is in a continual state of activation, but the amount of force 
generated is ultimately regulated by a variety of extracellular factors, both physiological nd 
chemical, The active tension exerted by vascular smooth muscle in a vessel wall is known as 
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tone. By operating in a state of sustained constriction (or tone) peripheral vascular resistance 
may be regulated, thereby modulating cardiac output, maintaining systemic blood pressure and 
regulating organ blood flow. 
For the sake of clarity, a simplified model of tone will be considered (Figure 1.1). Overall vascular 
tone might be considered as a composite phenomenon comprising basal tone and agonist- 
induced tone, rather than a single entity. Basal tone compromises two elements, the myogenic 
and intrinsic tone. Myogenic autoregulation is dependent on stretch (pressure or flow on the 
endothelium), which directly induces compensatory contraction or relaxation of the smooth muscle 
and will not be considered in this review. Agonist-induced tone is controlled through (I) 
neurological control, involving the autonomic nervous system, (ii) circulating substances and (iii) 
locally-produced vasoactive substances. 
Sympathetic Innervation originates from the cardiac and vasomotor centres of the medulla. The 
preganglionic neurons ynapse in the thoracic sympathetic ganglia. The post-ganglionic fibres 
travel to supply the arterial and venous circulation. The neurotransmitter at the nerve endings is 
noradrenaline, synthesised locally from tyrosine, via dopa and dopamine, its action being 
dependent upon the nature and extent of its receptor stimulation (Smith and Kampine, 1990). At 
the nerve endings, stimulation of a i-adrenoceptors causes vasocontriction, particularly in the 
skin, skeletal muscles, and renal vascular beds. a 2- adrenoceptors onthe neuronal membrane 
provide a negative feedback mechanism limiting the release of noradrenaline from the nerve 
terminal (Berthelsen and Pettinger, 1977). 
Fig 1.1 
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The parasympathetic fibres arise in the motor nuclei of the brainstem and exit by way of the 
cranial nerves and the sacral division of the spinal cord. The neurotransmitter at the 
parasympathetic nerve terminal is acetyl choline, which acts on muscarinic receptors on the 
recipient organ. In the peripheral vasculature, the parasympathetic system causes vasodilatation 
in the vascular beds of the brain, myocardium, sex organ and the intestine. In other vascular 
beds, vasodilation occurs by means other than parasympathetic stimulation (Smith and Kampine, 
1990). 
The vascular endothelium represents another source of vasoactive substances. It produces three 
major relaxants the eicosanoids, nitric oxide and the yet to be identified endothelial-derived 
hyperpolarising factor (EDHF), on stimulation by various circulating substances. The vascular 
endothelium also produces the vasoconstrictor endothelin. 
The control of vascular esistance occurs through the dynamic interplay of all these described 
systems. Therefore, when its control is considered in an experimental sitting, it should ideally 
investigate all components together. However, this was not possible to achieve in this thesis and 
investigations were therefore limited to the role that the endothelium had in this system. 
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1.2.2. Vasorelaxants substances: 
1.2.2.1 EDRF 
- 
Nitric Oxide: 
Discovery of EDRF (Nitric Oxide): 
Furchgott et at (1980) elegantly demonstrated that denuded rabbit aorta was unresponsive to 
acetylcholine and proposed that the stimulated endothelium produced a chemical mediator that 
induced vascular smooth muscle relaxation. They termed this mediator Endothelium Derived 
Relaxing Factor (EDRF) (Furchgott and Zawadski, 1980). The chemical nature of EDRF 
remained unknown until Palmer et al (1987) and Ignarro et al (1987) demonstrated independently 
that EDRF derived from cultured endothelial cells and aqueous nitric oxide caused similar 
relaxation profiles (Palmer et al., 1987) (Ignarro et al., 1987). 
It is now clear that nitric oxide released from the endothelium contributes to the physiological 
regulation of blood pressure. In rats, Rees et al (1989) found that the blockade of nitric oxide 
formation with the inhibitor L-NMMA resulted In an immediate rise in blood pressure and that the 
subsequent administration f the substrate L-arginine reversed this effect (Rees et al., 1989). 
This has also been shown to be the case in humans; forearm plethysmography studies 
demonstrated that infusion of nitric oxide inhibitors caused a reduction in peripheral blood flow, 
which could be overcome by the use of L-arginine (Valiance t al., 1989). 
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Formation of Nitric Oxide: 
The chemical formation of NO has been demonstrated to involve the hydroxylation of the N 
terminal group of the guanidino group of L-arginine. This hydroxylation reaction leads to the 
generation of the free radical nitric oxide and L-citrulline (Sakuma et al., 1988). The L-citrulline 
has been shown to result in the formation of L-arginine via its combination with ammonia 
(Anggard, 1994). 
Nitric Oxide synthase nzymes: 
Synthesis of NO has been demonstrated in various mammalian tissues. These include the 
vascular endothelium, the brain and activated macrophages (Ignarro et al., 1988) (Marietta et al., 
1988) (Garthwaite et al., 1989). As unregulated production has been implicated in many 
pathological events, tightly controlled biosynthesis of nitric oxide is crucial. To this end nitric oxide 
synthetase is the most regulated enzyme in the human body. Once these tissues had been 
demonstrated to produce nitric oxide the search was on for the enzyme. 
Initial efforts to purify these enzymes were unsuccessful, asactivity was lost during purification. 
Bredt et al 1990 utilised their observation that these enzymes were calmodulin dependent, to 
isolate brain nitric oxide synthase (Bredt et al., 1990) (Bredt and Snyder, 1990). Using similar 
approaches, other isoforms of nitric oxide synthase have been isolated. From early studies of this 
complex set of enzymes it was apparent that macrophages contained a specific isoenzyme, 
different to all the others. This enzyme has been demonstrated to be Ca 2+ Independent (Knowles 
and Moncada, 1994). The calcium Independent enzyme has now been demonstrated in several 
other immune tissues and is not, as was first thought, macrophage specific. Since this 
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observation, immune cytokines have been shown to increase the expression of calcium 
independent NOS in various tissue, which has led to the term of inducible NOS (Galea et at., 
1995) (Salter et al., 1991) (Nussler et al., 1992) (Nussler et at., 1993) (Geller et al., 1993). The 
isoenzymes of nitric oxide synthase can be broadly divided into two categories: constitutive and 
inducible. The accepted nomenclature for the different isoforms of NOS remains under discussion 
as those parameters by which the different isoforms were initially thought o be differentiated 
would now appear less mutually exclusive (Sessa, 1994). 
1.2.2.2. Prostaglandins: prostacyclin: 
Over the last twenty years, much Interest has focused on the prostaglandins- a complex group of 
substances which have been demonstrated to be crucial to the interplay between platelets and the 
vascular wall. Arachidonic acid has been established as the most common fatty acid present in 
phospholipids (Moncada nd Vane, 1979) and is the precursor of all the bisenoic prostaglandins. 
It is liberated from membrane phospholipids by the phospolipase group of enzymes (Vankeman 
and Von Dorp, 1968). There are three distinct stages in the formation of prostaglandins from their 
arachidonic acid precursor. First, phospholipid cleavage to mobilise arachidonic acid, second the 
sequential conversion to the prostaglandin e doperoxides, and third the subsequent isomerisation 
/reduction of these endoperoxides to produce the biologically active compounds (Moncada and 
Vane, 1979). Prostaglandin synthesis has been shown to be initiated by several stimuli including, 
shear stress, hormones and proteinases (examples of which include bradykinin and anti diuretic 
hormone) activating the prostaglandin E2 synthesis pathway In the renal tubules (Grenier et al., 
1981) (Kirschenbaum et al., 1982). 
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Discovery of prostacyclin: 
The importance of prostaglandins in vascular functioning was demonstrated in 1974 with the 
discovery that the non-prostaglandin metabolite thromboxane, exhibited vasoconstrictor p operties 
(Hamberg and Samuelsson, 1974). Monacada and Vane discovered a second vasoactive 
metabolite of the prostaglandins; this was demonstrated to have diametrically opposing functions 
to those of thromboxane. They elegantly demonstrated that endoperoxides of prostaglandin were 
transformed by microsomal enzymes from rabbit and pig aortas into an unstable substance that 
inhibited aggregation of platelets and caused the relaxation of various vessels. However, they 
were unable to demonstrate that arachidonic acid was a precursor, concluding that a pre-requisite 
conversion to the endoperoxides was required (Moncada et al., 1976a). They postulated that the 
balance between the pro-aggregatory vasoconstrictor thromboxane and the anti-aggregatory 
vasodilator PGX may be critical for formation of thrombi. Bunting et at 1976, utilising fresh vessels, 
confirmed the original finding of Moncada et al (1976) and demonstrated that arachidonic acid 
was indeed capable of metabolism to prostaglandin X (Bunting et al., 1976). This compound, 
initially named prostaglandin X (PGX), was later identified as a metabolic intermediate of the 
known compound, 6-keto-PGF1 c and renamed prostacyclin due to its chemical structure 
(Johnson et al., 1976). 
Formation of prostacyclin: 
As stated previously, the final step in the conversion of arachidonic acid to one of its biologically 
active compounds i  dependent on a multitude of product specific enzymes. The predominance of 
one of these enzymes determines which prostaglandin is the major cellular product. This is best 
exemplified in the platelet, where the enzyme thromboxane synthetase predominates and leads to 
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the production of thromboxane (Ullrich and Haurand, 1983). The major prostanoid produced by 
endothelial cells is prostacyclin (PGI2): 
- 
a potent vasodilator and inhibitor of platelet aggregation 
(Bunting et al., 1976) (Gryglewski et al., 1976) (Moncada et al., 1976a) (Moncada et al., 1976b). 
Although many cells within an organ will not produce these agents, all smooth muscle cells can 
produce prostacyclin and it is probable that all endothelial cells can produce prostacyclin and 
prostaglandin E2. 
Prostacyclin synthetase (cyclo-oxygenase): 
Endothelial cells are known to generate PGI 2 (prostacyclin) upon stimulation by various receptor 
mediated ligands (Nawroth et al., 1984). Although prostaglandin production has been ascribed to 
phopholipases for the availability ofthe substrate archidonic acid, an important control mechanism 
exists at the cyclo-oxygenase level. Cytokines such as interleukin 1a (IL-1 a) or phorbol esters 
have been demonstrated to induce de novo synthesis of cyclo-oxygenase in ndothelial cells (Raz 
et al., 1988) (Wu et al., 1988) (Lin et al., 1989). However, several studies reported iscrepancies 
in the correlation between enzyme mass and the increase in activity, thus postulating the 
existence of different isoenzyme of cyclo-oxygenase (Bazan et al., 1994) (Kujubu et al., 1991), 
which has now been confirmed to be correct (Meade t al., 1993) (Feng et al., 1993). 
1.2.2.3 Endothelium-Derived Hyperpolarising Factor (EDHF): 
The existence of an endothelium-derived substance which causes vasodilatation by 
hyperpolarisation of the vascular smooth muscle cell membrane has been postulated since the 
late 1970s, when acetylcholine was demonstrated to hyperpolarise vascular smooth muscle 
(Kuriyama and Suzuki, 1978). The discovery of nitric oxide and prostacyclin has allowed the 
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development of compounds that inhibit heir synthesis. These have allowed aclassification f the 
mechanism ofvasodilatation to be made and have confirmed the presence of as yet unidentified 
endothelium-derived hyperpolarising factor (EDHF). The role of EDHF in mediation of 
endothelium-dependent r laxation, and the precise nature of the substance (or even whether 
EDHF is a group of substances) are all the subject of much current research. 
The nature of EDHF: 
The chemical identity of EDHF still remains obscure. Possible candidates included 
epoxyeicosatrienoic acids (EETs), endogenous cannabinoids, and recently two further candidates 
have been reported to have EDHF like functions; potassium ions and gap junctions. 
Epoxyeicosatrienioc acids (EET): 
It has been widely postulated that EDHF(s) derives from arachidonic acid. EETs are labile 
metabolites of arachidonic acid and are formed through cytochrome P450-dependent mono- 
oxygenase activity. Bauersachs et al (1994) showed in perfused rat coronary arteries relaxed to 
bradykinin that the nitric oxide and prostaglandin resistant relaxation was abolished by inhibitors 
of cytochrome P450 (Bauersachs et at., 1994). Campbell et at (1996) also demonstarted that 
inhibition of the P450 enzyme attenuated methacholine-induced relaxation of bovine coronary 
arteries to a similar extent as did tetraethylammonium (an inhibitor of Ca 2+-activated K+ 
channels) or a high [K+], both of which have been shown to prevent hyperpolaristion of the 
vascular smooth muscle (Campbell et al., 1996). In vessels incubated with labelled arachidonic 
acid, methacholine was shown to stimulate release of arachidonic acid metabolites, which Induced 
the EETs. Four different EET isomers were found to induce relaxation in constricted bovine 
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coronary arteries, all to a similar extent (Campbell et al., 1996), a finding that has been confirmed 
in other vascular beds (Rosolowsky and Campbell, 1993) (Pfister et al., 1991) (Gebremedhin et 
al., 1998) (Hecker et al., 1994). ETTs have also been shown to activate potassium channels in 
vascular smooth muscle cells (Gebremedhin et al., 1998) (Hu and Kim, 1993), further implicating 
them as a possible EDHF. 
Although some cytochrome P450 inhibitors inhibit he EDHF-mediated r sponse, not all have this 
effect. Moreover some of these inhibitors have been shown to inhibit potassium-channels 
(Zygmunt et al., 1996) and their use as evidence for ETT's mediating the sole component of 
EDHF must therefore be questioned. 
Gap Junctions: 
Although the chemical identity of EDHF remains to be determined there is now increasing 
evidence to suggest that nitric oxide and prostanoid-independent agonist induced relaxation 
preferentially diffuses from the endothelium to smooth muscle via gap junctions, rather than 
through the extracellular space (Javid et al., 1996) (Taylor et al., 1998) (Hutcheson et al., 1999). 
This hypothesis has been supported by the existence of myoendothelial g p junction plagues in 
conduit arteries (Christ et al., 1996), and dye transfer experiments have demonstrated direct 
chemical coupling between the two cell types (Beny and Gribi, 1989) (Beny and Connat, 1992) 
(Beny and Pacicca, 1994). 
Gap junctions are membrane-localised hemichannels, contributed by apposing cells. Each 
hemichannel is formed by 6 connexin protein subunits arranged around an aqueous central pore 
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that provides electrical continuity and permits intracellular movement of small molecules <I KDa 
in size. This facilitates intercellular communication and co-ordination of cell activities (Christ et al., 
1996). A family of connexins, having at least 13 identified members in mammals, have been 
described (Christ et al., 1996) (Falk et al., 1997) (Barrio et al., 1999) (Suchyna et al., 1999) (Van 
Rijen et al., 1997). Three of the characterised connexins (connexin 43, connexin 40, and connexin 
37) have been identified in cells of the vascular system, where they may have a role in the control 
of vasomotor function (Christ et al., 1996). Dantas and colleagues have recently demonstrated 
that there is an enhanced relaxation in the aorta of pregnant rats when compared with non- 
pregnant vessels. They also demonstrated that the increased relaxation in pregnant rat aorta is 
mediated through gap junctions; they blocked gap junctions with heptanol and the demonstration 
that connexin 43 mRNA was increased in these vessels. However, they demonstrated that these 
responses, although mediated through gap junctions were predominately nitric oxide mediated, as 
depolarisation with potassium had little effect on the relaxations obtained and the addition of 
heptanol to vessels constricted with K+ caused total loss of endothelium dependent relaxation 
(Dantas et al., 1999). 
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1.3: Vascular reactivity chances in pregnancy and pre"eclamasia: 
1.31: General cardiovascular effects: 
During pregnancy, dramatic changes occur in maternal physiology to accommodate the growing 
conceptus. Nowhere are these changes more evident than in the cardiovascular system. Blood 
volume and cardiac output increase by 40-50% (Duvekot and Peeters, 1994). These increases 
have occurred by the second trimester and are maintained until after parturition (Boslo et al., 
1999). Blood pressure throughout pregnancy remains low until the end of the third trimester, 
secondary to a reduced peripheral resistance (Duvekot and Peeters, 1994). However, in pre- 
eclampsia, total peripheral resistance increases, causing the blood pressure to rise (Bosio et al., 
1999). It has been postulated that the changes in vascular reactivity observed in both normal 
pregnancy and pre-eclampsia are caused by alterations in the vascular endothelium. 
1.3.2 Effects of pregnancy on vasoreactivity: 
Vascular reactivity to the pressor-effects of angiotensin II are decreased inpregnancy (Gant et al., 
1973). This allows an increased circulating concentration f angiotensin II without an increase in 
peripheral resistance. The reduced sensitivity of the vascular endothelium to pressor agents 
appears to be selective for angiotensin II, as other agents such as noradrenaline show no 
alteration of their pressor esponses with pregnancy (Ramsay et at., 1993). Evidence that this is 
mediated through changes in vascular reactivity come from the observation that rapid infusions of 
fluid do not alter angiotensin II sensitivity (Matsuura et at., 1983). The difficulties with in vivo 
studies in human pregnancy have led researchers to examine the vascular changes that occur in 
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pregnancy with indirect methods. These have included animal models and myography. 
Myography allows the study of vascular reactivity in ex vivo resistance vessels and can be used to 
determine the contribution of the endothelium to the observed changes. 
Considering the increased accessibility of the peripheral vascular system, there has been little 
direct research into the vascular changes that occur in human pregnancies. However, increases 
in endothelial derived substances which are known to cause vasodilation have been postulated to 
be important In this process. The next part of this thesis will consider those directly related to this 
thesis. Although there are many other alternative xplanations for the observed fall in total 
peripheral resistance, these are outside this thesis and will not be considered. 
To date, few studies have addressed the possibility of pregnancy-mediated differences in 
endothelium-dependent relaxation to various agonists in human resistance vessels. McCarthy et 
al utilised subcutaneous vessels from pregnant women and compared them to similar vessels 
from non-pregnant women. They were unable to demonstrate differences between the groups 
with respect to contraction with epinephrine (noradrenaline) or relaxation to acetylcholine 
(McCarthy et al., 1993b). Pascoal and Umas have confirmed this observation i  human omental 
vessels exposed to acetylcholine and bradykinin (Pascoal nd Umans, 1996). 
Uterine resistance vessels are juxtaposed to the developing placental bed and undergo 
considerable r modelling with pregnancy. Thus it is pertinent to study these vessels when 
examining the changes that occur during pregnancy. However, there is a paucity of data into the 
effect of pregnancy on myometrial resistance vessels. This is primarily due to the technical 
difficulties of sample collection. The studies that have investigated endothelium-dependent 
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relaxation in myometrial resistance arteries have utilised different vasoconstrictor and 
vasorelaxant agents making comparison difficult (Ashworth et al., 1996b) (Kublickiene t al., 
1997) (Svane et al., 1991). 
Svane, et at provided the first report concerning the vascular esponses in non-pregnant and 
pregnant human uteri. They examined the contractile and relaxatory responses of myometrial 
vessels to angiotensin It, vasopressin, U46619 (a thromboxane memetic), and noradrenaline. 
Resistance vessels were obtained to allow comparison ofthe non-pregnant and pregnant state. 
In addition, within the pregnant group, placental and non-placental bed vessels were compared. 
Svane et at were unable to produce any evidence that either pregnancy or placental localisation 
produced any changes in the smooth muscle responses to agonists important in the control of 
human uteroplacental resistance (Svane et at., 1991). These findings were subsequently 
confirmed by Steele t al (Steele et al., 1993). 
Using different endogenous vasodilators, Ashworth et at, 1996 and Svane et at, 1991 
demonstrated that there do not appear to be any changes in the vasculature of the pregnant 
uterus. However, neither study elucidated whether the mechanism of relaxation altered with 
pregnancy (Ashworth et at., 1996b) (Svane et at., 1991). An alteration in mechanism of 
vasodilatation, without a difference in total relaxation, may have important implications for 
pregnancy outcome; In disease states these alterations may be absent. 
6 
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1.3.3. The mechanism for the alterations in vascular reactivity in pregnancy 
1.3.3.1 Eicosanoids: 
Studies of maternal plasma levels of prostacyclin have yielded conflicting results. Lewis et at, 
1980 reported that plasma concentrations of the vasodilator 6-keto-prostaglandin F1a (6-keto-PG 
Fl(x), a stable metabolite of prostacyclin were increased in pregnant women when compared to 
non-pregnant controls (Lewis et al., 1980). Goodman et at, confirmed this finding by measuring 
the urinary excretion of 6-keto PGF1a (Goodman et al., 1982). However, Ylikorkala were unable 
to demonstrate any significant increase in the plasma levels of 6-keto-PGF1a in pregnant women 
(Ylikorkala et al., 1981). These differences inresults are probably due to different methodologies. 
Several longitudinal studies have sought to examine the change of prostacyclin levels during 
confinement and have shown increased levels of 6-keto-PGF1 a during pregnancy until the 
second trimester (Lewis et al., 1980) (Goodman et al., 1982). 
Inhibition of elcosanoid synthesis during pregnancy alters the angiotensin II infusion sensitivity 
towards that of the non-pregnant state (Everett et al., 1978) (O'Brien and Pipkin, 1979). This 
implicates an alteration in elcosanoid synthesis as being important in the vascular adaptations of
pregnancy. However, ex vivo studies of resistance vessels from several vascular beds have been 
unable to confirm these findings (Ashworth et al., 1997) (McCarthy et al., 1994) (Pascoal and 
Umans, 1996). Differences in results between the in vivo and ex vivo situations may have 
occurred ue to the use of non-specific elcosanoid synthesis inhibitors, which have other non- 
specific in vivo effects. 
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The evidence thus supports the hypothesis that elcosanoids are important in the observed 
vasodilator esponses observed in pregnancy. This has led to the hypothesis that altered 
eicosanoid production may lead to the observed hypertension that occurs in pre-eclampsia nd 
this will be discussed later in this review. 
1.3.3.2 Endothelial Derived Relaxing Factor 
-Nitric Oxide: 
Nitric oxide status in human pregnancy is far from clear. Seligman et al (1994) reported that there 
was a small but significant increase in plasma nitric oxide production of non-pregnant as 
compared to pregnant subjects (Seligman et al., 1994) and this was confirmed by Smarasson et al 
(1997) who compared plasma nitrate concentrations from a cohort of non-pregnant and pregnant 
women using a vanadium V chloride reduction reaction and chemiluminence (Smarason et al., 
1997). Several groups have demonstrated increased urinary and plasma concentrations 
throughout human pregnancy (Kopp et al., 1977) (Sala et al., 1995), These observations have led 
to the hypothesis that increased nitric oxide production mediates the vascular changes, which are 
so indicative of pregnancy. Myatt et al observed an increased urinary nitrate excretion in single 
voided urine samples (Myatt et al., 1992), however, other groups have failed to show any increase 
in 24-hour urinary nitric oxide concentrations between on-pregnant and pregnant controls (Brown 
et al., 1995b). All these studies had insufficient power to draw appropriate conclusions and only 
one of these studies controlled for nitrogen intake during the course of the investigation. This may 
have masked any significant results since a high dietary intake of nitrates causes its' increased 
excretion i  the urine. 
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Steele et al (1993) examined whether pressor responses of myometrial resistance arteries were 
altered after removal of the endothelium or the inhibition of nitric oxide (Steele et at., 1993). 
Removal of the endothelium from non-pregnant women produced no significant increase in the 
pressor esponse, however, denuded pregnant vessels showed enhanced responses. This effect 
was independent of nitric oxide. Steele et al (1993) concluded that in the pregnant state, 
endothelial cells appear to modify the contractile response to noradrenaline of the maternal 
vascular smooth muscle through a mechanism dependent on substances other than nitric oxide 
(Steele et al., 1993). This may imply a role for Endothelial Derived Hyperpolarisng Factor (EDHF) 
in the alteration of vascular esponses in pregnancy. 
Mechanistic changes in vasodilatation have also been studied with the use of L-nitro L-arginine 
methylester (L-NAME) I N-mono-methyl-L-arginine (L-NNMA) (Nitric oxide synthetase inhibitors) 
and indomethacin (eicosanoid synthesis inhibitor). Neither blockade of nitric oxide nor eicosanoid 
synthesis altered vessel behaviour, again implicating the vasoactivity mediator EDHF as important 
in the physiology ofthese vessels (Pascoal et al., 1998) (McCarthy etal., 1993a) (McCarthy et al., 
1994). 
In summary, the evidence for increased production of nitric oxide accounting for the vascular 
changes that are observed In human pregnancy is far from convincing. This may be compared 
with the four-fold rise in the excretion of the major metabolite of prostacyclin (PGI2), and 6-keto 
prostaglandin Fla, by the end of the first trimester. Although PGI2 can function as a circulating 
hormone, nitric oxide seems more likely to be locally synthesised for a local role. Nevertheless, at 
present there is no clear evidence that nitric oxide increase in human pregnancy. 
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1.3.3.3 Endothelial Derived Hyperpolarising Factor (EDHF): 
Although the chemical identity of EDHF remains to be elucidated the use of both nitric oxide 
synthase and cyclooxygenase inhibitors has allowed changes in the proportion of the relaxation 
attributable to EDHF to be investigated. Use of these inhibitors has demonstrated, in various 
vascular beds, that a reciprocal relationship exists between itric oxide and EDHF mediated 
responses (Randall and March, 1998). 
Kenny et al have recently examined the mechanism ofendothelium-dependent vasodilatation in 
human myometrial resistance vessels. They demonstrated with the use of both the eicosanoid 
inhibitor, indomethacin, and the nitric oxide synthase inhibitor, L-NAME, that an increased non- 
nitric oxide, non-prostanoid mediated component to vascular function occurs in pregnant versus 
non-pregnant vessels. They postulated that these increases occur through a decrease in nitric 
oxide and an increase in EDHF mediated responses, in these vessels (Kenny et at., 1999b). 
Gerber at at have also demonstrated that in pregnant rats EDHF-dependent response 
predominates when compared to non-pregnant rats (Gerber et al., 1998). These studies uggest 
an important function for EDHF in normal pregnancy adaptation. 
1.3.4. Effect of pre-eclampsia on vascular eactivity: 
Pre-eclampsia is associated with an elevation of blood pressure and increasing evidence 
indicates an involvement of the maternal endothelium. 
47 
Although the difficulty of in vivo human experimentation has limited the study of vascular eactivity 
in this condition, several studies exist to indicate that an altered reactivity occurs in pre-eclampsia. 
Gant et al demonstrated that while normotensive pregnancies exhibited a decreased sensitivity to 
infused angiotensin II, pregnancies that were destined to develop pre-eclampsia were 
characterised by increased sensitivity from as early as eighteen weeks (Gant et al., 1973). In a 
larger study Kyle et at confirmed the enhanced sensitivity to angiotensin II in pre-eclampsia but 
found that as a diagnostic test, it had a much lower sensitivity and specificity than initially reported 
by Gant et at (Kyle et al., 1996). Increased sensitivity to Infused physiological concentrations of 
noradenaline has also been noted in pregnancies complicated by pre-eclampsia (Kaaja et al., 
1999) (Manyonda et al., 1998). This suggests that an alteration in the vascular eactivity occurs 
with pregnancy and that this may be lost prior to the onset of disease. As stated previously, in 
vivo studies are difficult to conduct and vascular reactivity has thus been examined by indirect 
methods. 
Several ex vivo studies of resistance vessels have demonstrated an alteration In vascular 
reactivity in pregnancies complicated by pre-eclampsia. These studies have examined 
endothelium-dependent relaxation and have shown that in pre-eclampsia the agonist 
concentration required to obtain relaxation is significantly increased (McCarthy et al., 1993a) 
(Ashworth et at., 1997). This further implicates the vascular endothelium as important in the 
pathophysiology of this disease. These ex vivo studies thus confirm the observation of altered 
vascular reactivity and implicate the endothelium as pivot in this process. 
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1.4.5. The mechanism for the alterations in vascular reactivity 
-in 
pre-eclampsia: 
1.4.5.1 Eicosanoids 
Numerous studies have attempted to assess eicosanoid status in pre-eclampsia, but there are no 
clear conclusions. Studies have either considered the maternal vascular compartment or the fetal 
vascular compartment. 
In studying the maternal compartment with regard to the levels of the vasodilator prostacyclin and 
vasoconstrictor thromboxane, several groups have determined plasma levels. These have 
produced contradictory esults. Several studies have demonstrated decreased prostacyclin and 
increased thromboxane levels (Downing et al., 1980) (Lewis et al., 1980) (Goodman et al., 1982) 
(Makila et al., 1984) (Malatyalioglu et al., 2000), whereas others have been unable to elicit any 
differences (Yamaguchi and Mori, 1985). Varriations in results may stem from the methods of 
determination. On balance, the evidence from plasma levels is suggestive of a change in the 
prostacyclin / thromboxane ratio. 
The hypothesis of altered eicosanoid synthesis in pre-eclampsia has also been tested via 
measurement of the urinary excretion of these metabolites. In humans, urinary excretion of 
prostacyclin has been demonstrated to decrease in women with pre-eclampsia (Goodman et al., 
1982) (Barden et al., 1994) (Mills et al., 1999b), Levels of thromboxane showed no difference In 
pregnancies complicated by pre-eclampsia (Barden et al., 1994) (Mills et al., 1999b). Scafer, et al 
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investigated the urinary excretion of both prostacyclin and thromboxane in a rat model for pre- 
eclampsia nd demonstrated that both prostacyclin and thromboxane were decreased. They 
noted that despite an overall decrease in metabolites, the thromboxane / prostacyclin ratio 
changed in favour of the thromboxane (Scafer et al., 1993). 
The observation that prostacyclin production is reduced in pre-eclampsia led investigators to
determine if the endothelium was responsible for this altered production. This has been achieved 
via two methodologies, x vivo resistance arteries and in vitro cell culture experiments. Ex vivo 
resistance artery experiments have produced contradictory results. Ashworth et al reported 
enhanced relaxation of myometrial vessels from women with pre-eclampsia to bradykinin i  the 
presence of indomethacin and from this concluded that vasoconstrictor eciosanoids were partially 
responsible for the observed reduced relaxation (Ashworth et al., 1997). Other workers, utilising 
different vascular beds, have been unable to demonstrated alterations in vasodilation upon the 
addition of eicosanoid synthatase inhibitors (Pascoal et al., 1998) (Knock and Poston, 1996). 
Ashworth et al can be criticised in their protocol for not using correct time control experiments, and 
so the observed effect of indomethacin may be due to a return to normal vasodilatation of
resistance vessels. 
Cell culture xperiments have demonstrated that endothelial cells exposed to plasma from women 
with pre-eclampsia increase their production of the vasodilator prostacyclin (Baker et at., 1996a). 
This Is contrary to the original hypothesis and led Baker et al to investigate this further. Baker et 
at conducted time course xperiments and showed that at twenty-four hours an initial increase in 
the prostacyclin production was observed. This was followed at forty-eight ours by a reduction in 
prostacyclin production when compared to controls (Baker et al., 1996a). 
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1.4.5.2 Endothelial Derived Relaxing Factor 
-Nitric Oxide: 
The role of nitric oxide in the pathogenesis of pre-eclampsia is equally confusing. Several studies 
have demonstrated that rats infused with L-NAME or various other inhibitors of nitric oxide 
synthetase exhibit signs that are similar in character to pre-eclampsia (Yallampalli and Garfield, 
1993) (Molnar et al., 1994) (Buhimschi et al., 1995) (Zhang and Kaufman, 2000). These include 
increased systemic blood pressure and proteinuria. This has led to the hypothesis that a 
decreased nitric oxide production causes the observed vascular changes of pre-eclampsia. One 
of many problems with the rat model is the fact that it is difficult o extrapolate the findings to 
humans since rats do not suffer pre-eclampsia. Another problem is with the fact that if male rats 
are infused with L-NAME similar esults are obtained with increased blood pressure (Huang et al., 
1995) (Sventek et al., 1997). Pre-eclampsia is specific to pregnant women and therefore any 
model of this disease that is not pregnancy oreven gender specific must be questioned. 
The hypothesis that decreased nitric oxide production causes the observed vascular changes that 
occur in pre-eclampsia has been investigated with varying results. Several studies have 
examined urinary nitric oxide production as representative of in vivo nitric oxide production. 
Brown et at studied twenty-four hour urinary nitritelnitrate concentrations in women with varying 
degrees of pre-eclampsia and compared these to levels of women in the third trimester of normal 
pregnancies (Brown et at., 1995b). They were unable to show any differences between groups, 
either when nitrate was expressed alone or as a fraction of creatinine clearance. The expression 
of results as a function of creatinine clearance negates the problem of reduced renal output in pre- 
eclampsia. Brown et at concluded that no Increase In nitrate/nitrite production occurred in pre- 
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eclampsia. However, Davidge et al (1996) demonstrated that urinary nitrate / nitrite excretion was 
decreased in women with pre-eclampsia. Interestingly, they were unable to show significant 
differences in plasma concentrations between patients with pre-eclampsia and normotensive 
controls (Davidge et al., 1996b). 
The postulated altered production ofnitric oxide in pre-eclampsia has also been investigated via 
the direct measurement of serum nitrites t nitrates and indirectly by cGMP levels. Seligman et al 
(1994) utilised the Griess reaction and showed that there was a significant reduction i  nitrates in 
the serum of women with pre-eclampsia ascompared to normotensive controls (Seligman et al., 
1994). However, a more recent study demonstrated that there was an increase in the nitrate 
levels of women with pre-eclampsia (Smarason et at., 1997). The differences in these studies 
may again be due to the small numbers investigated. This is of special relevance, given that any 
differences observed are small. Furthermore, the study of Seligman et al was confounded by the 
administration f magnesium sulphate to their cohorts prior to blood sampling. Endothelial nitric 
oxide is calcium dependent and so magnesium ay have the effect of reducing endothelial nitric 
oxide synthase activity. Studies that have measured cGMP provide an indirect measurement of 
nitric oxide. These have shown that an increase in cGMP occurred in pre-eclampsia (Begum et 
al., 1996). One further methodological problem not addressed by any of these studies is the lack 
of control of dietary nitrogen intake, which may bias results with exogenous nitrites. Conrad et at 
(1999) have recently addressed this and demonstrated that in women with pre-eclampsia there is 
no alteration i  either nitric oxide or cGMP (Conrad et al., 1999). 
Evaluations of the mechanistic changes of resistance vessels in pre-eclampsia h ve provided 
contradictory results with respect to nitric oxide, probably due to the different vascular beds 
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studied. Ashworth, et al (1997) reported that myometrial vessels exhibited two possible 
alterations in mechanism when bradykinin was used as the vasodilator. They showed that 
eicosanoids may be important as discussed previously. They also showed that the addition of L- 
NMMA attenuated the endothelium dependent relaxation in vessels from women with pre- 
eclampsia. From this they concluded that there was a compensatory increase in the nitric oxide 
component (Ashworth et al., 1997). However, other studies of the mechanisms have failed to 
demonstrate differences in either eicosanoid or nitric oxide mediated relaxation in systemic 
vessels (McCarthy et at., 1993a). The resistance to eicosanoids and nitric oxide synthetase 
inhibitors in normal pregnant and pre-eclamptic blood vessels (Ashworth et at., 1997) must 
indicate a role for either EDHF or another endothelial-derived product in both pregnancy and pre- 
eclampsia. 
Increased nitric oxide production by the endothelium has been confirmed by cell culture. Baker et 
at have shown that endothelial cell exposure to the plasma of women with pre-eclampsia 
generated increased concentrations of nitric oxide when compared with exposure to control 
plasma. They postulated that this increase in nitric oxide may be detrimental toendothelial cells 
function through the generation of peroxynitrites (Baker et at., 1995b). Roggensack et at have 
demonstrated that vessels isolated from women with pre-eclampsia have increased expression of
endothelial peroxynitrite, further implicating an abnormal nitric oxide respond in the pathogenesis 
of this disease (Roggensack et al., 1999). 
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1.4.5.3 Endothelial Derived Hyperpolarising Factor (EDHF): 
To date there are no studies that have directly addressed the role of EDHF in the pathogenesis of 
pre-eclampsia, although several studies have produced results that have led to the hypothesis 
that it may be important in the pathophysiology of this disease. McCarthy et al (1993) were the 
first to suggest apossible role for EDHF in pre-eclampsia. They demonstrated that concentration 
response curves to acetylcholine from subcutaneous resistance vessels were attenuated in 
women with pre-eclampsia when compared to normal pregnant controls. They also demonstrated 
that these observed alterations in endothelial function were independent of elcosanoids and nitric 
oxide, postulating that they may be due to alterations in EDHF-mediated relaxation. This 
observation of an alteration in non-eicosanoid, non-nitric oxide dependent relaxation in pre- 
eclampsia has been confirmed in the omental and myometrial vascular beds (Ashworth et al., 
1997) (Pascoal et al., 1998). However, until the chemical nature and specific inhibitors of EDHF 
are discovered, all studies will remain as indirect conjecture. 
In summary the literature suggests that an alteration in vascular reactivity occur in both pregnancy 
and pre-eclampsia. However, the mechanism of this alteration remains unclear. With pre- 
eclampsia, as stated previously, there may be a circulating factor that causes the changes in 
endothelial cell function and vascular eactivity. One such candidate is Vascular Endothelial 
Growth Factor. 
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1.5 Vascular Endothelial Growth Factor (VEGF): biological structure: 
1.5.1 Vascular Endothelial Growth Factor: 
1.5.1.1 Discovery of VEGF: 
Ferrara et al first reported Vascular Endothelial Growth Factor (VEGF) in 1989. They 
demonstrated that medium exposed to bovine pituitary cells was capable of initiating a mitogenic 
effect that was specific to endothelial cells (Ferrara nd Henzel, 1989). However, VEGF had been 
reported previously In a different context. Senger et al (1983) demonstrated that isolated 
mammalian tumour cells produced a factor that increased vascular permeability (Senger et al., 
1983) (Senger et al., 1986) and termed this Vascular Permeability Factor (VPF). 
Connolly et at extended this early work and showed that isolated VPF was capable of producing 
an endothelial specific mitogenic effect (Connolly et al., 1989a). They postulated that VPF and 
VEGF might be one and the same as they shared a common NH2 terminal sequence. Keck et at 
(1989) confirmed this hypothesis by demonstrating that these factors hared a common gene and 
molecular weight (Keck et al., 1989). 
1.5.1.2 VEGF gene: 
The VEGF gene has been isolated from a variety of tissues: mouse, rat and guinea-pig (Leung et 
al., 1989) (Keck et al., 1989) (Senger et al., 1990) (Conn et al., 1990) (Breler et al., 1992). In 
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humans it originates from a single gene located on chromosome 6 (Keck et al., 1989) (Mattel et 
al., 1996). 
1.5.1.3 Structure of Vascular Endothelial Growth Factor: 
Protein purification yielded a 45-46 kiloDalton (kD) product and subsequent secondary structure 
analysis revealed a dimeric compound composed of two 23 kd subunits which were cross-linked 
with disulphide bonds (Ferrara and Henzel, 1989) (Gospodarowicz and Lau, 1989). 
Primary (amino acid) sequence analysis of VEGF shows there are eight conserved cysteine 
residues. These are integral for the inter- and intra- molecular bridging (secondary structure). 
Platelet derived growth factor (PDGF) has also been shown to contain eight conserved cysteine 
residues. A comparison of DNA sequence between PDGF and VEGF showed a striking 
conservation of all eight cysteine residues. Further sequence analysis of VEGF and the two 
PDGF chains revealed that there was a 21% and 24% homology when the amino and carboxyl 
terminal regions of VEGF extending beyond the mature form of PDGF were removed (Tischer et 
al., 1989). This led to the conclusion that VEGF and PDGF are from the same family of cytokines. 
1.5.1.4 VEGF splice variant: 
Analysis of the human VEGF gene demonstrated that the protein coding regions are arranged in 
eight exons (Tischer et al., 1991). Alternative splicing of these exons generates at least five 
different mRNA for VEGF, which encode 121,145,165,189, and 206 amino acids respectively 
(Leung et al., 1989) (Keck et al., 1989) (Tischer et al., 1991) (Houck et al., 1991). An important 
56 
biological property that distinguishes these VEGF isoforms is their ability to bind heparin and 
heparan-sulphate. The VEGF 121 transcript, with exon 6 and 7 deleted, encodes aweakly acidic 
and free soluble polypeptide that fails to bind to heparin. The VEGF 145 transcript has the exon 7 
deleted but contains exon 6 (Charnock-Jones et al., 1993). The amino acids encoded by exon 6 
contain ä heparin binding domain and also elements that enable the binding of VEGF145 to 
extracellualr matrix (Poltorak et at., 1997). VEGF ßs5, with exon 6 deleted but including the 
cationic polypeptide sequence ncoded by exon 7, is a basic and heparin-binding form, and a 
significant fraction remains bound to the extracellular matrix. All VEGF 121,145 and165 are able 
to induce proliferation ofendothelial cells and in vivo angiogenesis (Park et at., 1993) (Zhang et 
al., 1995) (Poltorak et al., 1997). The full transcript, containing exons 1 to 8, encodes the VEGF 
189 isoform. The additional 17-amino acids insertion in VEGF 206 is encoded by a 51 base pair 
nucleotide sequence which begins at its 5' 
-end with GT, a consequence s quence for the 5'- 
splice donor site necessary for RNA processing (Houck et al., 1991). Both VEGF 189 and VEGF 
206 are secreted but are more basic than the other isoforms and are almost completely bound to 
the cell surface and the extracellular matrix (Houck et at., 1992) (Park et al., 1993). This may 
account for their observed lack of mitogenic activity on endothelial cells (Houck et at., 1992). 
However, the longer isoforms can be released by proteases after cleavage at the C-terminus, 
which generates an isoform comprised of the first 110 NI2-terminal amino acids of VEGF by 
plasmin (Keyt et al., 1996) or a 38 kDa fragment by urokinase (Plouet et al., 1997). This may be 
important in tumours where increased expression of proteases, uch as plasminogen activators 
(PA), has been reported. However, loss of heparin binding, by alternative splicing of RNA or 
plasmin cleavage, results In a decreased mitogenic activity for vascular endothelial cells (Keyt et 
al., 1996). All five isoforms of VEGF have been shown to posses vascular permeability activity as 
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demonstrated bythe Miles assay of dye extravasation a d mitogenic activity (Houck et al., 1991) 
(Poltorak et al., 1997). 
1.5.2 Regulation of VEGF: 
1.5.2.1 Regulation of Vascular Endothelial Growth Factor: 
Increased in vivo expression of endogenous VEGF has been documented in many pathological 
tissues (Brown et at., 1992) (Hashimoto et at., 1994) (Plate et at., 1992) (Shweiki et at., 1992) 
(Banal et al., 1994) (Detmar et al., 1994) (Peer et al., 1995). Moreover, increased expression of
VEGF receptor mRNA has also been demonstrated to be endothelial cell specific in the same 
tissues (Plate et al., 1992) (Brown et at., 1995a) (ruder et at., 1995) (Wizigmann-Voos et at., 
1995). This implies that the control of VEGF action is affected by both the expression ofVEGF 
and its receptors. 
1.5.2.2 Factors effecting the expression of VEGF: 
The female reproductive tract undergoes cyclical changes that are associated with extensive 
modification ofvascular structure, This provides an excellent in vivo environment for the study of 
angiogenesis. Sheweki et al (1993), utilising this phenomenon, reported that sex steroids either 
directly or indirectly effect VEGF expression i  mouse uterus and ovary. Using in situ hybridisation 
and immunostaining, they showed that during the menstrual cycle mRNA expression for VEGF 
increased in tandem with oestrogen and progesterone levels (Shweiki et al., 1993). Ovarian 
steroids and VEGF will be discussed further in this chapter, when the role of VEGF in the 
reproductive tract is considered. 
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Although physiologically the sex steroids have been shown to regulate xpression of VEGF, in 
pathological states hypoxia has been implicated inthis process (Shweiki et al., 1992) (Brogi et al., 
1996). Utilising Western Blot and RNAase protection assays to assess protein and mRNA 
production, Minhenko et al (1994) exposed cultured endothelial nd non-endothelial cells to 
hypoxic conditions and demonstrated that VEGF was significantly increased in all cell lines, 
except those of endothelia! origin, which showed only weak expression after 24 hours stimulation 
(Minchenko et al., 1994b). In contrast several other groups have demonstrated that endothelial 
cells on hypoxic stimulation increase VEGF production. Ladoux et al (1993) have identified 
transcripts for VEGF in hypoxic rat brain endothelial cells (Ladoux and Frelin, 1993) and Namiki et 
al demonstrated that cultured micro-and macro vascular endothelial cells require hypoxic 
exposure of up to 48 hours to reach maximum VEGF protein and mRNA expression (Namiki et al., 
1995). Comparison of Namiki et al results after 24 hours showed similar profiles to Minchenko et 
al (1994) with only a minimal increase in expression. From this they postulated that hypoxic 
driven angiogenesis i  a chronic adaptive process aimed at increasing perfusion to ischaemic 
tissues (Namiki et al., 1995). Another noteworthy aspect of their study was that microvascular 
endothelial cells behaved ifferently to macrovascular cells increasing their production of VEGF 
within 24 hrs. This may represent the fact that the human microvascular system requires a 
greater capacity to undergo vascular emodelling in response to hypoxic insults than the 
macrovascular system. This also emphasises the fact that the correct cell type should be 
examined when considering endothelial function. 
Several studies have extended these in vitro observations and examined the effect of hypoxia on 
VEGF production i  an in vivo system (Minchenko et al., 1994c) (ruder et al., 1995). Minchenko 
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et al (1994) demonstrated, utilising an RNAase protection assay, that hypoxia produced Increases 
in the expression of VEGF in rat organs such as the heart, liver, brain, kidneys, and muscle 
(Minchenko et al., 1994a) (Minchenko et at., 1994c). Tuder et at exposed rats to low oxygen 
tensions for varying periods using a barometric hamber. After exposure, lungs were rapidly 
harvested and using in situ hybridisation, VEGF production was shown to increase in a time 
dependent manner within alveolar epithelial cells. Northern Blot analysis was used to confirm 
their original qualitative observation effect (ruder et at., 1995). Acute hypoxic insults have also 
been examined in an isolated perfused rat lung system and these produced comparable results to 
chronic stimulus (Tuder et al., 1995). 
The cellular mechanism regulating VEGF expression has been postulated to be similar to that of 
the erythropoietin gene (Epo) (Minchenko et al., 1994c) (Namiki et al., 1995). The Haem protein 
acts as the oxygen sensing mechanism for the Epo gene. Haem undergoes structure changes on 
the binding of Co 2+ and Niet and this stimulates the production of Epo in an analogous manner to 
hypoxia (Goldberg and Schneider, 1994). Evidence to support this hypothesis provided from 
cell culture work, which demonstrates that the presence of cobalt chloride or nickel enhance 
VEGF expression (Minchenko et al., 1994c) (Namiki et al., 1995). 
A further mediator of transcriptional responses to hypoxia is hypoxia-inducible factor-1 (HIF-1), 
whose binding sites have been identified in the 5'-promoter ofthe rat and human VEGF gene (Liu 
et al., 1995) (Forsythe et al., 1996). The accumulation f adenosine under hypoxic conditions has 
also been shown to induce VEGF expression (Takagi et al., 1996). In addition to increased 
expression of VEGF by cells, it has recently been demonstrated that hypoxia causes increased 
mRNA stability (Ikeda et al., 1995) (Stein et at., 1995) (Levy et at., 1996b). Sequences that 
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mediate increased stability have been identified in the 3'-untranslated region of VEGF mRNA 
(Levy et al., 1996b). A hypoxia- induced protein, HuR, which binds to this region and stabilises 
VEGF mRNA, has also been identified (Levy et al., 1996a) (Levy et al., 1998). 
A variety of cytokines and growth factors have been shown to modulate VEGF expression in 
various cultured endothelial cells. Factors that can up-regulate VEGF expression and induce the 
release of VEGF protein include EGF (Goldman et al., 1993), TGF-a (Detmar et al., 1994), TGF 
- 
0 (Pertovaara et al., 1994), keratinocyte growth factor (KGF) (Frank et al., 1995), IL-1a (Ben-Av 
et al., 1995), IL-6 (Cohen et al., 1996), IGF-I (Warren et al., 1996), TNF-a (Ryuto et al., 1996). 
Additionally, some small molecules such as phorbol esters (Tischer et al., 1991) (Finkenzeller et 
al., 1992), prostaglandin Ei and E2 (Harada et al., 1994) have been shown to modulate VEGF 
expression. Another small molecule that up-regulates VEGF expression is nitric oxide, which is in 
turn up-regulated by VEGF (Chin et al., 1997) (Hood et al., 1998). 
1.5.3 VEGF receptors: biological function and regulation: 
1.5.3.1 VEGF receptors: 
Radiolabelling studies have identified high and low affinity binding sites for 1251-labelled VEGF Iss 
on various endothelial cells. The dissociation constants for these vary from 10-12 to 9x10-12 Mfor 
the high affinity receptor and 10-11 to 9x10-l lM for the low affinity receptor (Vaisman et al., 1990). 
Receptor densities have been established for both receptor types and range from 3,000-25,000 
for the high affinity receptor and 3,000-18,000 for the low affinity receptors (Vaisman et al., 1990). 
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Cross-linking experiments with VEGF 165 to bovine vascular endothelial cells show three high 
molecular weight complexes of 225,195,175 kD. From these weights it was deduced that the 
receptor sizes were in the order of 180,150,130 kd (Vaisman et at,, 1990) (Myoken et at., 1991). 
As VEGF shared a close structural homology to PDGF it was originally suggested they might 
share a common receptor system. However, this was proven to be incorrect with the 
demonstration that when mRNA for the fetal liver tyrosine-kinase (fit) like gene was expressed on 
the Zenopus oocyte and stimulated with VEGF it caused a five-fold increase in CO. efflux 
(Shibuya, 1990). These in vitro experiments upport but do not confirm the hypothesis that the fit- 
1 receptor is a native VEGF receptor. Subsequent receptor purification and cross-linking studies 
have demonstrated that the flt-1 receptor is VEGF specific on endothelial cells and receptor 
antagonists have confirmed this finding (Clauss et al., 1990). 
Alternative splicing of fit-1 pre-mRNA also generates at least hree soluble forms of this receptor 
that were first identified as a rare cDNA in an endothelial cell cDNA library (Kendall and Thomas, 
1993) (Boocock et al., 1995) (Kendall et al., 1996). Soluble fit-1(sfit-1) contains the six N-terminal 
immunoglobulin (1g)-like extracellular loops followed by a unique 31-amino acid residue C-terminal 
sequence (Kendall and Thomas, 1993). The protein encoded by this cDNA was also Identified in 
the conditioned medium of human umbilical vein endothelial cells (HUVEC) (Kendall et al., 1996). 
Kendall et at (1996) demonstrated that the sflt-1 binds VEGF with a high affinity (Kd 10-20 pM) 
and is able to inhibit VEGF-induced in vitro endothelial mitogensis at concentrations that are 
substoichiometric to VEGF (Kendall and Thomas, 1993). In addition to inhibiting VEGF binding to 
cell surface receptors by sequestering it, sflt-1 also forms dominant-negative heterodimers with 
full-length VEGF receptors, including dimerization with the mitogenically competent Kinase 
Domain Receptor (KDR) receptor (Kendall et al., 1996). 
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The Kinase Domain Receptor (KDR), a novel endothelial cell specific receptor of the tyrosine 
kinase gene family had previously been demonstrated by PCR techniques (Terman et al., 1992). 
Cross-linking experiments in an expression vector were used by Terman et al (1992) to establish 
that the KDR receptor was also specific for VEGF (Terman et al., 1992). The in vivo importance 
of VEGF in vasculogenesis and angiogenesis acting through the KDR receptor has been 
confirmed in mice (Millauer et al., 1993). 
The KDR and fit-1 receptors hare structural similarities. Both have been shown to be type III 
receptor tyrosine kinases with inserted kinase domains of similar length. Each has been 
demonstrated to contain seven extracellular immunoglobulin-like domains, which exhibit high 
sequence homology (Terman et al., 1992) (Shibuya, 1990). Heparin also appears to have a 
differential effect on VEGF 165 binding with enhancement to KDR expressing cells and inhibition to 
fit expressing cells (Gitay-Goren et al., 1992) (Terman et al., 1994). 
VEGF receptor expression was initially thought o be limited to the endothelium. However, 
several reports now refute this, with receptors being reported on leucocytes, melanoma cells, 
trophoblast and oesteoblasts (Clauss et al., 1990) (Gitay-Goren t al., 1993) (Shore et al., 1997a) 
(Athanassiades et at., 1998) (Bellamy et at., 1999). Although VEGF binding to these cells does 
not stimulate proliferation it has been demonstrated to confer other functional properties; 
monocyte chemokinesis and oesteoblast differentiation (Clauss et al., 1990) (Wang et al., 1997). 
63 
The first step in ligand-dependent activation of receptor tyrosine kinases is receptor dimerization 
and 'autophosphorylation' at specific residues which has been shown to involve mainly 
transphosphorylation of one receptor by its dimerized partner (Heldin, 1995). Presumably VEGF 
receptors are activated in a similar fashion, but there are as yet no studies of VEGF receptor 
activation, and the sites of phosphorylation in mammalian cells have not yet been mapped. The 
bacterially expressed cytosolic domain of KDR undergoes autophosphorylation at tyrosine 
residues 951,996,1054, and 1059 (Dougher-Vermazen t al., 1994). 
VEGF-activated ndothelial cell receptors phosphorylate s veral cytoplasmic proteins including 
some that contain receptor phosphotyrosine-binding SH2 domains and can participate in 
downstream signal transduction (Guo et al., 1995). These tyrosine-phosphorylated proteins 
include phosphatidylinositol 3-kinase, which phosphorylates phosphotidylinositols to produce two 
products; a phosporylated inositol ring and phospolipase C (PLC) (Guo et al., 1995) (Kroll and 
Waltenberger, 1997). VEGF, probably acting predominantly through KDR, activates the MAP 
kinase cascade and is able to stimulate the PLC-Y pathway leading to the generation of inositol 
1,4,5-trisphosphate, mobilization ofCa2+ from intracellular stores, and activation of protein kinase 
C (Xia et al., 1996). The differences inKDR and fit-1 signal transduction that account for disparity 
in mitogenic signal generation are not yet known. 
A third class of VEGF receptor has recently been characterised. This new class is a low affinity 
receptor that appears to be specific for VEGF 165 and has been isolated on endothelial cell and 
tumour cells (Soker et al., 1996). This has been demonstrated to be Neuropilin 
-1(Soker et al., 
1998), which has previously been identified to be a neuronal cell guidance receptor for the 
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collapsin / semaphorin family (He and Tessier-Lavigne, 1997) (Kolodkin et al., 1997). Soker et at, 
1998 demonstrated that that neuropilin was an isoform specific for VEGF 1s5, but not VEGF 121 
(Soker et at., 1998). It binds to VEGF 165 via the VEGF exon 7-encoded domain, with a Kd of 
about 2-3x 10-10 M (Soker et at., 1996). Neuropilin-1 has also been shown to bind to the heparin 
binding form of PIGF, PIGF-2 but not for PIGF-1 (Migdal et al., 1998). Neuropilin is expressed by 
endothelial and tumour cells, such as breast carcinoma, prostate carcinoma, and melanoma. 
Soker et al (1998) proposed that neuropilin-1 may not function as an independent receptor as no 
responses were obtained when cells expressing only this receptor were stimulated with VEGFI65 
(Soker et at., 1998). However, gene disruption studies have shown that in mouse embryos 
lacking functional neuropilin 
-1 genes the cardiovascular system fails to develop properly 
(Kawasaki et al., 1999). These observations led Soker et al 1998 to postulate that neuropilin was 
a VEGFIss co-receptor, Soker et at (1998) provided evidence to support this hypothesis by 
demonstrating that neuropilin 
-1 enhanced the binding of VEGF 165 to the KDR receptor, and that 
this binding enhanced chemotactic and mitogenic activity (Soker et al., 1998). 
1.5.3.2 Factors regulating expression of VEGF receptors: 
Biological responses to VEGF may depend on either the overall cellular expression of each 
receptor or the relative expression to each other, in a similar manner to VEGF itself (Chapter 
1.5.2). Receptor expression appears to be controlled by tissue oxygen tension. In 1996, Brodgi 
et al were the first to report a paracrine in vitro regulatory effect of hypoxia on the production of 
VEGF receptors (Brogi et al., 1996). They demonstrated that hypoxic conditioned media from 
smooth muscle cells caused a 13-fold increase of the KDR, but not the fit-1 receptor expression, 
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in cultured macro and microvascular endothelial cells. This response was evident within 4 hours 
and peaked at 24 hours. However, culturing endothelial cells in hypoxic conditions had no effect 
on KDR or fit-1 receptor expression. From this they concluded that the smooth muscle cells 
produced a soluble factor that evokes this response and hypothesised that this was cytokine 
mediated. However, direct stimulation with VEGF, TNF-alpha, TGF beta 1, BFGF or with 
antibodies to the cytokines, was unable to effect the KDR receptor expression (Brogi et al., 1996). 
Waltenberger t al, 1996 also examined the effect of hypoxia on cultured endothelial cells. 
However, they obtained contrasting results to Brodgi et al (1996). They demonstrated that 
endothelial cells cultured in the presence of low oxygen tensions exhibited up-regulation f KDR, 
but not fit-1 receptors (Waltenberger et al., 1996). Methodological differences may explain these 
observations, with Waltenderger et al using lower oxygen tensions than Brogi et al (1996). When 
the biology of VEGF is considered these differing results may produce a hypothesis. VEGF 
functions to enhance blood supply to oxygen deficient areas; as such a paracrine factor would be 
of benefit to enhance distal blood supply. However, if the oxygen tension in the distal tissues was 
to drop further, then a subsequent enhancement is required, and this may occur with the direct 
up-regulation f KDR by hypoxia. It has become apparent that individual vascular beds function 
differently and therefore results may be dependent on the endothelial cell which is studied. 
Cultured bovine retinal endothelial cells, which express only KDR receptors, exhibited own- 
regulation of these receptors with acute exposure to hypoxia assessed via Northern blotting 
(Takagi et al., 1996). This has also been demonstrated in an in vivo system, were transient 
ischemia in rats, produced by raised intraocular pressure, causes a down-regulation of both VEGF 
and KDR mRNA (Ogata et al., 1998). However, Takagi et al (1996) in their culture system, 
demonstrated that VEGF binding increased with chronic hypoxia, without an increase in the 
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mRNA expression. This indicates that post-translation events may also occur to increase 
membrane expression ofthe KDR receptor (Takagi et al., 1996). 
In vitro cell culture studies have demonstrated that KDR receptor membrane expression is oxygen 
sensitive. Tuder et al, used an animal model to examine the in vivo situation. Utilising Northern 
blotting they showed that exposure to both acute and chronic hypoxia increased in vivo 
concentration f the KDR receptor rat lungs (Tuder et al., 1995). Moreover, recently the role of 
hyperoxia has been demonstrated to control the expression ofboth the VEGF receptor types in rat 
lungs. Klekamp et al, 1999 showed that the expression ofVEGF, fit-1 and KDR were significantly 
decreased with chronic hyperoxia and postulated that this may explain the detrimental effects of 
oxygen therapy (Klekamp et al., 1999). 
Although ypoxia appears to be an important regulator of both VEGF and its KDR receptor, other 
substances have also been show to effect expression. Tumour Necrosis Factor a (TNF a) is one 
such substance. TNF a is an inflammation and neoplasia-associated cytokine that alters 
expression of many genes (Vilcek and Lee, 1991) and can promote or inhibit endothelial cell 
growth and angiogenesis, depending on the system under study (Kiagsbrun and D'amore, 1991). 
Patterson et al were the first to report TNF a effect on VEGF receptor expression. They initially 
demonstrated that VEGF-stimulated DNA synthesis was inhibited in a dose dependent manner by 
the addition of TNF a (Patterson et al., 1996). Further investigation of this process, utilising 
Northern Blot analysis, showed it to be secondary to the down-regulation of both the KDR and fit 
receptor transcription (Patterson et al., 1996). However, higher doses of TNF a have been 
observed to upregulate angiogenesis through increased expression of KDR receptor (Yoshida et 
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al., 1997) (Giraudo et al., 1998). Although the effect of TNF a on endothelial cell angiogenesis 
remains to be completely understood, it is evident that it may have a biphasic response, initially 
inhibiting proliferation and then enhancing it. 
Despite our incomplete understanding of the regulatory mechanisms of both VEGF and its 
associated receptors, it is evident that this process it complex and multifactorial in nature 
1.5.4 Other members of the VEGF family: 
Four VEGF-related proteins have been identified, these are PIGF, VEGF-bNRF, VEGF-CNRP 
and VEGF-D/ FIGF. 
1.5.4.1 VEGF-B: 
VEGF-B, also named VRF (VEGF-related factor), is a secreted protein but lacks consensus 
sequence for N-linked glycosylation. VEGF-B is thus unlike other members of this family 
(Olofsson et at., 1996b). Two alternatively spliced forms have been identified, with 167 and 188 
amino acid residues (Olofsson et al., 1996b). VEGF-B forms disulphide-linked homodimers, and 
is able to form heterodimers with VEGF when co-expressed (Olofsson et al., 1996b) (Olofsson et 
at., 1996a). However, it has not been established if naturally occurring VEGFNEGF-B 
heterodimers exist. VEGF-B binds to fit-1, but not to KDR and fit-4 receptors (Olofsson et at., 
1996a). Recombinant VEGF-B157 stimulates thymidine incorporation i to DNA in human umbilical 
vein endothelial cells and bovine capillary endothelial cells, suggesting that it is an endothelial 
mitogen (Olofsson et at., 1996a). However, VEGF-B186 homodimers have no detectable 
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mitogenic activity on endothelial cells (Olofsson et al., 1998). VEGF-B is primarily expressed in 
the skeletal muscle and myocardium as a membrane-bound protein which can be released by 
heparin, and is co-expressed with VEGF in many tissues (Olofsson et al., 1996a). VEGF-B is also 
expressed in human placenta (Vuorela et al., 1997), human granulosa-luteal cells (Laitinen et al., 
1997), and most tumours analysed (Salven et al., 1998). Expression of VEGF-B is not responsive 
to hypoxia, and its mRNA was found to be unusually stable (half-life more than 8 hours), 
suggesting chronic rather than acute regulation (Enhoim et al., 1997). 
1.5.4.2 VEGF-C; 
VEGF-C, also named VRP (VEGF related protein), is a secreted protein with 339 amino acids 
residues and has a 32% identity to VEGF (Joukov et al., 1996) (Lee et al., 1996). It is a ligand for 
fit-4 (Pajusola et al., 1994) (Mustonen and Alitalo, 1995), and KDR (Joukov et al., 1996). VEGF-C 
stimulates the growth of human lung endothelial cells but with less potency than VEGF165, and the 
migration of bovine capillary endothelial cells in collagen gel (Joukov et al., 1996). VEGF-C, like 
VEGF, is also a vascular permeability factor (Joukov et al., 1996). 
The expression of VEGF-C is associated with the development of lymphatic vessels. Its mRNA 
was detected in mesenchymal cells of post-implantation mouse embryos, particularly in the 
regions where the lymphatic vessels undergo sprouting from embryonic veins, and in the adult 
mouse lung, heart and kidney, where flt-4 was also predominant (Kukk et al., 1996). Expression 
of VEGF-C has also been demonstrated in human placenta (Vuorela et al., 1997), human 
granulosa-luteal ce ls (Laitinen et al., 1997), CD 34 + cells, platelets and T-cells (Wartiovaara et 
al., 1998). Cytokines, including interleukin (IL)-1a, and tumour necrosis factor-a, can induce 
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VEGF-C expression (Ristimaki et al., 1998). Hypoxia, which is an important inducer of VEGF 
expression, has no effect on VEGF-C expression (Enhoim et al., 1997). 
1.5,4.3 VEGF-D: 
VEGF 
-D, also called FIGF (c-fos-induced growth factor), a new member of the VEGF family and 
closely related to VEGF-C, is a mitogen for fibroblasts and endothelial cells (Orlandini et al., 1996) 
(Yamada et at, 1997). It can activate KDR and fit 
-4, but does not bind to fit-1 (Achen et at, 
1998). In adult human tissues, VEGF-D mRNA is mainly expressed in heart, lung, skeletal 
muscle, colon and small intestine (Yamada et al., 1997) (Achen et al., 1998). 
1.5.4.4 Placental Growth Factor: 
Placenta growth factor was first described in 1991 (Maglione t al., 1991). At that time it was 
thought to be specific to placenta nd as such was termed Placenta Growth Factor (PIGF). This 
is now known not to be the case as several tumour cells, including renal cell carcinoma nd 
thyroid tumours, express it (Viglietto et al., 1997). 
Structure of Placenta Growth Factor: 
Placenta Growth Factor (PIGF) is a 149-amino acid sequence protein which when analysed 
demonstrates a sequence homology of 53% to VEGF. This increases to 71% when the 
conserved amino acids are considered (Maglione t al., 1991). These observations led to the 
inclusion of PIGF in the VEGF family of proteins. PIGF's have been shown to be dimeric 
glycoproteins that contain N-terminal hydrophobic secretory leader sequences, which promote 
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active secretion. PIGF gene contains 7 exons that can generate three alternatively spliced forms, 
PIGF 149,170 and 221 (also called PIGF 
-1, -2 and -3) (Maglione et al., 1993) (Cao et al., 1997). 
PIGF has high affinity binding to the flt-1 receptor with the Kd in the range of 100-200 pM, but not 
to the KDR receptor (Park et al., 1994). 
Observations of molecular mass indicate differences in the secondary structure of PIGF and 
VEGF. PIGF contains two extra carbohydrate moieties as compared to VEGF, which contains 
only one. This difference in secondary structure may account for the proposed variations in the 
function of PIGF as compared to VEGF. PIGF has been established as a dimeric structure similar 
to VEGF and has recently been demonstrated to form dimers with VEGF in vitro and in vivo 
(Maglione et at., 1991) (DiSalvo et al., 1995). This only serves to highlight the emerging 
similarities between VEGF: PIGF and may account for differing biological functions. 
PIGF Receptors: 
The close sequence homology between VEGF and PIGF led to the hypothesis that these two 
growth factors may initiate their biological function through the same receptor system. Kendel et 
at (1994) demonstrated that like VEGF, PIGF was capable of binding to the fit-1 receptor but was 
unable to bind the KDR receptor system (Kendall et at., 1994). Park et at (1994) showed that 
PIGF, although capable of binding to the fit-1 receptor was unable to initiate a stimulus via 
tyrosine phosphorylation. However, they demonstrated that below threshold concentrations of 
VEGF in the presence of equimolar PIGF-1 initiated both permeability and mitogenicity and 
concluded that PIGF-1 had a regulatory effect. This effect of PIGF on VEGF is not synergistic, as 
it is smaller than the maximal effect of VEGF alone. The authors postulated that the binding of 
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VEGF to the fit-1 receptor may act to reduce its the biological activity, in an analogous manner to 
the interleukin system, with fit-1 receptor acting as a decoy and possessing no biological activity. 
However, they fail to appreciate that the binding kinetics of VEGF and PIGF-1 are similar and that 
for this system to operate effectively, the PIGF-1 constant would have to be large in comparison to 
VEGF. This then allows for adequate displacement of VEGF from the fit-1 receptor. Moreover, 
PIGF-1 produced by eukaryotic ells has recently been demonstrated to induce angiogenesis in 
the rabbit cornea and chick chorioallantoic membrane assays and also has a high mitogenic effect 
on cultured endothelial cells (Ziche et al., 1997). PIGF in these assays was demonstrated to be 
as potent as VEGF (Ziche et al., 1997). The authors suggested the observed differences were 
due to human recombinant PIGF-1 lacking the two carbohydrate moieties. This is supported by 
the finding that PIGF-1 stimulates MAP kinase and mitogenicity of porcine aortic endothelial cells 
expressing fit-1 in vitro (Landgren et al., 1998). 
PIGF transcripts are expressed abundantly by villous trophoblasts of human term placenta (Khaliq 
et al., 1996) (Vuorela et al., 1997) (Shore et al., 1997b) (Clark et al., 1998b). Expression of PIGF 
was also detected in human vascular endothelial cells (Barleon et al., 1994), and in lower levels in 
adult heart, lung and skeletal muscle (Maglione et at., 1991) (Maglione t at., 1993), The exact 
roles of PIGF in vivo remain to be determined. However, in contrast to VEGF, PIGF expression 
was found to be down-regulated by hypoxia in vitro (Shore t al., 1997b). 
72 
1.5.5 General Biological functions, *, 
1.5.5.1 Stimulation of proliferation of endothelial cells: 
VEGF stimulates cell growth in a variety of endothelial cells, examples of which include human 
umbilical vein endothelial cells, bovine aortic, adrenal tissues (Connolly et al., 1989a) (Ferrara nd 
Henzel, 1989) (Plouet et al., 1997). It also stimulates tubular formation of endothelial cells in 
Matrigel and Collagen gel assays (Connolly et al., 1989a) (Goto et al., 1993). Although the 
process of angiogenesis in vivo is known to be a complex one, there is accumulating evidence to 
suggest that VEGF is a direct angiogenic factor in vivo as well as in vitro. 
1.5.5.2 Increase in vascular permeability: 
Senger et al (1993) demonstrated that VEGF was a permeability factor (Senger et al., 1983). 
They showed that ascitic fluid from cancer patients stimulates an increase in blood vessel 
permeability when assessed using the Miles assay. 
VEGF acts to induce increased permeability atconcentrations of I nM; this is significantly lower 
than other known vascular permeability factors, such as bradykinin or substance P (Connolly et 
al., 1989b). VEGF has been shown to be unique among angiogenic and permeability factors, by 
possessing the ability to induce both responses (Connolly, 1991). VEGF induces a transient 
increase in vessel permeability which lasts for a maximum of thirty minutes (Wu et al., 1996) 
(Bates and Curry, 1996). Recently, VEGF has been shown to have both a transient and chronic 
effect on vascular permeability. 
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Using frog mesenteric vessels, Bates et at (1996) examined the time effect of a single VEGF 
exposure on vascular permeability. They noted a transient increase in permeability that subsided 
after thirty minutes to a base line. Examination of permeability after twenty-four hours 
demonstrated a subsequent i crease in permeability that lasted a further twenty-four hours (Bates 
et al, 1996). The authors explained this by considering two possible mechanisms. Firstly, VEGF 
being a mitogenic trigger might enhance vascular permeability via induction of mitosis. It has 
been previously shown that endothelial cells increase their vascular permeability on entering 
mitosis (Lin et al., 1988). Secondly, the exposure of cells to VEGF causes fenestrae formation 
(Roberts and Palade, 1995) and it was this that caused the increased permeability. Both these 
explanations are possible as they occur over a similar course of time. However, the authors fail to 
appreciate that fenestrae formation may be a secondary event to the process of mitosis. 
The subcellular mechanism for this effect has been postulated to be nitric oxide mediated as 
permeability effects are lost with prior exposure to nitric oxide synthase inhibitors (Wu et al., 
1996). The role of nitric oxide in the function of VEGF remains to be elucidated. 
1.5.6 VEGF and its function in reproductive bioiogy: 
1.5.6.1 VEGF and placental expression: 
Poor placental development and the subsequent failure of trophoblast invasion into the maternal 
decidua have been associated with intrauterine growth retardation and pre-eclampsia (Brosens et 
at., 1970) (Fox, 1986) (Meekins et al., 1994). This association implicates abnormal placental 
angiogenesis as pivotal in the pathology of these diseases. This led to the Investigation of
cytokines in placental development. 
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There are several reports that have tried to address this important question. Studies have 
investigated the expression of VEGF using the polymerase chain reaction (PCR) with similar 
results. Sharkey et al, (1993) demonstrated that four isoforms of VEGF were expressed by the 
human placenta, VEGF 121, VEGF 145, VEGF 165, VEGF 198 (Sharkey et al., 1993). Anthony et at, 
used a two round PCR protocol to confirm this finding, along with the addition of a further VEGF 
zos isoforms (Anthony et at., 1994). This discrepancy may have arisen from the different PCR 
protocols employed (Anthony et al., 1994). However, examination f the most abundant form has 
yielded contradictory esults. Initially, using Western Blot analysis, VEGF 121 was reported to be 
the primary expression product (Houck et at., 1991). Anthony et at (1994) obtained results from 
cultured placental tissues that suggested that VEGF 165 predominated. However, there are several 
methodological differences that may explain these differences. Removal of placental tissue from 
its regulatory hormone milieu may have profound effects on VEGF 121 expression and produce 
inconclusive r sults. From data in the literature, it is apparent that VEGF 121 is the most abundant 
form. 
It is evident that the human placenta produces various amounts of all the VEGF isoforms, with the 
VEGF 121 predominating. However, the functions of the different isoforms within the 
uteroplacental environment remain to be determined. 
In situ hybridisation for VEGF mRNA has shown that in first trimester human placentae, 
expression was limited to the cytotrophoblast and syncytiotrophoblast surrounding the vilii 
(Sharkey et al., 1993). However, in term placentae mRNA changed and was confined to the 
syncytiotrophoblast, extravillous trophoblast and maternal macrophages (Sharkey et al., 1993). 
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The differing spatio-temporal observations of VEGF in early and late gestation placenta indicate 
that VEGF may play a role in both placental development and endothelial maintenance. Using an 
immuniohistochemistry technique, these original observations have been confirmed, with the 
VEGF protein localised in the first trimester to cyto and syncytiotrophoblast and as gestation 
progressed to syncytiotrophoblast only (Barleon et al., 1994). 
1.5.6.2 VEGF and Pre-eclampsia: 
The role of angiogenic growth factors in the pathogenesis of pre-eclampsia h s been advocated 
since Taylor et al (1990) demonstrated that the plasma of women with pre-eclampsia produced a 
mitogenic response on incubation with cultured fibroblast, but not endothelial cells (Taylor et al., 
1990a). Since this report several others have observed that the plasma from women with pre- 
eclampsia is indeed mitogenic for cultured endothelial cells, assessed both with increased 
incorporation thymidine and cell number (Endresen et al., 1995). This difference in results may 
stem from the fact that Rodgers et at used human umbilical vein endothelial cells that were not 
primary cultures. It has been demonstrated that various cytokines have no mitogenic effect on 
endothelial cell lines (Cines et al., 1998). Taylor et at (1990) partially characterised their novel 
growth factor via acid treatment and protein filtrates and determined it to be In the order of 160 kd. 
However, to date no further characterisation f this factor has been produced in the literature. 
The observation that plasma from women with pre-eclampsia has a mitogenic action led Baker et 
al (1995) to investigated the possible role of VEGF in the pathophysiology of pre-eclampsia 
(Baker et al., 1995b). They demonstrated that serum from women with pre-eclampsia had 
significantly increased concentrations of VEGF compared to normotensive controls. However, 
this study Is not without limitation. VEGF levels were only detected in 10 out of 78 women 
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sampled, with the rest below the limit of detection of the assay. Therefore, whether VEGF is 
increased in pregnancies complicated by pre-eclampsia nd its role in the pathogenesis of this 
disease remains to be elucidated. 
77 
Chapter Two: Materials and Methods: 
The following chapter will describe the methods utilised in this thesis and the validation 
experiments that were performed to ensure that results were consistent. In Chapter 3 the pilot 
data and final protocol designs will be discussed. Individual chapters will contain experimental 
design. Demographic details of patients will be displayed as Tables to the relevant chapters. 
2.1 Materials 
All chemicals were supplied by Sigma, Poole, Dorset, UK unless otherwise stated. 
2.2: Blood sample collection: 
2.2.1 Ethical approval: 
All of the blood and tissue samples used during the course of this project were collected from 
Nottingham City Hospital. The local ethics committee approved this study prior to its 
commencement a d all subjects gave written, informed consent. 
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2.2.2. Blood samples: 
2.2.2.2 Preparation of plasma: 
Venous blood samples were taken within 24hrs of admission and were collected from nulliparous 
women diagnosed with pre-eclampsia (see Chapter 1.1.1). Patients that received 
antihypertensive th rapy were excluded, preventing any bias occurring within this group. To act 
as controls, blood was collected from gestation-matched normotensive pregnant women without 
complications of pregnancy or underlying illness. Blood samples were collected from the median 
cubital vein through an 18 gauge needle into pre-cooled glass tubes containing EDTA 
(Beckington, UK) using a Vacutainer®. Blood was then immediately transferred tothe laboratory 
on ice and centrifuged at2,500 revolutions per minute for 15 minutes at a constant temperature of 
4°C. Once centrifuged, 500pl aliquots of plasma were placed into Eppendorff tubes (Anachem- 
Scotlab; Luton, UK) and then stored at 
-80°C until use. 
The use of plasma in experimental protocols avoids the confounding variable of cellular products, 
which are released into serum during blood coagulation. These would only complicate an already 
diverse metabolic process and may produce in vitro alterations that are not relevant to the in vivo 
situation (Fox and DiCorleto, 1984). 
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2.2.2.2 Generation of serum for cell culture: 
Blood samples were collected from normotensive women of varying estations and parity who 
attended Nottingham City Hospital antenatal c inic for routine antenatal care. Blood samples were 
collected through an 18 gauge needle into pre-cooled glass tubes (Beckington, UK) using a 
Vacutainer®. Blood was then immediately transferred to the laboratory on ice and left to clot at 
4°C for 3 hours. After this time samples were centrifuged as described in Chapter 2.2.2.1. Once 
centrifuged, serum samples taken on the same day were pooled and placed into universal 
containers (Sterilin, UK) in 5 ml aliquots and then stored at 
-80°C until use. 
2.2.3 Removal of VEGF from plasma using Dynabeads: 
Dynabeads are uniform, monodisperse polymer particles, which are coated with a thin polymer 
shell to encase a magnetic material and provide a defined surface area for the adsorption or 
coupling of various molecules. The polymer contained within the beads is superparamagnetic, in 
that it exhibits magnetic properties only when placed within a magnetic field. This property allows 
their use in the isolation of specific proteins or cells. 
The beads are coated with a specific ligand for the cell or protein under consideration. They are 
then added to the heterogeneous suspension to bind to the target molecule. The resultant 
complex can be removed from the suspension by placing within a magnetic field (the Dynal MPC). 
In this field the beads become magnetised; the suspension can then be removed leaving the 
target molecule. 
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Dynabeads were coated with VEGF antibody according to manufacturers instructions (see 
appendix I). The coated Dynabeads were placed in the Dynal MPC and washed four times: twice 
in PBS/BSA (pH 7.4 for 5 minutes at 4°C), once in Tris/BSA (pH 8.0 for 4 hours at 37°C), and 
once in PBS/BSA (pH 7.4 for 5 minutes at 4°C). 
The tube containing the pellet of washed Dynabeads was removed from the Dynal MPC, I ml of 
pooled plasma (see Chapter 8.3) from women with pre-eclampsia w s added, and the Dynabeads 
were gently re-suspended. The bead-sample mixture was then rotated for 120 minutes at 4°C, 
after which time it was placed in the Dynal MPC, the supernatant being removed and stored until 
required at 
-80°C. 
2.3.1 Vascular Endothelial Growth Factor Assay: 
The assay used in this thesis was developed by Anthony et al (1997). The author spent several 
periods of time at the University of Southampton with Dr F. W. Anthony performing the assay and 
validating it for this thesis (Anthony et aL, 1997). 
2.3.1.1 Radioimmunoassay: 
Recombinant human VEGF 165 (Genetech; Code M3-RD280, U. S. A) was used as the standard 
and the tracer. VEGF was labelled to a specific activity of 35 mCi/mg with 125 f using a modified 
chloaramine t method of iodination (Dr FW Anthony). 100 pl aliquots of standards (0.2 to 50 
Ng/L) were produced in a solution of 0.05 M phosphate buffer (pH=7.4) containing 5% bovine 
serum albumin (BSA) by serial dilution from a stock solution of 100 µg/L. 
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All standards and samples were measured in triplicate. 200 µl of the standards (0.2 to 50. tg1) 
and plasma samples were aliquoted into LP3 tubes (LIP Ltd, UK) to which 200pL of radioactive 
tracer (30 000 c. p. m in 0.2% BSA in phosphate buffer containing 200 ug/mL heparin) and 200 NL 
of rabbit polyclonal ntiserum to VEGF (Genetech: Lot No 11094-70B, diluted l in 20 000 in 0.2% 
BSA in phosphate buffer) was added. Following overnight incubation, 100pL aliquots of Sal-cel 
donkey anti-rabbit coated cellulose suspension (Code AA-SACI, DS, Tyne and Wear. UK) were 
added to all tubes, which were then incubated at room temperature for thirty minutes. After 
incubation I mi of distilled water was added and tubes centrifuged at 1500g for 15 minutes. After 
decantation the radioactivity ofthe pellets was counted and analysed by computer using the RIA- 
CALC, LKB-Wallac package (see Fig 2.1). 
2.3.2 Validation of the assay: 
Although Anthony et al (1997) have previously validated this assay, several experiments were 
performed to confirm these characteristics in the hands of the author of this thesis (Anthony et al., 
1997). 
2.3,2.1 Reproducibility: 
The reproducibility of the assay method was calculated from a plasma standard (pooled plasma 
from normal pregnant women) aliquoted and stored at 
-800 C until required, The inter-assay 
variation was evaluated from measuring the plasma standard in thirteen consecutive experiments. 
The intra-assay variation was calculated from eight measurements in the same experiment. 
Fig 2.1 
The standard curve for the calculation of the 
production of Vascular Endothelial Growth 
Factor (VEGF) 
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Mean (µg/1) +/- S. D Coefficient of variation 
Intra-assay 4.02 +1- 0.19 4.81% 
Inter-assay 3.22 +/- 0.19 5.97% 
2.3.2.2 Sensitivity: 
The sensitivity is defined in terms of the slope of the dose-response curve, and is the detection 
limit of the assay. A significant difference was shown between the percentage binding of the 
lowest standard (0.2µg/ml) and the zero binding levels (t-test, p=0.015, n=3). 
2.3.2.3 Specificity: 
Anthony et al, demonstrated that their assay has no cross-reactivity with the closely related 
placenta growth factor (PIGF), or basic fibroblast growth factor (bFGF) and is not influenced the 
addition of a2-macroglobulin at a concentration of 100mg/L; this pilot work was therefore not 
repeated (Anthony et al., 1997). 
VEGF 100% 
PIGF 0% 
BFGF 0% 
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2.4. Reverse Transcription Polymerase Chain Reaction (RT"PCR): 
2.4.1 Sample collection: 
It was also wished to study the expression of VEGF and its associated receptors in the feto- 
matemal unit of control pregnancies and those complicated by pre-eclampsia. The feto-maternal 
unit comprises two major components, the placenta nd the myometrium. 
Therefore, biopsies of placentae from women with pre-eclampsia were taken along with 
normotensive controls. Once the attending midwife had examined the placenta, a1 cm-cube 
biopsy of the placenta was dissected using scissors from the centre of the placental bed. Samples 
were then immediately frozen in liquid nitrogen and stored a 
-80°C until use. 
Uterine biopsy samples were obtained from women undergoing elective Caesarean section. For 
inclusion, patients had no hypertensive or growth complications in their present or previous 
pregnancies and had no other medical complications. At Caesarean section, following delivery of 
the placenta, a full thickness biopsy of myometrium was obtained from the upper margin of the 
incision. Samples were then immediately frozen and stored in liquid nitrogen until use. In a similar 
manner, samples were also collected from women diagnosed with pre-eclampsia. 
Biopsies were also collected from non-pregnant women of reproductive age undergoing 
abdominal hysterectomies fornon-malignant causes. Once the specimen had been removed, the 
anatomical rea above the cervix was incised and a piece of full thickness myometrium removed 
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and frozen in liquid nitrogen. The area removed is analogous to the lower segment in late 
pregnancy 
2.4.2 Sample preparation: 
Powdering samples: 
Myometrial nd placental biopsies were ground into a powder using a powdering un and metal 
pestle. All samples were powdered under liquid nitrogen so as to reduce RNA degradation. Once 
samples had been powdered they were stored in liquid nitrogen until RNA extraction. 
2.4.3 RNA extraction: 
RNA extraction was achieved using a commercially available kit (Purescript RNA Isolation Kit; 
Gentra Systems, Inc. USA). RNA extraction was carried out as detailed in the manufacturers 
instructions. The manufacturers RNA handling recommendations were adhered to, working in as 
far as possible an RNAase free environment. This was achieved by performing RNA extractions in 
a laminar flow hood, and using machine packaged sterile plasticware. 
2.4.3.1 Protein-DNA precipitation: 
50-100 mgs of powdered sample was weighed out into a sterile 1.5 ml Eppendorff tube 
(Anachem-Scotlab; Luton, UK). 1 ml of protein-DNA precipitation solution (Gentra Systems, Inc. 
USA) was then added to the powdered sample. The tube was then gently inverted ten times and 
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placed on ice. The solution was centrifuged at15,000xg for 5 minutes, during which time the DNA 
and protein precipitated out and formed a pellet. 
2.4.3.2. RNA precipitation: 
The supernatant, which contains the RNA, was aliquoted equally into three 1.5 ml Eppendorff 
tubes (Anachem-Scotlab; Luton, UK). To these 1 ml of 100% isopropanol was added and mixed 
thoroughly by gentle inversion of the tube 50 times and placed in a freezer at 
-200C for 2 hours. 
The solution was then centrifuged at 15,000x g for 5 minutes. The RNA was then visible as a 
small, translucent pellet. The supernatant was poured off, and the RNA washed with 1 ml of 70% 
ethanol. This solution was then centrifuged at 15,000x g for 2 minutes and the ethanol poured off. 
The tube was then inverted onto clean absorbent paper and allowed to air dry for 15 minutes. 
2.4.3.3 RNA hydration: 
The air-dried tubes were then placed on ice and 500µI RNA hydration solution (Gentra Systems, 
Inc. USA) was added and allowed to rehydrate for 30 minutes. Once rehydrated, RNA was stored 
at 
-80°C. 
2.4.4 Reverse transcription 
cDNA was then generated from the total RNA using a commercially available reverse transcription 
kit (Reverse-iT, 1St strand synthesis kit; Advanced Biotechnologies: UK). 
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20 of total RNA template was pipetted into a thin walled PCR tube (Anachem-Scotlab; Luton, 
UK). 1µl of anchored oligo dT (Advanced Biotechnologies; UK) was added to the RNA template; 
this was then made up to a final volume of 12 µl with molecular biology grade water (BDH, Poole, 
UK). The PCR tube was then placed in a heating block (MJ Research PTC-200 DNA Engine). To 
remove any secondary structure, the reaction mixture was heated to a temperature of 70°C for 5 
minutes and then cooled to 4°C. Reverse transcription was achieved using 1µI of murine- 
monoclonal leukaemia virus (M-MLV) reverse transcriptase (Advanced Biotechnologies). This was 
performed in the presence of 4µI of 5x Ist strand synthesis buffer, 2µI deoxynucleotide 
triphosphate (dNTP) mix (5mM), and 141 of RNAase inhibitor. The mixture was incubated at 42°C 
for 1 hour to allow cDNA synthesis. Incubating the solution at 90°C for 10 minutes terminated the 
reverse transcription. This cDNA produced was then stored at 
-200C for subsequent use. 
2.4.5 Polymerase chain reaction (PCR): 
The original description of the polymerase chain reaction (PCR) was by Saiki et al (1985) (Salk! et 
al., 1985). It relied on the observation that the enzyme DNA polymerase xtends DNA in 
Escherischia coli (E. Coli) (Bambara et al., 1978). Utilising two oligonucleotide s quences as 
primers and catalysing the reaction with DNA polymerases they were able to generate synthetic 
DNA. This technique was rapidly confirmed and extended (Mullis et al., 1986) (Mullis and 
Faloona, 1987). However, early PCR was inhibited by the use of E. Coli DNA polymerase I to 
catalyse the extension of the annealed primers. This is heat intolerant, and as protocols require 
heating to high temperatures, each round of synthesis required the addition of fresh enzyme. This 
was overcome with the incorporation of the heat stable DNA polymerase from the thermophilic 
bacterium Thermus aquaticus (Taq polymerase) into PCR protocols. This enzyme has been 
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demonstrated to be stable up to temperatures of 950C and replacement on every round of 
annealing is not required. The use of increased annealing temperatures has decreased 
mispriming and increased the purity of long fragment products (Saiki et al., 1988) (Holland et al., 
1991). PCR amplification of DNA was achieved using oligonucleotide primers. These are short 
stranded DNA molecules that are complementary to a defined sequence of the DNA template. 
The annealing of primers to the specific region of a single strand of DNA to be amplified is crucial 
for the initiation of a new DNA molecule (Watson et al., 1992). The primers are extended on single 
strand DNA template by the enzyme Taq DNA polymerase in the presence of dNTPs under 
suitable reaction conditions (Watson et al., 1992). The synthesis of new strands can be repeated 
by heat denaturation of double strand DNA, annealing of primers by cooling the mixture, and 
extension by setting a suitable temperature for the enzyme reaction. 
The expression of ß- actin was used as a positive control to check that the PCR technique was 
working and the reverse transcription was successful. In addition the ß-actin was used in the data 
analysis which will be discussed inChapter 5. 
The same PCR protocol was employed for the different molecules tudied. 2µI of cDNA was 
amplified using a ready load master mix (22.5µI), which contained Mg Cl 2 (2mM), a mixture of 
dNTPs and Taq DNA polymerase (Advanced Biotechnology) and 0.25µ1 of each primer (sense 
and antisense). The PCR was carried out using a thermal cycler (PCR system PTC-200 Peltier). 
The conditions and the primers used for each molecule are as follows; 
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2.4.6 Primers: 
0-actin: ß-actin mRNA was amplified using the primers; Sense (5'-AAG GAT TCC TAT GTG 
GGC-3'); and the Antisense (5'-CAT CTC TTG CTC GAA GTC-3') under the following conditions: 
950 C for 1 minute and 30 seconds, then 950 C for 30 seconds, 540 C for 130 seconds for a total 
of 9 cycles then 720 C for 10 minutes. The reaction was terminated by cooling to 40 C. 
VEGF: A nested PCR (two round PCR) was used for the amplification f the VEGF mRNA using 
the previously described primer pairs I and J, and C and H (Boocock et al., 1995). The first round 
of amplification was performed using the primers I: (Sense 5'-GGC TCT AGA TCG GGC CTC 
CGA AAC CAT-3'); and J (Antisense 5'-GGC TCT AGA GCG CAG AGT CTC TTC-3') under the 
following conditions: 950C for 1 minute and 30 seconds, 950C for 30 seconds, 6000 for 30 
seconds, 720C for 1 minute for a total of 34 cycles then 720C for 10 minutes. In the second round, 
the cDNA was amplified with the pair of primers C (Sense 5' 
--GAC TGT GTG CCC ACT GAG 
GA-3') and H (Antisense 5'-GGC TCT AGA TCA CCG CCT CGG CTT GTC AC-3') under the 
conditions: 950C for I minute and 30 seconds, then 9500 for 30 seconds, 640C for 30 seconds, 
720C for 1 minute and repeated for a total of 30 cycles then 720C for 10 minutes. Cooling to 40C 
terminated the reaction. 
PIGF: PIGF mRNA was amplified using the primers (Sense 5'-AGA TGC CGG TCA TGA GGC 
TGT-3') and (Antisense 3'-GTT ACC TCC GGC GAA CAG CA-3'). The reaction was held at 950C 
for 1 minute and 30 seconds the PCR was performed for 9 cycles of denaturation at 950C for 30 
seconds, annealing at 620C for 30 seconds and extension at 720C for 1 minute. This was followed 
by a final extension at 720C for 10 minutes. Cooling to 40C terminated the reaction. 
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Flt-1: Flt-1 mRNA was amplified using the primers (5'-GTC ACA GAA GAG GAT GAA GGT GTC 
TA-3') and the antisense primers (5'-AGC CAC AGT CCG GCA CGT AGG TGA TT-3') (Boocock 
et al., 1995). The reaction was held at 950C for 1 minute and 30 seconds, denatured at 950C for 
30 seconds, annealing at 620C for 30 seconds and extension at 720C for 1 minute. This was 
followed by a final extension at 720C for 10 minutes. Cooling to 40C terminated the reaction. 
KDR: A nested PCR was used for the amplification of the KDR cDNA. A two round PCR was 
performed using the primers C (Sense 5'-CAT CAC ATC CAC TGG TAT TGG-3') and D 
(Antisense 5'-GCC AAG CTT GTA CCA TGT GAG-3') (Boocock at al., 1995) under the following 
conditions: 950C for 1 minute and 30 seconds, the 950C for 30 seconds, 590C for 30 seconds, 
720C for 1 minute for a total of 29 cycles then 720C for 10 minutes. The reaction was terminated 
by cooling to 4°C. 
Products were visualised on 1% agarose gel stained with ethidium bromide and viewed under 
ultraviolet light (Fig 2.2,2.3,2.4). 
2.4.7: Analysis of the data: 
Optical densitometry of the bands following PCR were measured using Aida software in a 
luminescent image analyser PC (Science Systems, Fuji Photo film, UK). The expression of the 
housekeeping genes is assumed to be similar in the same tissue type between different 
individuals. Based on this assumption, ß-actin was used as an index for the comparison of the 
expression ofVEGF, PIGF, KDR and fit-1 in the placental and myometrial samples. Since PCR 
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VEGF, PIGF, Flt-1, KDR and ß-actin 
KDR 
Fft-I 
PIGF 
VEGF 
B-actin 
Fig 2.2 
400 bp 
200 bp 
300 bp 
Fig 2.3 
RT-PCR of normal pregnant myometrial samples for 
VEGF, PIGF, Flt-1, KDR and ß 
-actin 
KDR 4 400 bp 
FR-1 
PIGF 
VEGF 
B-actin 
200 bp 
300 bp 
200 bp 4- 
300 bp 
4 400 bp 
Fig 2.4 
RT-PCR of myometrial samples from women with 
pre-eclampsia for VEGF, PIGF, Flt-1, KDR and 
ß-actin 
KDR 
Fn-1 
PIG[ 
VEGF 
B-actin 
400 bp 
200 bp 
300 bp 
400 bp 
300 bp 
f-- 200 bp 
4 100 bp 
90 
for each sample was performed in triplicate and optical densitometry assumed to be not normally 
distributed, the median of the ratios and the range of the optical densitometry ratios were 
calculated. 
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2.5: Isometric myographyft. 
2.5.1 Introduction: 
An improved understanding of contractile function of resistance vessels has come about with the 
technique of myography. Bevan and Osler first detailed isometric myography (Bevan and Osher, 
1972), which utilises the scaled down organ bath first described by Dale in 1914. Blood vessels 
are mounted on two wires, one attached to a force transducer and the other to a displacement 
device. This set-up allows the simultaneous measurement of the contractility of isolated small 
arteries to agonist stimulation. 
2.5.2 Resistance vessels studied-collection and dissection: 
2.5.2a Uterine biopsy samples: 
Uterine biopsy samples were obtained from women undergoing elective Caesarean section as 
described previously (Chapter 2.4.1). Specimens were collected into oxygenated ice-cold 
physiological salt solution (PSS) (see Appendix II). In a similar manner, biopsies were obtained 
from women with pre-eclampsia. Uterine biopsies were also collected from non-pregnant women 
as described previously (Chapter 2.4.1). 
Resistance arteries of 200-550pm diameter were dissected from these samples using a 
stereomicroscope. Dissection was performed in similar cold, oxygenated PSS. Once vessels had 
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been dissected they were assigned to one of the experimental protocols and unless otherwise 
stated experiments were performed on fresh tissues. 
2.5.2b Omental biopsy samples: 
In addition, the results obtained from myometrial vessels were compared with similar sized 
systemic vessels. Work in our laboratory prior to the commencement of this thesis had 
demonstrated that omental vessels were the optimum available to use as these had comparable 
diameters to myometrial vessels (Ashworth, 1998). Biopsies of the omentum were taken at the 
same time as myometrial vessels. The surgeon would identify a vessel traversing the tissue and 
them divide the tissue to include this vessel. Vessels were dissected in cold PSS; the 
temperature was maintained at 4 °C by placing the dissection dish onto ice. Once a suitable 
artery had been identified, a coarse dissection was undertaken to remove excess adipose tissue. 
On completion of this stage the vessel was pinned out and fine dissection was performed. This 
involved the removal of the vein and as much adipose tissue as possible from the artery. The 
vessel was then cut at both ends and mounted directly onto the myograph. 
Vessels from both vascular beds studied had their problems. One common problem was that 
biopsies were too small and no suitable vessel could be found, Also some vessels failed to 
respond to vasopressin; these vessels were abandoned. The success rate of dissection and 
mounting improved with experience. The overall success rate for myometrial nd omental vessels 
once mounted was 65%. One further problem involved the recruitment ofnon-pregnant women, 
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as over the course of this thesis the routine use of hysterectomy for the treatment of menorrhagia 
was replaced by an alternative medical therapy. 
2.5.3 Myography 
- 
vessel mounting: 
2.5.3a Myome trial arteries: 
40µm stainless teel wires, which are used routinely in myography (Mulvany and Halpen, 1976), 
had been shown to distort when myometrial resistance vessels are stretched. Wire compliance 
affects the calculation of the vessel diameter and so indirectly, the results obtained. Previous 
work in the laboratory where this thesis was conducted had demonstrated that 50µm wires were 
resistant to distortion and as such were utilised. 
Once vessels had been dissected they were mounted in oxygenated ice-cold PSS onto the 
Mulvany Wire myograph (Fig 2.5). A 50µm stainless teel wire was held between the two jaws 
and attached to one of the screws on the left-hand jaw. The vessel was then threaded along the 
wire until it lay between the jaws and this wire was attached to the other screw. A second wire 
was introduced through the lumen and attached to the screws on the right-hand myograph jaw. 
The two wires were then aligned so that they were parallel: if they are not, errors occur in the 
normalisation process (see 2.4,1 
-normalisation). Once mounted, vessel length was measured 
with a calibrated eyepiece graticule. The PSS was changed and the organ bath temperature was 
then raised to 370C over one hour, via heated chambers adjacent to the organ chamber. During 
the experiment, constant oxygenation was achieved by passing 95% oxygen and 5% carbon 
Fig 2.5 
A Mulvany wire myograph 
To micrometer screw gauge 
f 
To pressure transducer 
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dioxide (BOC, UK) through the PSS. After a constant 370C temperature was attained, 
normalisation f the vessels was performed. 
2.5.3b Omental arteries: 
Omental arteries were mounted in a similar way to that described above. However, 40µm 
stainless teel wire was substituted for 50µm (see Chapter 2.4.3a). 
2.5.4 Myography 
- 
normalisation: 
The maximal contractile response of a vessel ring depends both on its internal diameter and its 
length. The wire myograph aims to preserve true isometric onditions by maintaining these 
parameters, and to maximise the active characteristics (size of contraction and degree of 
relaxation) whilst minimising the contribution from the resting tone, Normalisation, the process by 
which these goals are achieved, is a two-stage process. 
The first is the determination of the internal diameter of the vessel ring at a transmural pressure of 
13.3 KPa (100 mm Hg) under passive conditions (Mulvany and Halpen, 1976). This was achieved 
by constructing length-tension curves for each vessel by stretching it in small steps and between 
stretches, the distance between the two parallel wires was measured, and the passive transmural 
pressure recorded. This allowed the internal diameter for which the effective pressure was 13.3 
KPa to be calculated from the Laplace relation (see appendix ill). This is termed i. ioo. 
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The second part of the normalisation process was to set the internal diameter, as a proportion of 
Lioo at which a maximum active transmural pressure can be achieved in response to a specific 
stimulus. This requires experimental investigation for each different ype of vessel used. Previous 
work in our laboratory had determined these characteristics for myometrial and omental arteries of 
200 
- 
550 µm normalised internal diameter from normal pregnant women and non-pregnant 
women (Ashworth, 1998). 
Omental resistance vessels 0.85 Lioo 
Myometrial resistance vessels 0.90 Lioo 
As the same vessels were utilised in the identical system these preliminary experiments were not 
repeated. 
2.5.5. Vasoconstrictor I dilator agonists investigated addition: protocol and 
concentrations: 
2.5.5.1: Vasopressin: 
Vasopressin (VP), also known as anti-diuretic hormone, is a hypothalamic hormone, released via 
the pituitary gland. Although it is a potent vasoconstrictor, it has been assumed to play little role in 
routine homeostasis of blood-flow, but rather to be of importance incirculatory shock when both 
its vasoconstrictor and anti-diuretic properties have a significant role (Smith and Kampine, 1990). 
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However, studies of species other than humans would suggest that the direct vasoconstrictor 
effects of vasopressin do have a role in the physiological regulation of peripheral resistance 
(Montani et al., 1980) (Johnson et al., 1981) (Liard et al., 1982) (Woods and Johnston, 1983). 
Such studies are limited by the difficulty of studying in vivo effects of hormones, and the likely 
inter-species variability, as well as by the varying responses found in different vascular beds. 
Much of the in vivo and in vitro work has been conducted in animal models, such as dogs 
(Montani et al., 1980) (Liard and Spadone, 1984) (Aki et al., 1994) and rabbits (Carter and 
Gothlin, 1970) and whether this can be extrapolated to humans remains to be determined. 
Vasopressin exerts its action through at least hree receptor types; VIA, (vascular), V2 (renal) and V3 
(V1B) (pituitary). These have been characterised by their primary structures (Lolait et al., 1992) 
(Morel et al., 1992) (Bimbaumer et al., 1992) (de Keyzer et al., 1994) (Thibonnier et al., 1994), 
their coupling mechanisms (Thibonnier et al., 1994), their tissue distribution and their 
pharmacological properties (Morel et al., 1992). AVP stimulation of V2 receptors causes the 
activation of adenylate cyclase resulting in the production ofcyclic AMP. V2 receptors are present 
in renal epithelial cell lines, as well as in the medullary parts of the kidney where they have been 
shown to control free water and urea absorption (Butlen et al., 1978) (Jans et al., 1989). 
In contrast, stimulation of the ViA and ViB receptors activates phopholipase A2, C and D 
(Thibonnier, 1992). This activation results in the formation of inositol 
-1,4,5 - triphopshate and 
1,2 
- 
diacylglycerol, the mobilisation ofintracellular calcium, and the activation of protein kinase C 
resulting in protein phosphorylation (Michell et al., 1979). VIA receptors have been shown to be 
present on vascular smooth muscle cells, platelets, hepatocytes, and can effect contraction, 
proliferation and cellular hypertrophy (Thibonnier and Roberts, 1985) (Jard et al., 1987). 
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Several groups have identified receptors specific to vasopressin in the human peripheral 
vasculature. Tagawa et al, Calo et at, and Jovanovic et al have demonstrated the Via receptor to 
be present in vessels from human forearm, gastric arteries and uterine vasculature (Tagawa et at., 
1995) (Cato et al., 1997) (Jovanovic et al., 1997). More importantly, Bossmar et al demonstrated 
that in patients with primary dysmenorrhoea, the reduction in uterine blood flow seen in this 
condition was partially ameliorated by the vasopressin Via antagonist, SR 49059 (Bossmar et at., 
1996). These observations uggest that vasopressin may exert a physiological influence on 
vascular tone, through specific receptors which are distributed throughout he cardiovascular 
system. 
2.5.5.2: U46619 (Thromboxane mimetic): 
Prostaglandins are a complex group of substances demonstrated to be crucial to the interplay 
between platelets and the vascular wall. Arachidonic acid has been established as the most 
common fatty acid present in phospholipids (Moncada and Vane, 1979) and is the precursor of all 
the bisenoic prostaglandins. It is liberated from membrane phospholipids by the phospolipases 
group of enzymes (Vankeman and Von Dorp, 1968). The Importance of prostaglandins in 
vascular functioning was demonstrated in 1974, with the discovery that one of its non- 
prostaglandin metabolites, thromboxane, exhibited vasoconstrictor p operties (Hamberg and 
Samuelsson, 1974). 
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There are three distinct stages in the formation of prostaglandins from their arachidonic acid 
precursor; first, phospholipid cleavage to mobilise arachidonic acid; second the sequential 
conversion to the prostaglandin e doperoxides; and third the subsequent isomerisation /reduction 
of these endoperoxides to produce the biologically active compounds (Moncada and Vane, 1979). 
The final step in the conversion of arachidonic acid to one of its biological active compounds is 
dependent on a multitude of product specific enzymes. The predominance of one of these 
enzymes determines which prostaglandin is the major cellular product. This is best exemplified in 
the platelet, where the enzyme thromboxane synthetase predominates and leads to the 
production ofthromboxane (Ullrich and Haurand, 1983). 
2.5.5.3: Endothelin: 
Endothelin is a potent endogenous vasoconstrictor peptide, which was first isolated and 
sequenced from the cultured supernatant of porcine aortic endothelial cells (Yanagisawa et al., 
1988). The EC5o value (8.2 
-log molL) for endothelin is at least one order of magnitude lower 
than the reported values for angiotensin II, vasopressin or neuropeptide Y, indicating that 
endothelin is the most potent mammalian vasoconstrictor peptide known to date (Yanagisawa et 
al., 1988). There are three subtypes of endothelin; endothelin 1,2 and 3. However, only 
endothelin-1 is produced by endothelial cells (Inoue t al., 1989). 
Like many biological active peptides, the three endothelin isopeptides are produced from the 
corresponding 200 residue prepropolypeptides; each encoded for on three separate genes (Inoue 
et al., 1989). Endothelial cells produce ET-1 through constitutive and inducible pathways. ET-1 is 
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released continuously from endothelial cells via the constitutive pathway, occurring at a constant 
rate and regulated mainly at the level of protein biosynthesis. There are also limited storage sites 
as ET-1 can be rapidly released in response to external stimuli (Harrison et al., 1995). 
In the original study by Yanagisawa et at (1988), an initial dilator phase proceeded the 
vasoconstrictor effect of ET-1. This suggested the existence of more than one type of ET 
receptor. ETA receptors are found on the smooth muscle cells and mediate a major part of the 
vasoconstrictor effect of ET-1. ETB receptors are found on the endothelial cells and mediate 
endothelium-dependent vasodilatation (Bigaud and Pelton, 1992), via production of prostacyclin 
(PGI 2) and nitric oxide (de Nucci et al., 1988). Stimulation of ETB receptors by selective agonists 
can also induce vasoconstriction (Clozel et al., 1992) and this has led to the hypothesis that there 
are two types of ETD receptors. 
2.5.5.4: Bradykinin: 
Bradykinin (BK) is a nonapeptide which is liberated form its substrate kininogen by the action of 
kallikrein (Graf et al., 1994) (Oza et al., 1990) (Regoli et al., 1990). In the circulation, it has been 
shown to have differing vasoactive effects depending on the particular species and tissue studied 
(Toda, 1977). In humans BK is a vasodilator in skeletal muscle vessels, kidney vessels, 
mesenteric vessels, and in cardiac vessels (Cherry et at., 1982). Bradykinin acts locally through 
binding to the BK2 
-receptor on the endothelium to stimulate the production of the vasodilators 
nitric oxide, prostacyclin and the putative EDHF (Cherry et at., 1982) (O'Kane et al., 1994) 
(Mombouli and Vanhoutte, 1995) (Mombouli et al., 1996). 
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2.5.5.5: Histamine: 
In humans, at least hree different histamine receptors have been demonstrated. These include 
the HI receptor on vascular smooth muscle cells which have been shown to mediate contractions 
in isolated human coronary arterial muscle preparations. The H2 receptor on smooth muscle has 
been demonstrated, along with Hi receptors on the vascular endothelium, to mediate vessel 
relaxation through both an endothelium-dependent and independent action. The discovery of the 
H3 receptor on rabbit cerebral arteries (Ea-Kim and Oudart, 1988) (Ea Kim et al., 1992), prompted 
the investigation of these receptors in humans. Ortiz et al (1992) demonstrated that human 
pulmonary arterial constricted to muscle 5-hydroxytryptamine, underwent endothelium dependent 
relaxation to low dose histamine, whereas higher doses resulted in vasoconstriction (Ortiz et al., 
1992). They demonstrated, using a variety of histamine receptor antagonists, that the observed 
vasodilatation was mediated through the Hi receptor situated on the endothelium and through a 
combination ofeicosanoid and nitric oxide synthesis. 
With regard to human myometrium, H1 and H2 receptors have been demonstrated to be both 
present and functional (Cruz et al., 1989) (Martinez-Mir et at., 1992) (Rudolph et at., 1993) 
(Gonzalez et al., 1994). Stimulation of the Hi receptor causes the contraction of isolated 
myometrial muscle, with stimulation of the H2 receptor causing relaxation. (Martinez-Mir et at., 
1992). It has also been shown that H, receptor affinity Increases in the myometrium of term 
pregnancies when compared to non-pregnant controls; this increased affinity occurs with a 
concomitant decrease in the number of receptors available for binding (Gonzalez et at., 1994). 
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However, the distribution of these receptors and the pharmacological determination of which 
receptors are responsible for the observed relaxation still remains to be elucidated. 
2.5.5.6: Acetylcholine: 
Acetylcholine is synthesised from choline and acetyl coenzyme A; catalysed by the action of the 
enzyme choline acetyltransferase. This synthesis occurs mainly in the axon terminal of the 
parasympathetic nervous ystem, were it acts upon muscarinic receptors on the recipient organ. 
In the peripheral vasculature, the parasympathetic system causes vasodilatation in the vascular 
beds of the brain, myocardium, salivary glands, sex organs and possibly the intestine. 
There is much evidence suggesting that in humans that acetylcholine, acts independently of the 
nervous ystem, and is responsible for the automaticity in a number of tissues. Evidence comes 
from the observations that the enzymes necessary for its synthesis and breakdown are found in 
these tissues, and that drugs that potentiate or inhibit he action of acetylcholine modify the 
activity of the tissues. One such tissue is the placenta, which contains more choline 
acetyltransferase and acetylcholine than are found in cholinergic nerves. It has been postulated 
that the role of acetylcholine in this location is to cause vasodilatation f the blood vessels of the 
placenta nd adjacent tissues so as to facilitate nutrition of the embryo (Morris, 1966) (Morris and 
Grewaal, 1971) (Carter and Olin, 1973) (Egund and Carter, 1980). 
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2 5.6 Addition protocol: 
Once the normalisation process was complete, the agonists of interest were added. The 
concentrations of the agonist to be investigated were determined from literature data and previous 
data in the laboratory. Each vasoconstrictor was added in 0.5M incremental concentrations at 1- 
minute intervals. Once a steady state contraction had been obtained the vasodilator was also 
added in incremental concentrations at 1 minutes intervals. After the addition of the last 
concentration vessels were washed with PSS at least four times or until the vessel returned to its 
base line. At the end of each experimental protocol the vessel was constricted to 123nm 
potassium replaced physiological salt solution (KPSS) (see appendix II) in the presence of 
noradrenaline. 
2.5.6 Concentrations added: 
2.4.6.1 Vasopressin: 
Vasopressin 
-1x10-10-1x10-8 M (Akerlund et al., 1983) (Ashworth, 1998) 
2.542 U46619: 
U46619- W0 
-» 
-1x10 -r M (Hansen et al., 1996) (Kenny et al., 1999b) 
2.5.6.3 Endothelin: 
Endothelin 
-1x10 -11 -1x10-7 (Reizebos et al., 1994) (Ashworth, 1998) 
103 
2.5.6.4 Bradykinin: 
Bradykinin 
-1x10-10-1x10-8 M (Knock and Poston, 1996) (Ashworth, 1998) 
2.5.6.5 Histamine: 
Histamine 
- 
3x10-11-1x10-7 M (Toda, 1990) (Ashworth, 1998) 
2.5.6.6 Acetylcholine: 
Acetylcholine 
- 
3x10-7 1x10-3 M (McCarthy et al., 1993b) (Ashworth, 1998) 
2.5.6 Longitudinal storage of vessels: 
Vessels were stored, so that the effect on vessel physiology ofprolonged VEGF interaction with 
the endothelium could be studied (see Chapter 8). Vessels were stored in 10 mis of PSS with 
1 U/ml heparin at a temperature of 40C overnight. Heparin was added to the solution as 
preliminary experiments had shown that plasma clotted with overnight incubation (Ashworth, 
1998). Prior to, and after storage, pH was measured using a 840 series blood gas analyser 
(Chiron Diagnostics Ltd, Suffolk, UK), and I ml of PSS was removed and stored at 
-200C for 
glucose concentration determination ( =6). Glucose concentrations were measured on an 
Olympus AU 600 analyser by the Department of Clinical Chemistry using a hexokinase method. 
The inter-assay coefficient of variation was 1.18% 
. 
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2.6 Cell Culture: 
2.6.1 Basic Cell Culture techniques: 
All cells were cultured in an incubator at 37°C, at an atmosphere of 5% C02 and 95% oxygen. All 
plastic cell culture products were from Corning Costar (Coming, NY, USA), unless otherwise 
stated. All media, solutions and fetal bovine serum for culture of decidual cells and bovine 
microvascular endothelial cells were supplied by Gibco BRL: UK. Dermal microvascular 
endothelial cells, culture media and supplements for culture of were supplied by Clonetics; UK as 
well as the culture media for human umbilical vein endothelial cells. All antibiotics and 
trypsin/EDTA were supplied by Sigma (Sigma UK) unless otherwise stated. 
2.6.1.1 Passaging cells and freezing cells: 
Culture media was aspirated from the culture flask. Cells were washed with warmed Hanks 
Balanced Salt solution (HBSS) and after aspirating this solution, warmed Trypsin/EDTA was 
added (2m1/T25 flask, 6ml/T75 flask). Cells were visualised at two-minute intervals for signs of 
separation: rounding and floating. Once separation was noted the flask was struck four times to 
mechanically dislodge cells. The effects of the trypsin/EDTA were then neutralised by the addition 
of an equal volume of fetal bovine serum (FBS). Cells were then centrifuged at 1000 rpm for 5 
minutes. The supernatant was then aspirated, leaving a pellet of cells. If cells were to be grown 
they were then resuspended in IN of their specific culture medium, counted using a 
hemocytometer and plated at the density required. However, cells for storage were re-suspended 
in FBS containing 10% DimethylSulphoxide. These were counted and 1x10-6 cell aliquots were 
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produced in 1ml crytotubes. These tubes were then placed in a cryostat chamber containing 
propan-1-ol and placed in a 
-800C freezer from 24 hours. The propan -1-ol freezes at a constant 
rate and prevents cell damage from sudden freezing. After 24 hours the cryotubes were 
transferred into liquid nitrogen. 
2.6.1.2 Media changing: 
Cell medium was changed on a daily basis. New culture media was warmed to 370C in a water 
bath. Culture flask medium was aspirated and new medium pipetted into the flask/well. When 
cells reached confluence they were either passaged or stored in liquid nitrogen (Chapter 2.5.1.1). 
2.6.1.3 Defrosting cells: 
Reconstitution f cells stored in liquid nitrogen was achieved as follows. 5 mis of culture medium 
was pipetted into a T-25 culture flask that was then heated in the culture incubator. The 
cryopreserved cells were then removed from the liquid nitrogen and thawed by heating in a water 
bath at 37°C. Cells were then plated at 250,000 cells per flask. 
2.6.2 Primary Cell Cultures: 
2.6.2.1 Human Decidual Microvascular Endothelial Cells: 
Decidual endothelial cells were isolated by a modified method of (Gallery et al., 1991). 
Myometrium biopsies were obtained as described in Chapter 2.4,1. and placed in ice cold RPMI 
1640 containing penicillin (50 U/ml), streptomycin (50pg/ml), and amphotericin B (50ng/ml). The 
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decidua was dissected from the myometrium and minced finely with scissors. The minced tissue 
was then incubated in trypsin 1-250 (0.12 g/dL: ICN, UK) and pronase (0.08 g/dL) at 370C for 10 
minutes. The fragments were washed five times with Hanks' balanced salt solution (HBSS) and 
then a scalpel blade was used to separate cells from the vessels. The cell suspension was then 
collected, centrifuged at 1000 xg for 5-minutes and resuspended in 480 µl of Hanks balanced salt 
solution containing 5% fetal calf serum. 20µI lectin europaeus 1 (UEA 1) 
- 
coated Dynalbeads 
(4x108 beads/ml) (see appendix 1) was then added to the cell suspension and incubated with 
"head over end" rotation for 10 minutes at 4CC. The solution was then washed with 1mi Hanks 
balanced salt solution plus 5% fetal calf serum in a magnetic particle concentrator for a total of 
five times. Cells were plated down on 35-mm2 tissue culture dishes in a growth medium 
consisting of medium 199, which contained penicillin (50 µg Iml), 0.1 mg/ml endothelial cell 
growth supplement, 10u/ml heparin, and 40% (v/v) pooled normotensive pregnancy serum. 
Media was changed daily until cells were grown to confluence. Once confluence was reached, 
cells were passaged using Trypsin 0.05% 
-EDTA. After the first passage, once cells reached 
confluence they were stored as a cryoprecipate in 10% DMSO. 
Production of quiescent cells: 
Previous work in the department had determined that cells rendered quiescent in medium not 
containing serum or endothelial growth factor supplement changed their cell morphology, rounded 
up and floated off the culture plate. In contrast, cells grown in serum depleted media which 
contained endothelial growth factor supplement appeared normal, with few or no floating cells. 
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Thus cells that were required to be quiescent prior to the start of an experiment were cultured in 
this manner for 24 hours beforehand. 
2.6.3 Cell Lines: 
2.6.3.1 Human Dermal Microvascular Endothelial Cells: 
Human dermal microvascular cells (HdMEC) were purchased from Clonetics (USA) as a 
cryoperserved aliquot of 500,000 cells in passage 3. Cells were cultured in modified endothelial 
basal medium (EBM) containing human recombinant epidermal growth factor (10 ng/mL), insulin 
(5 µglmL), hydrocortisone (1 pg/mL), gentamicin (50 µg/mL), amphotericin B (50 ng/mL), and 5% 
fetal bovine serum (FBS). Cells were passaged with 0.025% trypsin-0.01 % EDTA. 
Production of quiescent cells: 
Quiescent cells were produced by culturing in serum depleted media without insulin and 
hydrocortisone, but containing 0.05% bovine serum albumin, gentamicin, and amphotericin for 24 
hours before commencement of experiments. 
2.6.3.2 Human Umbilical Vein Endothelial Cell line: 
The HUVEC used in these experiments were transformed cell line, SGHEC-7 and were a 
generous gift of Dr Guy Whitley of St Georges' Hospital Medical School, London, UK. Cells were 
supplied as a proliferating T-75 flask at passage 16 and were cultured in modified endothelial 
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basal medium (EBM) containing human recombinant epidermal growth factor (10 nglmL), insulin 
(5 µg 1mL), hydrocortisone (1 pglmL), gentamicin (50 µg/mL), amphotericin B (50 nglmL), and 5% 
fetal bovine serum (FBS). Cells were passaged with 0.025% trypsin-0.01 % EDTA. 
Production of quiescent cells: 
Quiescent cells were produced by culturing in serum depleted media without insulin and 
hydrocortisone, but containing 0.05% bovine serum albumin, gentamicin, and amphotericin for 24 
hours before commencement of experiments. 
2.6.3.3 Bovine Aortic Microvascular Endothelial Cell Line (B88): 
The bovine microvascular endothelial (B88) cell line was a gift from Gensia (San Diego, CA) and 
supplied as a cryoperserved aliquot of 500,000 cells. These cells were used as they had been 
previously demonstrated to produce significant differences inendothelial products on stimulation 
with plasma from women with pre-eclampsia (Baker et at., 1995b) (Baker et at., 1996a). The 
cellular characteristics Include growth as a monolayer, a cobblestone morphology atconfluence, 
positive immunostaining forvon Willebrand factor, the secretion of prostaglandins, itric oxide and 
tissue-type plasminogen activator, 
Cells were grown in medium consisting of alpha-modified minimum essential medium (a-MEM: 
GIBCO) containing 10% horse serum, 2 mmol/L L-glutamine, gentamicin (5µg/mL), kanamycin 
(20µg / mL) and nystin (10 U/mL). Cells were passaged with 0.025% trypsin-0.01 % EDTA. 
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Production of quiescent cells: 
Quiescent cells were produced by culturing in serum depleted media replaced with 0.05% bovine 
serum albumin, 2 mmol/L -glutamine, gentamicin (5µg/mL), kanamycin (20µg I mL) and nystin 
(10 U/mL) for 24 hours before experiments. 
2.6.4 Media and protein collection: 
2.6.4.1 Collection of media from cultured cells: 
After cultured endothelial cells had been exposed to the substance of interest for 24 hours, the 
culture media were collected and aliquoted into 250pl aliquots and then stored at 
-800C until 
assayed. 
2.6.4.2 Deproteinisation of media: 
Previous work carried out in the laboratory prior to this thesis had demonstrated that plasma 
affected the Griess reaction for the determination f nitrite, because the free ammonium groups 
within proteins react to form azo-dyes and as such a colour change. Therefore, all samples 
required its removal before the Greiss reaction could be employed. Deproteinization was 
achieved by the addition of 200µI of medium to 400µI of 0.5M NaOH and 4001I 10% ZnS04. This 
mixture was then vortexed for 30 seconds and centrifuged at 14,000 RPM for 5 minutes at 40C. 
The supernatant was then removed and stored at 
-800C until assayed for nitrite. 
110 
2.6.4.3 Extraction of proteins from cultured cells: 
After culture media had been collected from the experimental dishes, cells were washed three 
times with 1 ml HBSS to remove any dead cells. Cellular proteins were extracted by the addition 
500µI of protein extraction buffer (see appendix IV) to the culture well. Once cellular proteins were 
in solution 250µI aliquots were collected and stored at 
-800C until use. 
III 
2.7 Assays 
2.7.1 Griess Reaction: 
Nitrite production was determined using the spectrophotometric Griess reaction. The 
concentration f nitirite in the sample was calculated by comparison to a standard curve of nitrite 
and absorbance was measured at 550 nm on a spectrophotometer (Labsystems, UK). 
The standard curve was constructed from a stock solution of nitrite. The stock solution was 
produced by dissolving NaNO2 (0.069g) in pure water (10ml), producing a 0.1 M solution. 10µI of 
stock solution was added to 990µI water to give a 1000µM nitrite solution. 64µI of this solution 
was then added to 946µI of culture media to give a 128µM solution. 1: 1 dilutions were then 
carried out to produce the standard curve of 64,32,16,8,4,2,1,0.5,0.25,0.125 µM nitrite (Fig 2.6 A). 
100µI of standards and unknown solutions were aliquoted into a 96-well plate. Equal volumes of 
Greiss reagents #1 and #2 were mixed together (see appendix V) and 100µI of this mixture was 
added to each well and incubated at room temperature for 10 minutes. The optical density was 
then determined on a spectrophotometric plate reader (Ladsystems, UK) at 550nm. Each 
determination was carried out in triplicate and the mean of these used in the final determination. 
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2.7.1.1 Reproducibility: 
The reproducibility of the assay method was calculated from the measurement of a standard 
(pooled media from stimulated cells) aliquoted and stored at 400 C until required. The inter-assay 
variation was evaluated from measuring the media standard in six different experiments. The 
intra-assay variation was calculated from eight measurements in the same experiment. 
Mean (µM) +! 
- 
S. D CV 
Intra-assay variation 
Inter-assay variation 
2.7.1.2 Sensitivity: 
4.57 +l- 0.25 5,46% 
3.95 +/- 0.42 10.80% 
A significant difference was shown between the optical absorbance of the lowest standard (0.25 
µg/ml) and the zero optical absorbance l vels (t-test, p= 0.033, n=3) 
2.7.2 6-keto prostaglandin F , (x assay: 
Production of the stable metabolite 6-keto prostaglandin Fiawas measured using a commercially 
available nzyme linked immunosorbent assay (ELISA; Cayman Chemicals, Ann Arbor, MI). The 
rabbit antiserum 
- 
6-keto PGFia (either free or tracer) complex binds to a mouse monoclonal nti- 
rabbit antibody that has been previously attached to the well. The plate is washed to remove any 
unbound reagents and then Ellman's Reagent (which contains the substrate to 
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acetylcholinesterase) i  added to the well. The product of this enzymatic reaction has a distinct 
yellow colour and absorbs trongly at 412 nm. The intensity of this colour is proportional to the 
amount of free 6-keto-PGF1a present in the well during the incubation. Although this assay was 
commercially available and the manufacturer p oduces performance characteristics, everal 
validatory experiments were performed to confirm these characteristics. The standards and 
unknowns were all measured in triplicate and the means used in the final determination (Fig. 2.6 
B). 
2.7.2.1 Specificity: 
6-keto Prostaglandin Fra, 100% 
2,3-dinor-6-keto Prostaglandin F ja 8.70% 
Prostaglandin F 2a 2.10% 
Prostaglandin E20.92% 
Prostaglandin Fia 0.80% 
2.7.2.2 Reproducibility: 
The inter-assay variation was evaluated from measuring the standard in five different 
experiments. The intra-assay variation was calculated from eight measurements in the same 
experiment. 
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Mean (nglml) +/- S. D cv 
Intra-assay variation 304.30 +1-18.54 6.09% 
Inter-assay variation 273.56 +1- 27.47 10.05% 
2.7.2.3 Sensitivity: 
A significant difference was shown between the percentage binding of the lowest standard (7.8 
ng/ml) and the zero binding levels (t-test, p= 0.001, n=3) 
2.7.3 Protein assay: 
The concentration f protein was determined using a commercially available spectrophotometric 
assay (Bio-Rad). This assay is based on the Lowry assay, utilising the reaction of protein with 
alkaline copper tartrate solution and Folins reagent, producing a characteristic blue colour. The 
concentration of protein in the sample was calculated by comparison to a standard curve of 
albumin and absorbance was measured at 750 nm. 
Protein standards were constructed by dissolving bovine albumin (0.02g) in deionised istilled 
water (1 Omis) to produce a2 mg/mI stock solution. Standards were prepared containing from 0.5 
mg/mi to 2.0 mg/ml protein. All standards were prepared In the same extraction buffer as the 
sample. 5 pl of the standards were then diluted in 20pI of extraction buffer and aliquoted into a 
microtitre plate. 25 pl of sample was pipetted Into the microplate. Reagent At (25x1) was then 
added to each well using a pipette. Folin reagent B (200µI) was then added and the plate gently 
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agitated for 30 seconds. It was left to stand for 15 minutes and the absorbance measured at750 
nM on a plate reader (Labsystems, UK). All standards and unknowns were measured in triplicate. 
3.7.3.1 Reproducibility: 
The inter-assay variation was evaluated in nineteen different experiments. The intra-assay 
variation was calculated from five measurements in the same experiment. 
Mean (mg/ml) +/- S. D CV 
Intra-assay variation 
Inter-assay variation 
3.7.3.2 Sensitivity: 
0.272 +1- 0.012 4.63% 
0.265 +1- 0.021 7.81% 
A significant difference was shown between the percentage binding of the lowest standard (0.1 
g/ml) and the zero binding levels (t-test, p= 0.007, n=3) 
3.7.4 Lactate Dehydrogenase determination: 
Cellular viability was assessed by measurement of lactate dehydrogenase (LDH) levels. The 
assay was based on the measurement of reduced nicotinamide adenine dinucleotide formed from 
nicotinamide adenine dinucleotide plus lactate. Medium (50p1) was added to 1 ml of reagent 
(Sigma Diagnostics, UK). LDH was measured at 250C by the change in absorbance at 340nm 
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using a UNICAM UV/ visible spectrophotometer. For assessment ofmaximal LDH release, LDH 
concentrations were also measured after cells had been exposed to 1% Triton X-1 00 for 24 hours. 
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2.8 Statistical Analysis: 
The placing of a numerical value on the uncertainty of results is one of extreme importance in
science, as it allows colleagues to assess the validity of our conclusions. However, of similar 
importance, is selection of the appropriate statistical test to determine whether a Null hypothesis 
should be rejected, as an incorrect analysis may give rise to an invalid conclusion. This section 
will highlight the main statistical tests utilised in this thesis, along with the reasoning behind such 
analyses. 
2.8.1 Basic terminology: 
2.8.1.1 Null hypothesis (H0): 
This is a hypothesis based on a proposition that there is no difference between one'control' group 
and another 'experimental' group. 
2.8.1.2 P value: 
This is the probability ofhaving the experimental data that supports (HO). Although the value for P 
is arbitrarily chosen, aP<0.05 is assumed to be statistically significant. 
2.8.1,3 Type I error (a): 
The attainment of a statistically-significant result when the null hypothesis i  in fact correct (a 
`false positive' result) 
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2.8.1.4 Type II error (ß): 
The attainment of a statistically non-significant result when the null hypothesis is not correct (a 
'false negative' result). 
2.8.1.5 Power: 
For any hypothesis test, the value of a is determined inadvance, and is usually set at 5%. The 
value of ß depends upon the size of the effect that one is interested in, and also the sample size. 
The power of a study is the ability to detect an effect of a specified size, where the power is 1-ß or 
100*(1-0) %. P may also be fixed in advance by choosing an appropriate sample size. 
2.8.1.6 ED5c: 
The log molar concentration f a drug required to produce a50 % maximal response. 
2.8.1.7 E max:: 
The term E max in this thesis corresponds to the response obtained from the highest 
concentration f vasoactive drug used. 
2.8.1.7 Normality testing: 
Prior to statistical analysis data were examined for normality of distribution; this was achieved by 
use of the skew test. This test calculates a value for the symmetry of data around the mean, a 
result of I indicating symmetry. In both plasma measurements and cell culture experiments the 
data obtained showed a high degree of skewness, therefore, distribution-free statistics were 
employed. However, the myography data showed a normal distribution and as such parametric 
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statistical analysis were performed. All data were stored on a personal computer, in a form 
appropriate for use with Stat View for Windows, Abacus Concepts, Inc. 
2.8.2. Plasma concentrations of Vascular Endothelial Growth Factor: 
Where plasma concentrations of Vascular Endothelial Growth Factor (VEGF) were measured, the 
data were from unpaired groups and had a skewed distribution i both. These were compared 
using the Mann-Whitney statistical test. Mann-Whitney is a non-parametric test that is equivalent 
to the Students t-test for comparing data from two independent groups. This test requires all the 
data points to be ranked as if they were from a single sample. The sum of the ranks of one of the 
groups is calculated, the P value then being obtained from probability tables. The Mann-Whitney 
test relies on several assumptions. These are that the two samples have been independently and 
randomly drawn from their respective populations, the measurement scale is at least ordinal, the 
variable of interest is at least continuous, and the populations only differ with respect to their 
medians- if they differ at all (Altman, 1991). 
Further analysis of the data was carried out to determine whether levels of Vascular Endothelial 
Growth Factor could be related to the clinical signs of the disease. Those parameters considered 
were: proteinuria (gll), plasma uric acid (µmol/L) concentrations and liver function tests, blood 
pressure measurements and fetal weight (assessed by individual birth weight ratio). These 
parameters all displayed skewed distributions and as such non-parametric correlations were 
employed. The Spearman rank correlation coefficient was used to determine P-values for these 
data. This test quantifies the strength of any relationship between two variables. It Involves the 
ranking of both (X) and (Y) values. From these values the d; value (I indicates the ith value) can be 
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calculated, this is the difference between the ranked individual paired value of Xi and Yi. From this 
the r$ value is calculated and used to determine the P-value from Pearson's probability tables. 
However, if the study number is greater than 30 then a Z-value may be calculated and the 
appropriate P-value obtained from Z-tables (Altman, 1991). 
2.8.3 Myography Experiments: 
The technique of wire myography was utilised in this thesis to 
1) determine the vascular reactivity changes that occur with pregnancy and pre-eclampsia 
2) make comparisons of the effects that incubation with VEGF and plasma had on resistance 
vessel behaviour. 
Detection of a significant result depends upon the power, the level of significance and the size of 
the sample to be analysed. Then null hypothesis for all the myography experiments stated that: 
1) the degree of vessel relaxation to the endothelium dependent vasodilator would be the same 
in all vessel groups tudied. 
2) the degree of induced vessel tone would the same in all vessel groups tudied. 
For each series of myography experiments the power was designated at 80% and a significance 
level of 5% was felt to be appropriate. In order to calculate the sample size required to fulfil these 
parameters, the degree at which biological relevance would be achieved was assigned. In 
pharmacology a halving or doubling in the response would be regarded as biologically significant 
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(Bowman and Rand, 1984). From pilot data from vessels from six patients, the EC5o to bradykinin 
was calculated to be 
-7.5 +/- 0.6 x10.1° M. A significant pharmacological effect would be a 
0.5x10-1° M shift in the EC 50, Therefore the standardised difference was calculated as 0.5/0.6 
0.83. From these data the total sample size was determined from Altman's nomogram to be 60 
i. e. 30 in each group (Altman, 1991). However, both the effect of VEGF and plasma were noted 
to be significantly greater than a 0.5x10.10 M shift and as such sample sizes of 6 were required to 
give an a error of 0.05 and aß of 0.9. The next consideration was how best could the data be 
statistically analysed. 
One suitable method of statistical analysis would have been to determine the ED5o values from 
the dose response curves; these can then be analysed by use of the paired Student t-test. This 
indicates whether a shift in the dose response curve is statistically significant. However, in 
several cases this was not possible, as incubation with VEGF made the ED50 value unattainable 
with protocol concentrations of vasodilators. Further increase in vasodilator concentration was 
deemed not to be physiological aswell as too expensive. 
The technique of analysis of variance was also utilised to confirm the statistical analysis, as the 
experimental design required testing to be carried out in relation to six concentrations of
vasodilators. The variances of these results were similarly demonstrated to be approximately 
equal, this being another assumption ofthe test. The repeated measure analysis of variance was 
employed as the statistical test, this being an extension of the paired t-test. The strength of the 
design is that repeated measures are made on the same tissues, and as such the variation 
between tissues is reduced. Specific hypotheses about the concentration f vasodilators that was 
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required to produce asignificant result were analysed by the use of the post-hoc Bonferroni-Dunn 
test. This is an application ofthe Student's t-test with an adjustment made for multiple testing. 
2.8.4. Cell Culture Exaeriments: 
Data from cell culture experiments were shown to be of a skewed nature, therefore, the non- 
parametric Mann-Whitney test was utilised. Experiments were designed, to allow comparison of
the production ofmarkers of endothelial cell activation when various cell lines were incubated with 
the plasma from the women with pre-eclampsia and control plasma from uncomplicated 
pregnancies. The experimental design allowed for comparison between two independent groups. 
Cell culture experiments were likewise designed to assess the effect of incremental doses of the 
cytokines, VEGF and Placental Growth Factor, on production of the same endothelial markers. 
These require a different statistical approach as the data have more than two unpaired groups. 
This can be achieved via a one-way analysis of variance. However, skewed data requires anon- 
parametric equivalent, this being the Kruskal-Wallis analysis. Analysis of variance may be defined 
as a technique whereby the total variation present in a set of data is partitioned into two or more 
components. Associated with each of these components is a specific source of variation, so that 
in the analysis it is possible to ascertain the magnitude of the contribution of each of these 
sources to the total variation. Specific hypothesis testing about whether the response to the 
cytokine follows a dose response was carried out via the use of the Mann- Whitney test between 
each group with an adjustment made to correct the significance value. The adjustment made was 
to multiply the obtained P-value by the number of groups under examination. 
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2.9 Presentation of data: 
2.9.1 Myography: 
All myography data presented in this thesis will follow the same format as that shown for example 
in (Fig 2.7 and 2.8), The vasoconstrictions were expressed as a percentage of the maximal 
contraction to KPSSI noradrenaline. Vasodilator responses are presented as the degree of 
relaxation expressed as a percentage ofthe minimal size of the constricted vessel to vasopressin. 
Data points are expressed as means +l- standard error of the mean. Numerous concentration 
response curves (CRCs) were generated. Where possible, comparator pairs have been drawn to 
identical scale and mounted to allow direct visual comparison. 
c 
cc 
L 
O 
Title 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Fig 2.7 
Relaxation profile: 
degree of relaxation to incremental doses of 
vasodilator drug expressed as percentage 
contraction to vasoconstrictor drug 
-12 -11 -10 -9 -8 -7 -6 -5 
Log [Bradykinin] xlO . 10 M 
Legend: 
details of the graphs 
Statistical comparisons: 
Analysis of groups using: repeated 
measures ofanalysis of variation (ANOVA) (p), post hoc Bonferoni 
Dunn (*) 
, 
ED. and E max. 
Title 
140 
120 
Contraction profiles: 
ö 100 contraction to incremental 
doses of drug. Expressed as i 80 percentage ofmaximal 
= contraction to KPSS/ 
0 
v 60 noradranaline 
C1 40 
20 
0 
-11 -10 -9 -8 "7 
Log [Vasopressin] x10 "10 M 
Le end: 
details of vessels in 
experiment 
Fig 2.8 
Statistical comparisons: 
Analysis of groups using: repeated 
measures ofanalysis of variation (ANOVA) (p), post hoc Bonferoni 
Dunn (*) 
, 
ED50 and E max. 
124 
Chapter Three: Validation, Pilot data and Protocols: 
Numerous pilot studies were undertaken before final protocols were devised. These are 
summarised in the next part of the thesis together with the protocols that were subsequently 
designed from it for the main studies. 
3.1 Pilot data and determination of experimental protocol: 
3.1.1 Selection of an appropriate contractile agonist; 
3.1.1.1 Aims: 
As it was hypothesised that the interaction of VEGF with the endothelium was important in the 
pathogenesis of pre-eclampsia, it was necessary to determine whether it altered pressor 
responses. For this reason several vasoconstrictor agents were required to determine whether 
pressor responses were altered in pre-eclampsia and whether VEGF could initiate these 
alterations in normal pregnant vessels. Previous work had determined that vasopressin produced 
reproducible contractions and as such this was taken to compare all other vasoconstrictors 
examined (Ashworth, 1998). 
3.1.1.2 Experimental design: 
Previous work in the laboratory where this thesis was conducted had demonstrated that the 
vasoconstrictors noradrenaline, angiotensin II, 5-hydoxytryptymine were Incapable of producing 
sustained contractions in myometrial vessels (Ashworth, 1998) and such this preliminary work 
was not repeated. As both endothelin (Taylor et al., 1990b) (Alfredo et al., 1991) (Mastrogiannis 
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et al., 1991) (Nova et al., 1991) (Clark et al., 1992) (Kraayenbrink et aL, 1993) (Wolf et al., 1996) 
(Maleska et at., 1996) (Bussen et al., 1999) and eicosanoids (Pedersen et al., 1983b) (Pedersen 
et at., 1983a) (Ylikorkala, 1983) (Makila et at., 1984) (Walsh, 1985) (Yamaguchi and Mori, 1985) 
(Minuz et at., 1988) (Scafer et at., 1993) (Mills et al., 1999a) have been implicated in the 
pathogenesis of pre-eclampsia it was considered that these agents were the most relevant to 
investigate. 
Myometrial specimens were collected as described in Chapter 2.4.2 from pregnant (n=5 each 
agonist) and non-pregnant women (n=5 each agonist). Two vessels were mounted on two 
identical myographs as described previously (Chapter 2.4.3). Vessels were randomised to one 
arm of a Latin square xperimental design, one vessel was designated as A and the other as B. 
Vessel A was exposed to vasopressin as described previously (Chapter 2.4.4). After the vessel 
had returned to its resting state it was exposed to Incremental doses of the agent under 
examination (U46619 (9,11-dideoxy-1Ia, 9a epoxymethano-prostaglandin Fla) or Endothelin) 
(Chapter 2.4.5). Vessel B underwent the opposite protocol. The Latin square design was used to 
determine if the vasoconstrictor under consideration affected the contractility of the control 
vasoconstrictor (vasopressin) and vice versa. 
3.1.1,3 Results: 
Vasopressin, as shown previously, produced sustained contractions in tissues from both non- 
pregnant and pregnant vessels. The thromboxane mimetic (U46619) produced reproducible and 
sustained contractions in both the non-pregnant and pregnant groups (Fig 3.1 & 3.2). Prior 
constriction with vasopressin did not alter a subsequent constriction curve obtained with U46619 
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(Fig 3.3 & 3.4), this was also observed with the converse (non-pregnant (P= 0.39 (ANOVA)), 
pregnant (P=0.59 (ANOVA)). Comparison of non-pregnant and pregnant U46619 constriction 
curves revealed that there was no significant differences between the two groups (P = 0.63, 
repeated measures analysis of variance (ANOVA)) (Emax 144.4+/- 25.7 Vs 112.4+/- 25.3: p= 0.30, 
unpaired t-test). 
As with U46619, endothelin produced sustainable and reproducible contractions in both study 
groups (Fig 3.5 & 3.6). The constriction curves to endothelin remained unaltered with a prior 
constriction to vasopressin. Non-pregnant (P=0.59: ANOVA)( E max 102.3+/- 18.2 Vs 117.2+/- 
13.5: P=0.53, unpaired t-test), Pregnant (P=0.17 ANOVA) (EmaX137.3 +/-11.2 Vs 118.7+/-10.2: 
P=0.16, unpaired t-test). 
However, comparison ofthe three vasoconstrictors demonstrated a significant difference in their 
potencies. Non-pregnant EC5o: Vasopressin = 
-9.0+/-0.2, U46619 = -7.5+1-0.4, Endothelin =- 
7.4+/-0.1 (P=0.003; ANOVA). Pregnant EC so: Vasopressin = -9.4+/-0.1, U46619 = -8.0+/-0.1, 
Endothelin = 
-8.5+/-0.2(P=0.001). Post hoc analysis demonstrated that significant differences 
occurred between the vasopressin and endothelin responses in both non-pregnant (P=0.0004) 
and pregnant groups (P=0.0007), and also between vasopressin and U46619 in both non- 
pregnant (P= 0.0008) and pregnant (P=0.0001) vessels. There was no significant difference 
between endothelin and U46619 in either group (P>0.5). 
A comparison the EC5o of non-pregnant and pregnant vessels for the vasoconstrictors 
investigated, emonstrated that there was no significant difference between the responses to 
vasopressin (EC5o 
-9.0+/-0.2 Vs -9.4+/-0.1: P=0.12, t-test) and U46619 (EC5o 
-7.6+/-0.3 Vs - 
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7.5+/-0.4: P=0.39, t-test). However, the endothelin responses were enhanced in pregnancy (EC5o 
-7.4+/-0.1 Vs -8.5+/-0.2; P=0.001) (Figs 3.5 & 3.6). 
3.1.1.4 Discussion: 
It has previously been demonstrated that low concentrations of potassium cause sustained 
contractions when compared to 123nM potassium, however, the size of contraction varied widely 
(Ashworth, 1998). It was suggested from these findings that this large variation was due to both 
the degree of depolarisation and the position along the length I active tension curve between 
vessels. As these were likely to influence subsequent endothelium-dependent relaxation, this 
mode of constriction was unsuitable (Ashworth, 1998). 
Both endothelin and U46619 produced sustained contractions, which were comparable to both 
vasopressin and 123mM KPSS 1 Noradrenaline. U46619 contractions showed no significant 
differences with pregnancy and this is in accord with several other studies (Skajaa et al., 1990) 
(Svane et at., 1991) (Kublickiene et at., 1994) (Kublickiene et at., 1995). Comparison of these 
vasoconstrictor potencies hows that AVP is the most effective vasoconstrictor in human 
myometrial resistance vessels and further adds evidence to support its role in the regulation of 
myometrial blood flow. 
In this study myometrial vessels from non-pregnant women exposed to vasopressin and U46619 
showed significantly higher En,. values than normotensive pregnant controls, with no apparent 
shift in the EC5o values. This might have been postulated from the work of Gant et al (1973) 
which demonstrated that the pressor effects of angiotensin 11 are decreased inpregnancy (Gant et 
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al., 1973). In a similar manner, pregnancy has also been shown to alter the vascular eactivity of 
guinea-pig uterine arteries to norepinephrine, phenylamine, angiotensin It, serotonin, and the 
thromboxane-memetic U46619 (Weiner et al., 1989b) (Weiner et al., 1991) (Weiner et al., 1992b) 
(Weiner et at., 1992a) (Jovanovic et at., 1995b). Weiner et al showed that the vasoconstrictor 
effect of these substances is significantly reduced in pregnant uterine arteries with intact 
endothelium when compared to that of vessels from the non-pregnant guinea-pig with the same 
endothelial status (Weiner et al., 1989b) (Weiner et al., 1991) (Weiner et al., 1992b) (Weiner et al., 
1992a). They also demonstrated that these effects were mediated through changes in endothelial 
function, as removal enhanced the responses in the arteries from pregnant animals, returning 
them toward the non-pregnant state, but responses remained unaltered in non-pregnant arteries 
(Weiner et al., 1989b) (Jovanovic et al., 1995b). 
Steele et al (1993) also implicated the endothelium as pivotal to the vascular adaptations that 
occur in pregnancy. They demonstrated that, although there were no differences in the 
contraction responses curves for intact vessels, removal of the endothelium from myometrial 
vessels from pregnant women significantly enhanced the constriction responses to noradrenaline 
when compared with non-pregnant controls in a similar state, and postulated that the increased 
sensitivity is countered by an endothelium-derived relaxing factor (Steele et al., 1993). This would 
suggest that during pregnancy the endothelium undergoes various alterations that allow the 
modulation ofsmooth muscle. This effect may be hypothesised to allow increased control over 
the local blood flow to the feto-maternal unit. 
In contrast to AVP and U46619, which showed blunted responses of myometrial resistance 
vessels during the third trimester of pregnancy, the concentration response curves to endothelin 
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were significantly enhanced over non-pregnant vessels. This is in accordance with previous pilot 
data collected in our laboratory (Ashworth, 1998). The literature and this thesis would suggest 
that in vitro responses to vasoconstrictors are reduced via endothelial modulation. However, 
enhanced responses have also been reported to vasopressin in guinea-pig uterine vessels 
(Jovanovic et al., 1995a). Jovanovic et al (1995) showed that these responses were independent 
of modulation by the endothelium, and suggested that either vasopressin receptor density was 
increased or that their coupling effect was enhanced. This study did not investigate the role of the 
endothelium with respect to the enhanced response to endothelin with pregnancy. 
There are several possible hypothesises that might be put forward to explain the observation of
enhanced responses to endothelin in pregnancy. ET-1, as a vasoconstrictor, may have an 
increased role in the control of myometrial blood flow during pregnancy. ET-1 is known to 
contribute to the process of angiogenesis. Stiles et al (1997), while investigating vascularity in 
human gliomas, have shown that ET-1 is important in the progressive angiogenesis of the human 
glioma (Stiles et al., 1997). During pregnancy, the uterus supplies the developing placenta with 
blood, through the formation of new blood vessels. Therefore, it could be postulated with the 
increased proliferation of the uterine smooth muscle in pregnancy, that ET-1 might contribute to 
the vascularisation f the increased muscle mass. 
Vasopressin produced sustained contractions In comparison to KPSS/ noradrenaline at 
significantly enhanced potencies to both the other vasoconstrictors and with a pregnancy-related 
shift in the EC5o. As such vasopressin was used as the vasoconstrictor f choice for the 
Investigation of the different vasodilators, however see Chapter 10. 
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3.1.2. Reproducibility of dose response curves vessels obtained to the 
vasopressin: 
3.1.2.1 Aims: 
The vasoconstrictor agent used was required to be capable of being used repeatedly on the same 
vessel with consistent results. Therefore confirmation was required that vasopressin conformed 
to this requirement. 
3.1.2.2 Experimental design: 
Myometrial (M) and omental (0) biopsies were collected from non-pregnant (n=7; M) (n=5; 0), and 
pregnant (n=11; M) (n=6; 0) and women with pre-eclampsia (n=6; M) (n=8; 0) as described 
previously (Chapter 2.4.2). Vessels were dissected fresh and mounted within 2 hours of collection. 
After normalisation, vessels were constricted with incremental doses of vasopressin as described 
in Chapter 2.4.5. A total of two constriction profiles were performed for each vessel. 
3.1.2.3 Results: 
In all groups tudied, the two dose response curves were compared with each other by paired t- 
tests of the EC5o and Emax responses and by repeated measures analysis of variance. In all the 
vessels except those from omentum from women with pre-eclampsia there were no significant 
differences between the first and second constriction curves (Tables 3.1 and 3.2. ). In the group of 
Table 3.1 
Reproducibility of vasopressin contraction curves for non- pregnant, 
pregnant and pre-eclamptic myometrial vessels 
Non-Pregnant 
First constriction curve 
Second constrcition curve 
t-test (paired) p= 
ANOVA p 
Pregnant 
First constriction curve 
Second constriction curve 
t-test (paired) p= 
ANOVA P= 
Pre-eclampsia 
First constriction curve 
Second constriction curve 
Statistical comparisons: 
ED 50 Emax 
-9.1+l-0.1 122.57+1-8.48 
-9.0+/-0.05 124.29+/-7.26 
0.17 
0.24 
0.81 
Statistical comparisons: 
ED 50 Ex 
-8.9+/-0.1 109.32+/-13.63 
-9.2+/-0.1 128.41+/-16.47 
0.19 
0.89 
0.12 
Statistical comparisons: 
ED 50 Emaz 
-9,2+1-0.2 115.11+1-12.65 
-9.1+1-0.1 120.99+1-6,40. 
t-test (paired) p= 0.49 0.55 
ANOVA p=0.28 
Table 3.2 
Reproducibility of vasopressin contraction curves for non- pregnant, 
pregnant and pre-eclamptic omental vessels 
Non-Pregnant Statistical comparisons: 
ED 50 Emax 
First constriction curve 
-8.5+1-0.0 76.87+1-8.40 
Second constriction curve -8.5+1-0.1 84.23+/-8.98 
t-test (paired) p= 0.99 0.65 
ANOVA p=0.94 
Pregnant Statistical comparisons: 
ED 50 Emax 
First constriction curve 
-8.7+/-0.3 70.57+/-5.96 
Second constriction curve -8.5+/-0.2 77.08+/-5.08 
t-test (paired) p= 0.68 0.08 
ANOVA p=0.13 
Pre-eclampsia Statistical comparisons: 
ED 50 Emax 
First constriction curve 
-8.8+/-0.1 79.76+/-5.57 
Second constriction curve -8.8+/-0.1 91.57+/-3.52. 
t-test (paired) p= 0.78 0.02 
ANOVA p=0.54 
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omental vessels from women with pre-eclampsia there was a significant difference in the Emax 
values. It was also noted that in all groups the second Emax response was greater than the first. 
3.1.2.4 Conclusions: 
Vasopressin produces a sustained contraction in all groups tudied that could be repeated at least 
twice on the same vessel without signs of fatigue. However, it was noted that in all groups there 
was a greater esponse in the second CRC when compared to the first. This reached significance 
in the group of omental vessels from women with pre-eclampsia. As these differences were 
considered to be a possible source of a p-error it was considered that time control experiments 
should be incorporated into the final protocol. 
3.1.3 Variability of vessels obtained from the same patient to vasopressin: 
3.1.3.1 Aims: 
" to determine whether vessels segments from the same experimental sample produced 
comparable contraction curves to allow time comparisons to be made. 
3.1.3.2 Experimental design: 
Myometrial (M) and omental (0) vessels were collected, from non-pregnant (n=8: M) (n=5: 0), and 
pregnant women (n=7: M) (n=5: 0) and women with pre-eclampsia (n=8: M) (n=5: 0). Three vessels 
were dissected from each biopsy (Chapter 2.4.1) and mounted on separate myographs. The 
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protocol in Chapter 2.4.5 was then followed and vessels ubjected to incremental doses of 
vasopressin. 
3.1.3.3 Results: 
In all groups tudied, sustained contractions were produced by all vessels exposed to vasopressin 
(Figs 3.7,3.8 and 3.9. and Table 3.3). The dose response curves obtained were compared with 
each other by comparison oftheir EC 5o and E max values. No significant differences were noted in 
any of the groups investigated. 
3.1.3.4 Conclusion: 
Vasopressin produces comparable contractions in vessels egments from the same patient and 
thus allowed time comparisons to be incorporated into the final protocol. 
3.1.4. Selection of an endothelium-dependent vasodilator: 
3.1.4.1 Aims: 
As it was hypothesised that the interaction of VEGF with the endothelium was important in the 
pathogenesis of pre-eclampsia, it was necessary to determine whether it altered vasodilator 
responses. As such several endothelium dependent vasodilator agents were required to 
determine whether their responses were altered in pre-eclampsia and whether VEGF could initiate 
these alterations in normal pregnant vessels. Previous work had determined that bradykinin, 
acetylcholine and histamine produced reproducible ndothelium dependent concentration 
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Table 3.3 
Variability of dose response curves to vasopressin for non- pregnant, 
pregnant and pre-eclamptic omental vessels 
Non-Pregnant ( =5) Statistical comparisons: 
ED 50 Emax 
Vessel one curve 
-8.5+1-0.0 76.88+1-8.40 
Vessel two curve -8.7+/-0.3 66.76+/-5.80 
Vessel three curve -8.7+/-0.2 72.61+/-7.70 
ANOVA (factorial) p= 0.83 0.66 
Premant Statistical comparisons: 
ED 50 Emax 
Vessel one curve (n=5) 
-8.4+1-0.1 67.23+1-10.06 
Vessel two curve (n=5) 
-8.4+1-0.1 67.36+/-10.19 
Vessel three curve (n=5) -8.6+1-0.2 70.39+1-8.94 
ANOVA (factorial) p= 0.67 0.95 
Pre-eclampsia (n=5) Statistical comparisons: 
ED50 Emaz 
Vessel one curve 
-8.9+/-0.3 83.42+/"14.87 
Vessel two curve 
-8.8+/-0.2 95.33+/-8.64 
Vessel three curve -8.8+/-0.2 81.23+1.12.66 
ANOVA (factorial) p= 0.90 0.65 
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response curves in myometrial vessels and as such this was not repeated (Ashworth, 1998). It 
has also been previously demonstrated that both bradykinin and acetylcholine produced 
reproducible ndothelium dependent relaxation in omental resistance vessels (Ashworth et al., 
1996b) (Pascoal and Umans, 1996), however, no such data existed on histamine. Therefore 
experiments were designed to investigate whether histamine caused endothelium dependent 
relaxation in omental resistance vessels. 
3.1.4.2 Experimental design: 
Omental vessels (n=4) were dissected as described previously (Chapter2), and mounted in intact /
and endothelium stripped pairs. Following equilibration and normalization, vessels were then 
constricted with cumulative doses of vasopressin. Once a sustained contraction was attained, 
cumulative doses of bradykinin were added to the vessel chamber, to confirm endothelial 
stripping. After conformation that one of the pairs had been stripped of its endothelium a further 
constriction was initiated with incremental doses of vasopressin, again once a sustained 
contraction was attained, cumulative doses of histamine were added to the organ bath, 
3.1.4.3 Results: 
Omental vessels with the endothelium denuded were unable to produce any significant relaxation 
to bradykinin (Fig 3.10), which served to confirm the absence of the endothelium. However, the 
addition of histamine to the same vessels produced a significant relaxation response (Fig 3.10). 
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3.1.4.4 Conclusions: 
Histamine produces non-endothelium dependent relaxations In human omental vessels. As such 
histamine was not used in experiments that utilised omental vessels. 
3.1.5 Reproducibility of dose response curves vessels obtained to the 
vasodilators: 
3.1.5.1 Aims: 
" 
To confirm previous data from our laboratory that the agents to be used produced ose 
response curves. 
" 
To demonstrate hat the dilator agents used were capable of being used repeatedly on the 
same vessel with consistent results. 
3.1.5.2 Experimental design: 
Myometrial and omental vessels were obtained from non-pregnant women, pregnant women and 
women with pre-eclampsia as previously described (Chapter 2.3) and were then exposed to 
vasopressin (Chapter 2.3.5). Once a sustained constriction was attained, cumulative 
concentrations of the vasodilator agent under consideration were added to the myography 
chamber (Chapter 2.2.5). 
However, during the course of the preliminary experiments it became apparent that acetylcholine 
may not cause an endothelium dependent relaxation in pregnant myometriai resistance vessels. 
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As such a further experimental protocol was designed to test this hypothesis. The experimental 
work during this set of experiments was carried out under the close supervision ofan experienced 
technician (Mrs A. Y. Warren), who confirmed that the preparation ofdrugs was correct and that the 
correct dosages were added to each myography bath. 
Two vessels were dissected and mounted on separate myographs, omental vessels were also 
dissected to act as positive controls (these had been demonstrated to display endothelium 
dependent relaxation to acetylcholine). Once equilibration and normalisation had been completed 
vessels were randomised to one arm of a Latin square experiment (see Chapter 3.2.1.2). 
3.1.5.3 Results: 
Endothelium dependent relaxation: 
Myometrial vessels produced endothelium dependent relaxation to bradykinin and histamine in all 
groups (see Fig 3.11,3.12,3.13 and Table 3.4), although the endothelium dependent relaxation to 
bradykinin was significantly reduced in the women with pre-eclampsia (see Chapter 6). Omental 
vessels produced endothelium dependent relaxation in response to bradykinin and acetylcholine 
(See Table 3.5 & 3.6). The endothelium dependent response to aceylcholine was also significantly 
attenuated in the women with pre-eclampsia (see Chapter 6). 
In preliminary studies, acetylcholine produced no endothelium dependent relaxation i  myometrial 
resistance vessels. The Latin square design was used to demonstrate that the endothelium was 
present and functional prior to exposure to acetylcholine. Yet in spite of the presence of a 
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Table 3.4 
Reproducibility of histamine relaxation curves for non- pregnant, pregnant and 
pre-eclamptic myometrial vessels 
Non-Pregnant 
First relaxation curve 
Second relaxation curve 
t-test (paired) p= 
ANOVA P= 
Pr nant 
First relaxation curve 
Second relaxation curve 
t-test (paired) p= 
ANOVA P= 
Pre-eclampsia 
First relaxation curve 
Second relaxation curve 
Statistical com arisons: 
ED 50 Emax 
-9.2+1-0.2 78.27+1-3.54 
-9.2+1-0.3 80.04+1-4.88 
0.83 
0.96 
0.63 
Statistical comparisons: 
ED 50(mod] Emax 
-8.7+/-0.3 43.27+/-2.57 
-8.8+1-0.2 53.18+/-0.87 
0.93 
0.01 
0.074 
Statistical comparisons: 
ED 5o(mA Emax 
-9.7+1-0.3 40.88+/-3.48 
-9.3+/-0.2 52.17+/-5.37 
t-test (paired) p= 0.08 0.09 
ANOVA p=0.07 
Table 3.5 
Reproducibility of bradykinin relaxation curves for non- pregnant, pregnant and 
pre-eclamptic omental vessels 
Non-Pregnant ( =6) Statistical com arisons: 
ED 50 Emax 
First relaxation curve 
-8.3+/-0.3 90.08+/-5.30 
Second relaxation curve -8.1+1-0. l 88.24+/-4.30 
West (paired) p= 0.35 0.4 
ANOVA p=0.84 
Pregnant Statistical comparisons: 
ED gp Emax 
First relaxation curve 
-8.9+l-0.1 98.10+/-0.91 
Second relaxation curve -8.7+/-0.4 93.79+/-1.89 
t-test (paired) p= 0.39 0.06 
ANOVA p=0.32 
Pre-eclampsia Statistical comparisons: 
ED 50 Emax 
First relaxation curve 
-7.8+/-0.6 81.18+/-9.47 
Second relaxation curve -8.0+/-. 5 91.12+1-3.12 
t-test (paired) p= 0.42 0.85 
ANOVA p=0.85 
Table 3.6 
Reproducibility of acetylcholine relaxation curves for non- pregnant, pregnant 
and pre-eclamptic omental vessels 
Non-Pregnant ( =4) Statistical comparisons: 
ED 50 Emax 
First relaxation curve 
-5.5+1-0.4 67.9+1-4.8 
Second relaxation curve -5.9+1-0.5 
70.4+/-5.9 
t-test (paired) P= 0.75 0.72 
ANOVA P=0.2 
Pregnant 
First relaxation curve 
Second relaxation curve 
t-test (paired) p= 
ANOVA p= 
Pre-eclampsia 
First relaxation curve 
Second relaxation curve 
t-test (paired) p= 
ANOVA p= 
Statistical comparisons: 
ED 50 
Emax 
-6.6+/-0.4 69.63+/-6,16 
-6.4+/-0.2 73.37+/-5.47 
0.72 
0.52 
0.18 
Statistical comparisons: 
ED 50 Emax 
-5.4+/-0.5 19.66+1-2.15 
-6.0+1-0.5 22.57+/-2.19 
0.29 0.21 
0.90 
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functional endothelium, acetylcholine was unable to produce either relaxation or constriction in 
these vessels (Fig. 3.14). All the omental vessels studied relaxed to acetylcholine. The Latin 
square design also showed that this was not a time dependent phenomenon as a bradykinin 
doses response curves were obtained after exposure to acetylcholine (Fig 3.14 & 15). The 
omental vessels that acted as positive controls produced endothelium dependent relaxation to 
both acetylcholine and bradykinin (Table 3.6). 
Reproducibility of dose response curves: 
In each group studied, and for each vasodilator, comparisons of the two dose response curves 
were made by paired t-tests of the EC5o, Emax responses and by repeated measures analysis of 
variance. Both myometrial and omental non-pregnant and pregnant vessels produced no 
significant differences between the first and second ose response curves: myometrial (Fig 3.11, 
3.12 and Table 3.4) and omental (Table 3.5 & 3.6). However, in the group of women with pre- 
eclampsia there was a statistically significant difference between the first dose response curve 
and the second to bradykinin (Fig 3.13) 
3.1.5.4 Discussion: 
In the omentum, bradykinin and acetylcholine caused an endothelium dependent relaxation. This 
is in accord with several other studies which demonstrated relaxation to bradykinin (Ashworth et 
al., 1996b) (Pascoal and Umans, 1996) (Pascoal et al., 1998) and to acetylcholine (Pascoal and 
Umans, 1996) (Pascoal et al., 1998). However, see Chapter 7 for a further experimental work and 
discussion. 
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The demonstration of endothelium dependent relaxation to bradykinin and histamine in 
myometrial vessels confirms the previous work of Ashworth et al (Ashworth et al., 1996a) 
(Ashworth, 1998). However, the lack of response to acetylcholine in these vessels is 
contradictory to that of Ashworth et al (1996). Ashworth et al (1996) demonstrated that 
acetylcholine licited an endothelium dependent relaxation. However, the number of vessels 
utilised was small (n=3) and the standard error of the means were large. A further caveat to the 
results of Ashworth et al is the fact that vessels were stored for up to forty-eight hours after 
dissection. Vessel storage may have affected the results obtained as storage may have 
increased the density of the acetylcholine receptors on the vessels. This would have the effect of 
increasing the relaxation to acetylcholine that was obtained. This hypothesis of increased 
relaxation with storage was not formally tested. However, Kublickiene t at (1997) utilised the 
more physiological pressure myography system and demonstrated that acetyl choline produces 
endothelium dependent relaxation in myometrial vessels that have been contracted with 
noradrenaline (Kublickiene et al., 1997). Noradrenaline has been shown to be unable to produce 
sustained contractions when wire myography was utilised (Ashworth, 1998), a finding that has 
also been confirmed by the author of this thesis in preliminary experiments (n=2). These 
differences have been postulated to be due to the loss of the myogenic component of vascular 
tone which occurs In isometric studies (Dunn et al., 1994). However, this Is in contrast to the 
study of Steele et al which demonstrated that noradrenaline could induce contractions in both 
pregnant and non-pregnant myometrial vessels (Steele et al., 1993). Discussion With the Steele 
et al revealed these responses were obtained with the vessel partially depolarised with potassium 
(12mM). Preliminary data (n=2) confirmed this finding. 
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It is known that different endothelium dependent relaxatory agents act in different ways to initiate 
relaxations even in the same vascular bed (Adeagbo and Triggle, 1993) (Alonso et al., 1991) 
(Garcia-Pascual et al., 1995) (see Chapter 6&7) and a logical extension of this would be that the 
nature of the constrictor agent could further alter the subsequent relaxation. Several studies have 
demonstrated that omental vessels that are constricted with vasopressin undergo endothelium 
dependent relaxation to acetylcholine (Vila et al., 1991) (Pascoal and Umans, 1996) and this 
thesis has confirmed this (see Chapter 7). However, omental vessels constricted with U46619 
have been shown to undergo neither contraction nor relaxation to acetylcholine (Wallerstedt and 
Bodelsson, 1997), a result which may suggest that the choice of vasoconstrictor used is important 
to the results obtained. Given these differences and discrepancies, the use of acetylcholine asa 
vasodilator in myometrial resistance vessels was abandoned. 
The endothelium dependent vasodilators bradykinin and histamine were used for myometrial 
studies and acetylcholine and bradykinin were used for omental studies. The resistance vessels 
studied, were thus constricted to vasopressin, and could be relaxed with bradykinin, histamine 
and acetylcholine (in the omentum) on two occasions without tachyphylaxis or alteration of the 
response curves. However, the finding of a alteration in the response curves with consecutive 
relaxations in the group of women with pre-eclampsia meant that any protocol utilised would have 
to allow for time control vessels. 
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3.1.6 Variability of vessels obtained from the same patient to the vasodilators: 
3.1.6.1 Alms: 
9 To determine whether vessel segments from the same experimental sample produced similar 
comparable r laxation curves that would allow comparisons to be made with respect to time. 
3.1.6.2 Methods: 
Myometrial and omental vessels were collected, dissected and mounted within 2 hours. Three 
vessels were then mounted on separate myographs. Vessels were then subjected to incremental 
doses of vasopressin. Following the addition of the vasoconstrictor, vessels were exposed to an 
incremental dose of the vasodilator under investigation bradykinin, histamine, and acetylcholine. 
3.1.6.3 Results: 
In all groups studied, all three vessels exposed to the vasodilator f interest (Fig 3.16,3.17,3.18 
and Table 3.7,3.8 & 3.9) produced ose response curves. The dose response curves obtained 
were compared with each other by comparison of their EC 5o and E max values. No significant 
differences were noted in any of the groups investigated. 
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Table 3.7 
Variability of histamine r laxation curves for non- pregnant, pregnant and pre- 
eclamptic myometrial vessels 
Non-Pregnant ( =6) Statistical comparisons: 
ED 50 Emax 
Vessel one curve 
-9.3+/-0.3 77.50+/-4.28 
Vessel two curve -8.7+/-0.3 70.20+1-6.20 
Vessel three curve -8.7+/-0.6 70.31+1-13.64 
ANOVA (factorial) p= 0.44 0.63 
Pregnant (n=6) Statistical comparisons: 
ED 5o(mod] Emax 
Vessel one curve 
-8.8+1-0.3 42.90+1-3.30 
Vessel two curve 
-9.1+/-0.3 39.25+1-3.42 
Vessel three curve -8.7+1-0.4 42.29+1.2.49 
ANOVA (factorial) p= 0.68 0.69 
Pre-eclampsia (n=5) Statistical comparisons; 
ED 501mod, Emax 
Vessel one curve 
-9.0+1-0.2 42.38+/-2.57 
Vessel two curve 
-9.0+/-0.2 51.72+1-3.93. 
Vessel three curve -8.7+1-0.3 46.11+1-5.63 
ANOVA (factorial) p= 0.56 0.27 
Table 3.8 
Variability of braykinin relaxation curves for non- pregnant, pregnant and pre- 
eclamptic omental vessels 
Non-Pregnant (n=6) Statistical comparisons: 
ED 50 Emax 
Vessel one curve 
-8.3+/-0.3 90.08+1-5.30 
Vessel two curve -8.2+/-0.5 93.09+1-3.12 
Vessel three curve -8.0+/-0.3 93.81+/-1.97 
ANOVA (factorial) p= 0.83 0.76 
Pregnant (n=6) Statistical comparisons: 
ED 50 
Emax 
Vessel one curve 
-8.4+1-0.1 98.10+/-0.91 
Vessel two curve 
-8.5+/-0.3 94.82+/-2.01. 
Vessel three curve -8.2+1.0.3 91.07+/-3.64 
ANOVA (factorial) p= 0.75 0.14 
Pre-eclampsia (n6) Statistical comparisons: 
ED 50 Emax 
Vessel one curve (n=3) 
-8.3+/-0.3 90.29+/-3.65 
Vessel two curve (n=6) -8.2+/-0.9 90.72+1-4.35. 
Vessel three curve (n=6) -8.6+1-0.6 92.53+1-7.47 
ANOVA (factorial) p= 0.96 0.86 
Table 3.9 
Variability of acetylcholine r laxation curves for non- pregnant, pregnant and pre- 
eclamptic omental vessels 
Non-Pregnant (n=6) Statistical comparisons: 
ED 50 Emax 
Vessel one curve 
-5.5+/-0.4 67.89+/-4.83 
Vessel two curve -6.0+1-0.5 69,74+1-5.93 
Vessel three curve -5.7+/-0.1 73.19+/-2.74 
ANOVA (factorial) p= 0.79 0.73 
Pregnant (n=6) Statistical comp arisons: 
ED 50 
Emax 
Vessel one curve 
-6.0+/-0.6 69.63+/-6.16 
Vessel two curve 
-5.9+/-0.6 77.38+1-7.970 
Vessel three curve -6.4+1-0.5 77.90+1-7.34 
ANOVA (factorial) p= 0.75 0,67 
Pre-eclampsia (n=5) Statistical com parisons: 
ED g0[mod] Emax 
Vessel one curve 
-5.4+1-0.5 19.86+1-2.15 
Vessel two curve 
-5.3+/-0.2 22.04+/-2.53 
Vessel three curve -4.9+1-0.4 11.26+l-2.39 
ANOVA (factorial) p= 0.67 0.37 
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3.1.6.4 Discussion: 
All vasodilators investigated produced comparable dose response curves in different vessels from 
the same patient and thus allowed time control experiments to be incorporated into the protocol. 
3.1.7 Determination of vascular function following storage: 
3.1.7.1 Aim: 
" 
To determine if resistance vessels could be stored overnight without loss of receptor- 
mediated vasoreactivity. 
3.1.7.2 Experimental design: 
Myometrial vessels were obtained from pregnant women (n=16). The vessels were dissected out 
as described in Chapter 2.4.2. Some vessels were mounted and experimented on immediately 
while others were stored overnight before experimentation as described inChapter 2.4.6. 
After storage the vessels were mounted and the experimental protocol performed (Chapter 2.5.5); 
vessels were subjected to incremental doses of vasopressin and then bradykinin (Chapter 
2.4.5.1,2 and 5). 
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3.1.7.3 Results: 
In this study 81 % of the vessels stored gave a response to vasopressin. Stored vessels that were 
capable of responding demonstrated no significant differences in either their vasoconstrictor 
responses or their endothelium dependent relaxation responses when compared to fresh vessels 
(ANOVA; p=0.35, Vasopressin, p=0.10, Bradykinin) (Fig 3.19 & 3.20). There was no-significant 
increase in the pH of PSS due to storage (pH 7.40 +1- 0.06 Vs 7.54 +/- 0.15 t-test; p=0.089). 
There was also no significant difference in the glucose concentrations with storage overnight 
(6.28+/- 0.01 Vs 6.30+1- 0.05: t-test; = 0.67). 
3.1.7.4 Conclusions: 
The preservation of pH, glucose and response to the pharmacological gents vasopressin and 
bradykinin over the storage period, meant that longitudinal experiments could be undertaken 
without detrimental effects on vessels function with respect to vasopressin and bradykinin causing 
bias to the system. 
Fig 3.19 
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3.2 Definitive Experimental Protocol 
The definitive protocol was determined from the pilot data given above and in conjunction with 
other available literature (McCarthy et al., 1993b) (Ashworth et al., 1996a) (Knock and Poston, 
1996) (Ashworth, 1998). 
In order to compare contractions of resistance vessels to vasopressin between different groups of 
women a standard contraction was performed for each vessel. The standard contraction used 
was a KPSS contraction i  the presence of noradrenaline (1x10-5 M). However, as it had been 
suggested that such a contraction might result in tachphylaxis and affect results obtained by 
altering the membrane potential (personnel communication with Dr W Dunn), this contraction 
needed to be at the end of the protocol. lt was also necessary to demonstrate hat vessels 
exhibiting decreased endothelium-dependent r laxation were not doing so due to a smooth 
muscle abnormality. This was achieved by the use of the endothelium-independent vasodilator 
sodium nitroprusside (1x10.9 
-1x10 -5 M). 
Resistance arteries of 200 
- 
550 pm were dissected from the uterine and omental biopsy 
specimens, which had been collected into oxygenated ice-cold PSS as described. In all the study 
groups, vessels from the same patient, and where possible portions of the same vessel were 
allocated to each study arm. 
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3.2.1 Protocol for the investigation of vascular reactivity changes with 
pregnancy and pre-eclampsia: 
All vessels in this protocol were dissected and experiment begun within 2 hours. Vessels were 
mounted and normalised (Chapter 2) and then left for 15 minutes to attain a steady baseline. 
Once this was achieved the following protocol was performed. Three vessels were dissected and 
mounted on different myographs whenever possible. 
Myoqraph one: 
1) Contraction tovasopressin (1x10-l° 
-1x10-8 M) then relaxation to bradykinin (1x10.10- 3.3x10" 
Mý 10 
2) Chamber washed four times with 40 mis of PSS. 
3) Contraction tovasopressin (1x10-1° 
-1x10-8 M) then relaxation to bradykinin (1x10.1°- 3.3x10- 
10 Mý, 
4) Chamber washed four times with 40 mis of PSS. 
5) Contraction tovasopressin (lx10-l° 
-1x10-8 M) then relaxation to sodium nitroprusside (1x10 -s 
-1 x10-5 M). 
6) 123mM KPSS with the addition of noradrenaline. 
Myograph two: 
1) Contraction tovasopressin (1x10-'° 
-1x10-8 M) then relaxation to bradykinin (1x10-10- 3.3x10- 
M), 10 
2) Chamber washed four times with 40 mis of PSS. 
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3) Incubated with indomethacin 10-5 M for 40 minutes. 
4) Contraction tovasopressin (1x10-10-lxl0-$M) then relaxation to vasodilator. 
5) Chamber washed four times with 40 mis of PSS. 
6) Contraction tovasopressin (1x10-10-lxlO-8M) then relaxation to sodium nitroprusside (1x10-9- 
4x10-5 M). 
7) 123mM KPSS with the addition of noradrenaline. 
MyograDh t ree: 
1) Contraction tovasopressin (1x10-10--1x10-8M) then relaxation to vasodilator. 
2) Chamber washed four times with 40 mis of PSS. 
3) Incubated with indomethacin (1x10-5M) and L-NAME (1xlO-4M) for 40 minutes. 
4) Contraction tovasopressin (WO-10-WO-8M) then relaxation to vasodilator. 
5) Chamber washed four times with 40 mis of PSS. 
6) Contraction tovasopressin (1x10-'0-1x10-8M) then relaxation to sodium nitroprusside (1x10-s- 
1x10-5 M). 
7) 123mM KPSS with the addition of noradrenaline. 
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3.2.2 Protocol for the interaction of Vascular Endothelial Growth Factor and 
plasma from women with pre-eclampsia with the endothelium: 
Vessels were dissected and incubated overnight (16 hours) in the presence or absence of VEGF 
or plasma. Once dissected vessels were placed into 10mis of oxygenated cold PSS in a 20mis 
sterile screw cap tube (Sterilin). 1 iu/ml heparin was required to prevent the formation of a fibrin 
clot, and was also added to all control vessels. Allocation of each vessel to each experimental arm 
was performed randomly. 
For plasma experiments, a concentration of 2% plasma was chosen as had previously been 
demonstrated to have an effect in cell culture studies and on vessel behaviour (Baker et al., 
1995a) (Baker et al., 1996a) (Ashworth et al., 1998). 
After storage vessels were mounted and normalised (Chapter 2). Vessels were then left for 15 
minutes to attain a steady baseline. Once this was achieved the following protocol for myograph 1 
in Chapter 3.2.1 was performed. 
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3.3 Cell Culture pilot data: 
It has previously been reported that myometrial resistance vessels from women with pre- 
eclampsia exhibit a loss of endothelium dependent relaxation (Ashworth et al., 1998). Pilot data 
within the department had suggested that incubation of normal myometrial resistance arteries with 
the plasma from women with pre-eclampsia c used an alteration in myograph behaviour which 
was similar to that exhibited by vessels from women with pre-eclampsia (Ashworth et al., 1998). It 
is also well documented that plasma from women with pre-eclampsia alters the production ofnitric 
oxide and prostacyclin from cultured endothelial cells (Baker et al., 1995a) (DaVidge et al., 1996a) 
(de Groot et al., 1995). Therefore it was felt appropriate that incubation with both VEGF and 
plasma should be carried out in both the myography and cell culture systems. It was also 
considered that the subcellular mechanism ofaction of plasma nd VEGF could be studied with 
the use cell culture. 
3.3.1 Determination of optimal plasma concentration for stimulation and 
viability: 
3.3,1.1 Aim: 
As the effects of plasma on cultured endothelial cell production of nitric oxide and prostacyclin 
were to be determined. It was necessary to determine the optimal concentration for maximum cell 
stimulation with minimum loss of cell viability. 
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3.3.1.2 Experimental Design: 
Bovine microvascular endothelial cells were cultured as described previously (Chapter 2.5.2.3). 
Cells were grown to confluence in 24-well sterile culture plates (NUNC, Denmark). Once cells 
were confluent they were made quiescent (Chapter 2.5.2.3). This medium was then aspirated and 
fresh medium (1 ml) added containing pooled plasma from normotensive women or those with 
pre-eclampsia at increasing percentages (1%, 2%, 5%, 10%, and 20%). Pooled plasma was used 
to minimise individual subject variability and ensure optimum use of the plasma vailable. Heparin 
was added to the medium to give a final concentration f 10 U/ml. Heparin was added to prevent 
the plasma clotting in the wells during the experimental time course. Twenty-four hours after the 
addition of plasma, the media were collected as described previously (Chapter 2.5.3.1). The 
media were then assayed for nitrite production (stable product nitric oxide), 6-keto prostaglandin 
F1 a (a stable product of prostacyclin), and lactate deydrogenase (an assessment of cell viability) 
(see Chapter 2.6). 
3.3.1.3 Results: 
3.3.1.3a Nitric oxide: 
Nitric oxide production from stimulated B88 endothelial cells increased as the percentage of 
pooled plasma rose in the stimulating media (p = 0.003; Kruskal-Wallis) (Fig 3.21 a). Post hoc 
testing showed that a significant difference from the control occurred at 5% added plasma 
(p=0.02: Mann-Whitney-U test). 
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3.3.1.3b Prostacyclin: 
Prostacyclin was determined indirectly from the measurement of its stable metabolite 6 keto- 
prostaglandin Fla. 6Keto-PGF1a concentrations increased in a concentration dependent manner 
with increasing concentrations of plasma (p=0.012: Kruskal-Wallis) (Fig 3.21 b). Post hoc testing 
showed that a significant difference from the control occurred with the addition of 2% plasma 
(p=0.02: Mann-Whitney-U Test) 
3.3.1.3c Lactate dehydrogenase (LDH): 
Lactate dehydrogenase l vels are significantly increased with incremental concentrations of
plasma (p=0.03: Kruskal-Wallis) (Fig 3.22). Post hoc testing revealed that the addition of 20% 
plasma (from women with pre-eclampsia or controls) caused the LDH levels to significantly 
increase over the control (0% plasma) (p=0.02: Mann-Whitney-U test). 
3.3.1.4 Discussion: 
In contrast to the findings of Baker et al (1995,1996) and Davidge t al (1995,1996) there was no 
activation with regard to nitrite production of the B88 cell line at a concentration f 2% plasma. 
These differences may have come from differences in the assays used, however, the 
prostaglandin Fla assay utilised in both this thesis and the studies of Baker et al and Davidge t 
al were from the same manufacture (Cayman Chemical, Ann Arbor; USA). The Griess reaction 
utilised a similar protocol, however, the sources of the chemicals were different and so variations 
in purity may have affected the chemical reactions. Alternatively, the differences may reflect 
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differences inthe population ofpatients tudied, which is indeed another caveat for testing of the 
hypothesis that plasma from women with pre-eclampsia activates endothelial cells, 
Although differing concentrations of plasma were required to obtain results than those reported 
previously, the increase in the nitric oxide and prostacylin production from cells that had been 
stimulated with plasma from women with pre-eclampsia was the same. Therefore, it was 
considered that a concentration f plasma of 10% should be utilised in cell culture xperiments. 
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Chapter Four: Vascular Endothelial Growth Factor concentrations in 
regnancv and pre-eclampsia: 
4.1 Introduction: 
Roberts et al (1990) proposed that the alteration in endothelial function characteristic of pre- 
eclampsia was due to (a) factor(s) in the serum / plasma which caused increased vascular 
permeability, proteinuria, and vasospasm leading to hypertension (Roberts et al., 1989). VEGF is 
well documented to cause an increase in vascular permeability (Senger et al., 1986) (Connolly et 
al., 1989b) (Wu et al., 1996) (Wu et al., 1999) (Tilton et al., 1999) and has also been implicated in 
the renal disease associated proteinuria (Uchida et at., 1994) (Shulman et at., 1996) and 
promotes vascular coagulation (Ferrara et al., 1992). 
The concentration f VEGF in normal and abnormal pregnancies have been studied previously, 
however results are far from conclusive. Baker et at, (1995b) examined serum concentrations 
using a sandwich-type immunofluorescencent assay. Although they suggested that VEGF was 
increased in pre-eclampsia, they obtained measurable concentrations in 13 % (10) of all subjects 
sampled (78). From this 13% they demonstrated that a higher proportion of women with pre- 
eclampsia had measurable concentrations of VEGF when compared to the normotensive group (9 
Vs 1). However, Baker et at (1995b) presented no validatory data to confirm the sensitivity of the 
assay used. Two further studies, which utilised commercially available assays, have also 
produced conflicting results. Sharkey et at (Sharkey et at., 1996) found that both plasma and 
serum concentrations of VEGF were increased in pre-eclampsia using a competitive nzyme 
immunoassay assay (CEIA). In contrast Lyall et al (Lyall et al., 1997a), using a sandwich two-site 
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enzyme-linked immunosorbent assay (ELISA), demonstrated that the serum VEGF 
immunoreactivity was reduced in pre-eclampsia. Neither Sharkey et al, (1996) or Lyall et al, 
(1997) present confirmatory data to suggest that their commercially available assays were 
applicable to pregnancy. It is interesting to note that the assay utilised by Sharkey et al (1996) 
has been validated for pregnancy plasma nd serum samples by the manufacturers, whereas the 
assay utilised by Lyall et al (1997) has not (R&D systems, UK: VEGF ELISA data sheet). 
Furthermore, Lyall et al (1997) stated that the median serum concentration for the group of 
women with pre-eclampsia w s 2 pg/mi, whereas the manufacturers data sheet quotes 12 pg/mi 
as lower limit of detection (R&D systems, UK: VEGF ELISA data sheet). These observations 
must bring into question the use of this assay in pregnancy. 
Recently, Anthony et at have developed a competitive binding radioimmunoassay (RIA) for VEGF 
using a polyclonal ntibody (Anthony et al., 1997). In their pilot study of twenty normotensive 
pregnant subjects and twenty non-pregnant subjects, serum VEGF was detected in all subjects 
and levels were raised in comparison tonon-pregnant controls. In contrast, the commercial VEGF 
ELISA (R&D systems: UK) used by Lyall et al was unable to detect VEGF in 19 of the 20 maternal 
serum samples analyzed. Moreover, the recovery of exogenous VEGF added to pregnancy 
samples has been shown to be low or unrecordable with the R&D ELISA (Anthony et al., 1997) 
(Vuorela-Vepsalainen et al., 1999), whereas using the RIA, 82-101% of the added VEGF was 
recovered. Anthony et al (1997) postulated that these differing results could be explained by the 
formation of VEGF-protein complexes that are detectable using RIA but undetectable with the 
ELISA. 
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Therefore, the measurement of VEGF in pregnancy is still controversial, and as yet there have 
been no satisfactory assessment of VEGF concentrations in the condition of pre-eclampsia. This 
study utilised the assay developed and validated for pregnancy of Anthony et al (Chapter 2) to 
investigate these important questions, 
4.2 Aims: 
" 
To investigate he concentrations of VEGF in non-pregnant women, normal pregnant women 
and women with pre-eclampsia utilising the radioimmunoassay developed by Anthony et al. 
" 
To investigate whether VEGF concentrations correlate with the abnormal parameters ofthis 
disease. 
4.3 Experimental design: 
Plasma samples were collected from 22 subjects diagnosed as having pre-eclampsia (Chapter 
1.1). To act as controls, plasma was taken from 22 gestation matched normotensive women 
without any complications of pregnancy or underlying illness. Samples were also taken from eight 
non-pregnant women who were not taking the oral contraceptive pill. Samples were collected as 
described previously in the Chapter 2.2.2. Measurements of the total VEGF immunoreactivity 
were made by a competitive radioimmunioassay detailed in Chapter 2.3.1 which had previously 
been validated for pregnancy (Anthony et al., 1997). 
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4.4 Results: 
4.4.1: VEGF concentrations in non-pregnant and pregnant women and those 
with pre-eclampsia: 
Table 4.1 summaries the clinical data of the non-pregnant, pregnant controls and the pre- 
eclampsia group. As anticipated, systolic and diastolic blood pressures were significantly greater 
in the group of women with pre-eclampsia than in the control or non-pregnant group (P= 0.001). 
All VEGF concentration data is expressed in this thesis as µg/L, this is due to the fact that, 
although it would be preferable to express concentrations in molar values, this is not appropriate 
as VEGF exists in several isoforms of differing molecular weights (see Chapter 1). The median 
plasma concentration in the non-pregnant group was 0.56µg/l (interquartiie range 0.49-0.71 µg/1) 
and in the pregnant group 3.4µg/ (interquartile range 2.7-4.1 µgll). Plasma VEGF concentrations 
were also significantly raised In women with pre-eclampsia when compared to the normotensive 
controls (Mann-Whitney-U; P=0.001). The median plasma concentration of VEGF in the pre- 
eclampsia group was 5.7µg/l (interquartile range 4.8-6.9µg/l) (Fig 4.1). Analysis of the VEGF 
concentrations showed that a significant difference occurred between the three groups (Kruskal 
- 
Wallis test; p=0.0001) (Fig 4.1). Further analysis demonstrated VEGF concentrations were 
increased with pregnancy (Mann-Whitney-U; p=0.0001). 
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4.4.2 Effect of gestation on results: 
VEGF concentrations within the normotensive group increased with gestation (Spearman rank 
correlation: r= 0.45; P=0.025) (Fig 4.2). However, in the group of women with pre-eclampsia 
there was no significant correlation ofVEGF with gestation (Spearman rank correlation: r=0.01; P 
= 0.940). In a similar manner, blood pressure within the normotensive group rose with increasing 
gestation (Spearman rank correlation: r=0.47; P= 0.001), but no similar correlation could be 
demonstrated within the pre-eclampsia group (Spearman rank correlation: r=0.37; P= 0.250) (Fig 
4.3). 
4.4.3 Correlation with disease parameters: 
4.4.3.1 VEGF plasma concentrations with blood pressure 
There is no evidence for a bimodal distribution of the blood pressure in pregancy and as such 
data must therefore be considered as coming from a single group. There were significant 
correlations ofVEGF with both the diastolic and systolic blood pressure, demonstrating that VEGF 
concentrations and the maternal blood pressure rise in parallel (Figure 4.4 & 4.5). However, 
analysis of the individual groups showed that there were no significant correlation of VEGF 
concentration with systolic blood pressure in either the normotensive group or women with pre- 
eclampsia (Figure 4.4 & 4.5). There was also no significant correlation of VEGF concentration 
with diastolic blood pressure in the normotensive group (Figure 4.4 & 4.5). However, a significant 
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correlation of VEGF concentration with diastolic blood pressure occurred within the group with 
pre-eclampsia (Spearman rank correlation; p=0.001) (Fig 4.4). 
4.4.3.2 Plasma VEGF concentrations with other parameters: 
Plasma VEGF concentrations howed no significant correlation with either urinary protein 
(Spearman rank: r- 0.14; p=0.66); plasma uric acid (Spearman rank: r= 0.07; p=0.22); or 
platelet count (r= 0.17; p=0.70) (Fig 4.6,4.7 & 4.8). 
4.5 Discussion: 
VEGF plasma concentrations: 
In accord with previous tudies, the plasma concentrations of VEGF are in the picomolar range 
(Sharkey et at., 1996) (Kupferminc et al., 1997b) (Hunter et al., 2000) (Bosio et al., 2001); a 
concentration which stimulates biological responses in cultured endothelial cells (Bikfalvi et al., 
1991). However, Kupferminic et al report values which are three times higher than other studies. 
This may be due to their use of serum and not plasma; as higher concentrations of VEGF have 
been demonstrated in serum due to its release from platelets (Webb et al., 1998). 
Although, this study measured total VEGF it did not allow discrimination between separate 
isoforms (see Chapter 1). VEGF 189 and VEGF 206 each contain a highly basic 24 amino acid 
insert hat promotes binding to cell surface heparin sulphates. In contrast VEGF 121 and VEGF 165 
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are diffusible and therefore it would seem likely to be these isoforms which are recognised, 
however, further work using selective antibodies is needed. 
VEGF concentrations have previously been reported to increase in the first trimester of pregnancy 
when compared to non-pregnant controls (Evans et al., 1997) (Evans et al., 1998) (Wheeler et at., 
1999). This has been correlated to both gestational ge (to 10 weeks) and various hormones 
reflecting placental function, including ß-HCG and progesterone (Evans et al., 1997). The authors 
speculated that VEGF may be crucial for both the development of the placenta and the 
adaptations ofthe cardiovascular system. 
In relation to late pregnancy, this thesis shows that plasma concentrations of VEGF are increased 
in the third trimester when compared to non-pregnant controls. VEGF rose in the third trimester of 
normal pregnancy with gestation, when diastolic blood pressure, but not systolic blood pressure 
also rose. This finding confirms that of Bosio et al (2001), who showed that in normal pregnancy 
VEGF concentrations were constant between 10 weeks and 28 weeks and then rose with 
gestation to delivery (Bosio et al., 2001). The rise in blood pressure with gestation is also in 
accord is with numerous studies (MacGillivary et al., 1969). MacGillivary et al (1969) showed that 
diastolic blood pressure rose more substantially than the systolic as the pregnancy advances, 
This thesis only showed a significant increase in the diastolic blood pressure and this probably 
due to the sample size and the cross-sectional ture of the study. 
These observations led to the hypothesis that VEGF may be important with regard to the control 
of maternal blood pressure in the third trimester. In support of this hypothesis is the 
demonstration that there was a trend for the diastolic blood pressure to rise with VEGF 
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concentration in the control pregnant group, although this did not reach significance. This result 
may have not reached significance due to several possible reasons, firstly, a small sample size; 
secondly the inherent errors in blood pressure measurement with regard to the diastolic blood 
pressure in pregnancy, thirdly any association may be very weak and finally it may simply be an 
epiphenomemon. One methodological problem when measuring blood pressure indirectly during 
pregnancy, is whether the 4th or 5th Korotkov sound should be taken as the cut-off point for the 
diastolic blood pressure. In the non-pregnant state, it has been demonstrated that the 5th 
Korotkov sound correlates closely with the diastolic pressure recorded using a direct 
measurement technique (Rafetery and Ward, 1968). However, in pregnancy, use of the 5th 
Korotkov sound skews the data, as it has been demonstrated to be present with the cuff pressure 
at zero (MacGillivray et al., 1969). As such the less accurate 4th sound is used and may produce 
an increased false positive rate on the diagnosis of hypertension. 
Paradoxically, the only studies to date on the in vivo effects of VEGF on cardiovascular 
physiology, have shown that injection of VEGF into non-pregnant rats causes a transient drop in 
the blood pressure by the stimulation ofnitric oxide (Yang et al., 1996) (Webb et al., 1999). Yang 
et al (1996) also noted that the haematocrit was increased in the experimental nimals and 
hypothesised that this occurred through an increased vascular permeability, which subsequently 
reduced venous return and indirectly blood pressure (Yang et al., 1996). Although an Increase in 
vascular permeability may be one mechanism, VEGF has also been shown to act In an in vitro 
system, directly on the endothelium to cause vasodilatation via nitric oxide (Ni et al., 1997a). 
However, it remains to be clarified whether these observations are the same In human vessels, 
and particularly whether these effects occur In vessels from pregnant women (see Chapter 8). 
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This study confirms reports that VEGF is increased in pregnancies complicated by pre-eclampsia 
(Sharkey et at., 1996b) (Kupferminc et at, 1997a) (Bosio et at., 2001) (EI-Salahy et al., 2001). 
Although, Lyall et al (1997) and more recently (Reuvekamp et al., 1999) Helfer et at, (2000) and 
Livingston et at (2000) have demonstrated that reduced levels of VEGF occur in pregnancies 
complicated by pre-eclampsia, ll these studies utilised the same commercial assay, the deficits 
of which have been discussed in this Chapter's introduction (Reuvekamp et at., 1999) (Hefler et 
at., 2000) (Livingston et at, 2000). 
The data in this thesis demonstrates that as the maternal VEGF immunoreactivity rises there is a 
parallel rise in both the systolic and diastolic blood pressure. A similar association between these 
parameters has been demonstrated previously, with the authors postulating that VEGF was 
important in the pathogenesis of this disease (Kupferminc et al., 1997a). 
The increased concentration of VEGF in pre-eclampsia is consistent with the hypothesis that, 
VEGF as a circulating factor may be involved in the endothelial dysfunction. Further 
circumstantial evidence is provided by the work of Davidge et at (Davidge et at., 1996a); they 
found that fractionated plasma in the molecular weight range 42,000-62,000 kDa stimulated 
prostacyclin production in endothelial cells. This Is In the molecular weight range of VEGF, 
however, it is also in the molecular weight range of many other substances that have been 
implicated in the pathogenesis of pre-eclampsia, including renin (Brown et al., 1997c). Therefore, 
it is important o determine whether VEGF alters endothelial function in a similar manner to 
plasma from women with pre-eclampsia (Baker et al., 1995a) (de Groot et al., 1995) (Davidge et 
al., 1995b) (Baker et at., 1996a) (Davidge et al., 1996a) (Ashworth et at., 1998) and whether 
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inhibition of plasma VEGF with specific antibodies inhibits the observed changes of endothelial 
cell function (see Chapters 8 and 9). 
Hunter et al (2000) have described a longitundinal study of maternal VEGF in normal pregnancies 
and those complicated by pre-eclampsia. They confirmed the finding that VEGF immunoreactivity 
was increased in pregnancies complicated by pre-eclampsia, and also demonstrated that VEGF 
levels are elevated several weels prior to the onset of the clinical disease (Hunter et at., 2000). 
Bosio et at (2001) have recently confirmed in a similar longitundinal study that plasma VEGF 
concentrations, measured using the assay of Anthony et at (1997), of women destined to develop 
pre-eclampsia were elevated at least four weeks prior to the clinical onset of disease (Bodo et al., 
2001). 
Boslo et al (2001) also examined the relationship between maternal VEGF immunoreactivity and 
total peripheral resistance. Bosio et al (2001) studied 70 subjects, from an original cohort of 400; 
20 of these developed pre-eclampsia, 24 developed gestational hypertension (defined as 
hypertension without proteinuria) nd 26 acted as normotensive controls. Bosio et al (2001) also 
showed that VEGF concentrations correlated with the increased total peripheral resistance (TPR) 
associated with disease. Interestingly, the group of women with gestational hypertension alone 
neither showed increased TPR nor increased VEGF concentrations and this led the authors to 
postulate that the increased VEGF production occurred by mechanical stress on the endothelium 
as a result of an increased TPR. However, closer analysis of their data indicates that in some 
women who developed pre-eclampsia, the VEGF concentrations had risen prior to the increase in 
TPR, which is not consistent with their hypothesis. An alternative hypothesis for their data Is that 
160 
increased VEGF concentrations alter endothelial function, with the resultant effect of increasing in
the TPR. 
The observation that plasma VEGF concentrations are positively correlated with blood pressure 
and TPR (Kupferminc et al., 1997a) (Bosio et al., 2001) (Chapter 4.4.3) raises the important 
question: "Does VEGF either directly or indirectly alter vascular eactivity to cause peripheral 
vasoconstriction" which is addressed in Chapter 8. 
Source of VEGF: 
This study does not address everal important questions relating to the source of the circulating 
VEGF. Firstly, which tissues produce the increased VEGF concentrations with gestation? 
Secondly, are these tissues also the same sites for increased production in pre-eclampsia and 
gestation or do they differ? 
VEGF is widely distributed throughout the body's tissues, but in pregnancy, additional sites of 
importance may include decidual macrophages, placental macrophages, trophoblast, and 
fibroblasts, all of which have been shown to express VEGF mRNA and protein (Clark et al., 1996) 
(Wheeler et al., 1995). A number of studies have shown that the placenta nd the myometrium 
are an abundant source of VEGF (Sharkey et al., 1993) (Charnock-Jones et al., 1993) (Jackson et 
al., 1994) (Greb et al., 1995) (Harrison-Woolrych et al., 1995) (Brown et al., 1997a). Hunter et al 
(2000) in their longitudinal study demonstrated that the VEGF levels returned to non-pre- 
eclampsia levels within 24 hours of delivery. Therefore it could be hypothesised that the 
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maternofeta( interface causes the increased circulating concentrations of VEGF in normal 
pregnancy and pre-eclampsia (see Chapter 5). 
VEGF and renal effects: 
In the normal adult kidney, only the smallest plasma proteins are able to cross the glomerular 
barrier. This selectivity is primarily due to characteristics of the basement membrane and the 
endothelium. VEGF is normally expressed athigh levels by podocytes, and the visceral epithelial 
lining of Bowmans capsule, which support the glomerular capillaries (Brown et al., 1992). This led 
to the suggestion that, as VEGF causes an increase in vascular permeability (Senger et al., 1983) 
(Connolly et al., 1989a) (Connolly, 1991) (Wu et al., 1996) (Bates and Curry, 1996) (Bates and 
Curry, 1997), itmay have a physiological role in regulating renal glomerular permeability. 
It has also been demonstrated that VEGF may be important in the development of proteinuria in 
various pathological conditions (Uchida et at., 1994, Shulman et al., 1996) (Horita et al., 1998). 
As pre-eclampsia is partly defined by proteinuria, nd as VEGF has been implicated in renal 
disease, itwould be reasonable to hypothesise that it may be of importance inthe development of 
the renal pathology associated with pre-eclampsia. 
As well as proteinuria, hyperuricaemia is well documented as an associated biochemical 
abnormality of pre-eclampsia (Slemons and Bogert, 1917), which has been correlated with the 
severity of disease and histological changes in renal biopsies (Pollak and Nettles, 1960). 
Hyperuricaemia h s also been demonstrated to be a sensitive indicator of renal function and 
blood flow (Breckenridge, 1966) (Messerli et al., 1980a) (Messerli et al., 1980b). Therefore, if 
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VEGF is involved in the pathological changes that occur in the renal system in pre-eclampsia it 
may be expected that the maternal plasma levels of VEGF would correlate with both proteinuria 
and uricaemia s these are markers of renal damage. 
Contrary to our hypothesis, VEGF did not correlate to either plasma uric acid concentrations or 
urinary protein concentrations (Figure 4.6 & 4.7). Although these data does not support the 
hypothesis, it does not preclude it, as the tissue concentrations are more important than the 
circulating concentrations. Recently, it has been demonstrated in a Sprague-Dawley rat model of 
glomerulonephrosis, induced by the Intraperitoneal injection of bovine albumin, that both VEGF 
and its receptors (fit-1 and KDR) are dramatically up-regulated in the glomeruli of experimental 
animals when compared to controls, and that this is associated with increased proteinuria (Horita 
et at., 1998). However, the direct injection of VEGF into similar rats causes no increased 
proteinuria or renal histological changes (Webb et al., 1999). There are a number of reasons why 
these differences may have occurred; the VEGF may have been neutralised by a factor in the 
blood, or that the VEGF did not reach the kidney in sufficient concentrations to cause an effect. 
Despite the lack of correlation of maternal plasma VEGF concentrations to the markers of renal 
disease in this thesis, a role for VEGF in the renal pathology of pre-eclampsia h s recently been 
suggested by the work of Hunter and colleagues. They demonstrated that the injection of VEGF 
in dextran 40 into guinea-pigs causes the development of significant proteinuria,  significant drop 
in platelet count and an elevation of liver enzymes when compared to the control group (Hunter, 
2000). All these results are in accord with the clinical presentation of pre-eclampsia. Hunter and 
colleagues also injected VEGF into non-pregnant guinea-pigs and demonstrated that these 
animals did not suffer a similar derangement i  blood parameters or develop proteinuria (Hunter, 
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2000). However, guinea-pigs are not humans and extrapolations hould be treated with caution. 
Therefore, further studies are required of human pregnant kidney to determine if altered 
expression of VEGF or its receptors may explain the observed increase in proteinuria in pre- 
eclampsia. Such studies may include in situ hybridisation, immunohistochemical and quantitative 
RT-PCR for both VEGF and its receptors in human kidney biopsies. 
4.6 Summary: 
In summary it has been confirmed that circulating concentrations of VEGF are increased in 
pregnancies complicated by pre-eclampsia and that the increases rise in parallel with the maternal 
blood pressure. However, several important questions till remain to be addressed. These 
include the source of the increased VEGF both in normal and abnormal pregnancies, and whether 
VEGF can directly or indirectly alter vascular reactivity. 
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Chapter Five 
- 
mRNA levels of Angiogenic Growth Factors (VEGF and PIGF) 
and their receptors (fit-I and KDR) in placentas and myometrium from 
pregnant women and women with pre-eclampsia nd myometrium from non- 
pregnant women. 
5.1 Introduction: 
The origin of these increased maternal plasma / serum concentrations in both normal pregnancies 
and those complicated by pre-eclampsia remains to be determined. Although the placenta has 
been studied with respect to the expression ofVEGF, no study has examined the other half of the 
human feto-maternal unit, the uterine myometrium, asa possible source of VEGF in pregnancy 
and pre-eclampsia. 
The cellular secretion of the four isoforms of VEGF is dependent on their physical properties, with 
the larger isoforms being mainly extracellular matrix associated (Houck et at., 1992). These 
isoforms display varying specificites to the different VEGF receptors, and this may act to regulate 
function (Gitay-Goren et al., 1992) (Terman et al., 1994). To date no study has examined the 
effect of pregnancy or pregnancy complications onthe expression ofthese VEGF isoforms or that 
of PIGF on either side of the feto-matemal unit. 
5.2 Aims: 
" 
To examine semi-quantitatively the mRNA expression ofthe VEGF isoforms and PIGF In the 
placentas from normotensive pregnant women and in pregnancies complicated by pre- 
eclampsia 
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" 
To examine semi-quantitatively the mRNA expression ofVEGF, and PIGF in the myometrium 
of non-pregnant women, pregnant women and in women with pre-eclampsia. 
5.3 Experimental design: 
Placental samples were obtained from normal pregnant women (n=7) and women with pre- 
eclampsia (n=6) (Chapter 2.4.2). Samples of myometrium were also collected from non-pregnant 
women of reproductive age (n=6), pregnant women (n=7) and women with pre-eclampsia (n=7) as 
detailed in Chapter 2.4.1. Samples were then processed (Chapter 2.4.3) and RT-PCR (Chapter 
2.4.3-5) was performed on the samples for ß-actin, VEGF, PIGF, fit-1 and KDR (Chapter 2.4.5). 
5.4 Results: 
Table 5.1 and 5.2 summaries the clinical data of the non-pregnant, pregnant controls and the pre- 
eclampsia group. 
5.4.1 mRNA expression of the VEGF isoforms and its receptors in the 
placentas from pregnant women and women with pre-eclampsia: 
In placentas from normotensive control women and women with pre-eclampsia the VEGF121, 
VEGF165 and VEGF18s isoforms were expressed. Analysis of the data showed that the VEGF 121 
isoform in placentas from both normotensive controls (Kruskal-Wallis: P= 0.048) and women with 
pre-eclampsia (Kruskal-Wallis: P= 0.0013) was the most abundantly expressed. However, no 
significant differences were noted in the expression of VEGF121 (Mann-Whitney-U: P=0.89), 
VEGFI65 (Mann-Whitney-U: P= 0.67), or VEGFI89 (Mann-Whitney-U: P= 0.39) between the 
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placentas from the normotensive control group and the group of women with pre-eclampsia (Fig 
5.1). 
As well as VEGF mRNA, the placentas from the normotensive control women and the women with 
pre-eclampsia also expressed fit-1 and KDR receptor mRNA (Fig 5.2 & 5.3). Statistical analysis 
of the data revealed no differences in the expression of either receptor in the normotensive 
controls when compared to the pre-eclampsia group (flt-1: P= 0.77: Mann Whitney U test; KDR: 
P= 0.48: Mann Whitney U test). 
5.4.2 mRNA expression of PIGF in the placentas from pregnant women and 
women with pre-eclampsia: 
Although PIGF was expressed by all placentas tudied there was no significant difference in 
expression between the placentas from normotensive controls and the placentas from women 
with pre-eclampsia (Mann-Whitney-U: P=0.09) (Fig 5.4). 
5.4.3 mRNA expression of the VEGF isoforms and its receptors in the 
myometrium of non-pregnant women, pregnant women and women with pre- 
eclampsia: 
In the myometrial biopsies from non-pregnant women, normotensive control women and women 
with pre-eclampsia the VEGF121, VEGFI85 and VEGF189 isoforms were all expressed (Fig 5.5). 
Sub-analysis within the study groups, revealed that in the non-pregnant (Kruskal-Wallis: P=0.002) 
and the pre-eclampsia groups (Kruskal-Wallis: P= 0.008) the VEGF 121 isoform was most 
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abundantly expressed, however, in the normal pregnant group the expression of three isoforms 
were similar (Kruskal-Wallis; P=0.5). 
Analysis of the isoform expression between the study groups howed that there were significant 
differences inexpression: VEGF 121(Kruskal-Wallis: P= 0.04) VEGF 165 (Kruskal-Wallis: P=0.02) 
and VEGF 189 (Kruskal-Wallis: P=0.004). Post hoc testing demonstrated that all three isoforms 
were significantly increased in the pregnant group when compared to the non-pregnant group: 
VEGF 121 (Mann-Whitney: P=0.045), VEGF 165 (Mann-Whitney: P=0.04) and VEGF 189 (Mann- 
Whitney: P= 0.01). In contrast no significant differences were noted between the pregnant group 
and pre-eclampsia group: VEGF 121 (Mann-Whitney: P=0.96), VEGF 165 (Mann-Whitney: P=0.66) 
and VEGF 189 (Mann-Whitney: P=0.54). 
The myometrium of all three experimental groups, as well as expressing VEGF mRNA, also 
expressed fit-1 and KDR receptor mRNA (Fig 5.6 & 5.7). Statistical nalysis of the data revealed 
no differences inthe expression ofeither receptor between the three experimental groups (fit-1: 
P= 0.21: Kruskal 
- 
Wallis; KDR: P= 0.47: Kruskal 
- 
Wallis) although both receptors were present at 
somewhat higher density in the group with pre-eclampsia. 
5.4.4 mRNA expression of PIGF In the myometrium of non-pregnant women, 
pregnant women and women with pre-eclampsia: 
There was a significant difference in the expression of PIGF mRNA between the three study 
groups (Kruskal 
- 
Wallis: P=0.02) (Fig 5.8). However, post-hoc analysis was unable to reach 
significance when comparisons were made of the non-pregnant Vs normal pregnant groups 
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(Mann Whitney: P= 0.39) and the normal pregnant Vs pre-eclampsia groups (Mann Whitney: P= 
0.08). This apparent failure to reach significance may be due to insufficient numbers or to no 
difference existing between these groups. 
5.5 Discussion: 
5.5.1 Placental expression: 
The data presented in this thesis demonstrates, using a nested semi-quantitative PCR technique, 
that in third trimester placentas obtained from normal pregnancies at least hree isoforms of VEGF 
are expressed, VEGF 121, VEGF Iss, VEGF Iss. Several other studies have shown similar esults. 
Sharkey et al, (1993) demonstrated utilising the same nested RT-PCR protocols that four isoforms 
of VEGF were present in human first trimester and third trimester placenta, VEGF 121, VEGF 145, 
VEGF 165, VEGF 198 (Sharkey et at., 1993). Anthony et at, utilising a different two round PCR 
protocol were able to confirm this finding in first trimester placenta long with the addition of a 
further VEGF 206 isoform (Anthony et al., 1994). The discrepancy may have arisen from the 
different PCR primers and protocols employed (Anthony et al., 1994) (Sharkey et at., 1993) and 
as such both this study and Sharkey et al (1993) may have required extended protocols or 
different primers to detect the larger VEGF 206 isoform. Jackson et al (1994) demonstrated 
utilising Western blot analysis that the VEGF 121, VEGF 145, VEGF 165, VEGF 189 and VEGF 206 
isoforms were expressed by term placenta (Jackson et at., 1994). It is Interesting that the 
messages for larger VEGF molecules, which do not appear to be secreted in readily soluble form 
and become bound to the extra-cellular matrix (Houck et al., 1992) are produced at lower copy 
numbers and require xtended PCR protocols. The requirement of extended PCR protocols for 
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the detection of mRNA from extracellular matrix bound products has also been reported for basic 
fibroblast growth factor (Watson et al., 1992). This may represent longer half-life times for these 
molecules, however, there is at present no data to support this suggestion. 
This thesis demonstrated in both placentas from normal pregnant women and from women with 
pre-eclampsia, that the VEGF 121 isoform is most abundantly expressed. This confirms the finding 
of Houck et al (1991) who, using Western Blot analysis, also reported VEGF 121 to be the primary 
expression product of placenta (Houck et al., 1991). However, Jackson et al (1994) also utilised 
Western blotting and demonstrated that VEGF 206 was the most abundant isoform. The data of 
this thesis and that of Anthony et al (1994) would oppose the observation ofJackson et al (1994), 
unless the VEGF 206 isoform has an extended the half-life. However, the in vivo half-life of 
VEGF206 still remains to be determined. These differences may also have occurred for several 
reasons. Firstly, the antibodies ensitivities used in the Western immunoblotting may have 
differed. Secondly, different techniques were employed; this study utilised semi-quantitative RT- 
PCR, which quantifies mRNA, whereas the studies of Houck et al (1991) and Jackson et al (1994) 
used Western blotting, which detects transcribed protein. Thirdly, both Houck et al (1991) and 
Jackson et al (1994) did not express their results related to housekeeping gene product. Anthony 
et al (1994) utilising RT-PCR suggested that VEGF 165 was predominant, however, their results 
were obtained from cultured first trimester placental tissues. Removal of the placenta from its 
regulatory hormone milieu may have profound effects on VEGF expression, producing misleading 
results. 
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It is evident that the human placenta produces various amounts of all the VEGF isoforms. 
Although the biological significance of the different isoforms of VEGF is still unclear, VEGF 121, 
VEGF 145 and VEGF 165 are found to be efficiently secreted and appear to possess angiogenic 
activity (Houck et al., 1991) (Poltorak et al., 1997), whereas VEGF las and VEGF 206 contains an 
insertion encoded by exon 6 and remain predominantly cell-associated. However, the expression 
of both secreted and cell-associated isoforms of VEGF allows the possibility that VEGF acts in a 
paracrine manner in those tissues to regulate both vascular angiogenesis and permeability. The 
functions of the different isoforms within the uteroplacental environment thus remain to be 
determined. 
The localisation and distribution pattern of immunoreactive VEGF and its fit-1 receptor at different 
gestations have been examined by Ahmed et al (1995). They reported that both proteins were 
detected in the cytotrophoblast of first and second trimester placental tissue (Ahmed et al., 1995). 
Cytotrophoblast cells are undifferentiated stem cells which overlays the chorionic villi and display 
proliferate activity undergoing differentiation i to villous and extravillious trophoblast (Yeh et al., 
1989). This extravillous trophoblast then migrates towards and into the maternal decidua. In situ 
hybridisation for VEGF mRNA has shown that in first trimester human placenta, expression is 
limited to the cytotrophoblast and syncytiotrophoblast surrounding the villi (Sharkey et al., 1993). 
In contrast, in term placenta; mRNA distribution changed and was confined to the 
syncytiotrophoblast, extravillous trophoblast and maternal macrophages (Sharkey et al., 1993). 
Using an immuniohistochemistry technique, these original observations have been confirmed, with 
the VEGF protein localised in the first trimester to cytotrophoblast nd syncytiotrophoblast and as 
gestation progressed to only syncytiotrophoblast (Barleon et al., 1994). The differing spatio- 
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temporal observations of VEGF in early and late gestation placentae indicate that VEGF may play 
a role in both placental development and endothelial maintenance. 
Cooper et al 1995 examined the expression of VEGF mRNA in placentas from normotensive 
control women delivered through the third trimester and showed that expression decreased as 
gestation increase. A finding recently confirmed by Khaliq et al (1999). However, it could be 
suggested that the control group they used were not normal, as they were delivered prematurely, 
and this may have biased the data obtained. The premature deliveries in their normotensive 
group were for placental bruption, premature labour, and evidence of intra-uterine infection, all of 
which could affect the placental expression ofVEGF to give misleading values. Indeed placental 
abruption and pre-eclampsia have recently been shown to be associated with genetic mutations 
for the thrombophila genes; Factor V, methyltetrahydrofolate reductase and prothrombin 
(Kupferminc et al., 1999). The authors postulated that the result of these mutations leads to 
abnormal placentation and its subsequent sequelae, either pre-eclampsia or placenta bruption. 
Whether this alteration in expression with gestation is accompanied by an alteration in the VEGF 
isoform expression remains to be demonstrated. 
Charnock-Jones t at, 1994 and Clark et al, 1996 have utilised in situ hybridisation to reveal 
strong localisation of VEGF mRNA within the maternal decidual macrophages (Chamock 
-Jones 
et al., 1994) (Clark et al., 1996). Ahmed et at, 1995 utilised immunostaining to confirm VEGF 
protein production by these tissues and also demonstrated that extravillous trophoblast expressed 
high levels of the fit-1 receptor. From this they postulated that VEGF may act as a 
chemoattractant to the Invading trophoblast. Evidence supporting this comes from the study of 
Lash et al, 1999 who showed in an in vivo invasion model, that VEGF acted on an immortalised 
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trophoblast cell line (expressing the fit-1 receptor only) to increase motility but not invasion (Lash 
et al., 1999). However, Athanassiades t al, 1998 have recently failed to show a role for VEGF in 
the migration and invasiveness of an in vitro cultured immortalised human extra-villous trophoblast 
cell line (Athanassiades et al., 1998). The differences in the results obtained from Lash et al, 
1999 and Athanassiades et at, 1998 may be due to the cells utilised. However, most evidence 
would support a role for VEGF as promoting placental development through enhancing migration 
of trophoblast into the maternal decidua t implantation. 
Poor placental development has been associated with intrauterine growth restriction and pre- 
eclampsia (Brosens et at., 1972) (Fox, 1986) (Meekins et al., 1994) (Chapter 1.1). This thesis 
shows (Figure 5.1 & 5.2) no differences in the mRNA expression of VEGF in the placentas of 
pregnancies complicated by pre-eclampsia when compared to normal control placentas. Previous 
studies of VEGF in pregnancies complicated by pre-eclampsia have demonstrated that VEGF 
immunoreactivity is decreased inplacentas from women with pre-eclampsia (Cooper et al., 1996) 
(Lyall et al., 1997b). Lyall et at examined immunohistochemically the expression of VEGF in 
normal placentae and those complicated by pre-eclampsia (Lyall et al., 1997b). They 
demonstrated that syncytiotrophoblst VEGF staining was decreased in placentae from women 
with pre-eclampsia (Lyall et al., 1997b). However, in a similar manner to Cooper et al (1996), the 
control group selection and the selection of placental site may also have affected their study. 
Ranheim et at (2001) have recently examined utilizing Northern Blott techniques, and a more 
acceptable control group, the expression of VEGF mRNA in placentae from women with pre- 
eclampsia nd normal controls, demonstrating in line with this study that the mRNA remains 
unaltered in placentae from women with pre-eclampsia (Ranheim et at., 2001). 
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Baker et al (1995) examined the placental production ofVEGF in complicated pregnancies by the 
measurement of VEGF concentrations in umbilical vein serum (Baker et al., 1995b). Although, 
they were unable to demonstrate any differences inthe VEGF concentration between ormal and 
pre-eclamptic venous erum, there was a tendency for the vein serum from babies from women 
with pre-eclampsia to be lower than the control group. This finding has been confirmed by Lyall et 
al (1997). One problem with this study is that umbilical vein blood as taken to represent placental 
production. This may not be the case if the placenta secretes the VEGF into the maternal system, 
in which case a lower VEGF concentration might be expected in the fetal system. 
The literature would suggest the hypothesis that trophoblast expression offit-1 receptor might be 
increased in pregnancies complicated by pre-eclampsia, as it is this that may aid migration of the 
extravillous trophoblast into the maternal decidua. Although results of this thesis do not support 
this hypothesis, they due not exclude it, as placental tissues contain a mixed cell population that 
may mask any alteration in trophoblast fi -1 production. Further evidence to confirm or refute this 
hypothesis would require investigation of distribution changes of the fit-1 receptor within placentas 
from women with pre-eclampsia. 
This study found no differences in the expression of the VEGF receptors (fit-1 and KDR) in 
placental tissue from normal control women and women with pre-eclampsia. Although the 
expression of both receptor mRNA was not increased in pre-eclampsia, this does not exclude a 
role for these receptors in the pathophysiology of this disease, as alterations of membrane protein 
expression may dramatically alter the function of VEGF. However, this was not investigated 
further due to the limited time allowed for this thesis. Evidence to support a role for the fit-1 
receptor in the pathogenesis of pre-eclampsia comes from Helske et al (20001). They have 
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demonstrated utilizing the techniques of immunohistochemitry and Western Blotting that protein 
expression of the fit-1, but not KDR receptor are increased in the placenta of women with pre- 
eclampsia when compared to normal controls (Heiske t al., 2001). This data and that presented 
in this thesis may suggest that the fit-1 receptor undergoes a post-translational modification that 
reduces its turnover time, with the affect of increasing its cellular expression. 
This study demonstrates that PIGF mRNA is expressed by normal placenta nd is consistent with 
other studies (Maglione et al., 1991) (Khaliq et al., 1996) (Clark et al., 1998b). Khaliq et at (1996) 
used immunohistochemical techniques on term normal placentas and showed that PIGF was 
localised to the vasculosyncytial membrane and in the media of large blood vessels of the 
placental villi. Clark et at (1998) utilized in situ hybridization a d confirmed that PIGF mRNA was 
produced in large amounts by villous cytotrophoblast, yncytiotrophoblast nd extravillous 
trophoblast. These results suggest that PIGF may be an important paracrine factor for vascular 
endothelial cells in placental angiogenesis and as an autocrine mediator of trophoblast function 
(Khaliq et al., 1996). 
Khaliq et al (1999) also demonstrated that placental PIGF mRNA and protein increased with 
gestation, whilst VEGF decreased (Khaliq et al., 1999). In vitro studies on chick chorioallantoic 
membranes have demonstrated that VEGF mediates branching angiogenesis, whereas PIGF 
mediates non-branching angiogenesis (Kurz et al., 1998) (Wilting et al., 1996). Reports suggest 
that In second and third trimester placenta, angiogenesis changes from a predominately 
branching to non-branching, forming terminal villi, the functional unit of the placenta (Demir et al., 
1989) (Demir et al., 1997). These observations led Khaliq et al (1999) to postulate that early 
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pregnancy placental ngiogenesis is mediated by VEGF and that late placental angiogenesis is 
via PLGF (Khaliq et al., 1999). 
In addition Khaliq et at (1999) showed that maternal decidual cells stain strongly for PIGF protein. 
PIGF initiates its function through the fit-1 receptor (Park et at., 1994). As the placental 
extravillous trophoblast express fit-1 receptor it might be postulated that PIGF, in a similar manner 
to VEGF, promotes migration of these cells into the maternal decidua. However, the studies of 
Athanassiades et at (1998) and Lash et at (1999), which demonstrate hat PIGF neither caused 
migration or invasion, do not support this hypothesis. Both these studies utilized bacterially 
produced PIGF which has been reported to be devoid of biological activity on human 
microvascular endothelial cells (Birkenhager et al., 1996) and HUVEC (Cao et at., 1996). In 
contrast, PIGF 
-1 produced by human transfected fetal kidney cells is chemotactic, mitogenic and 
angiogenic to human umbilical vein endothelial cells. Therefore further work is required to 
ascertain whether non-bacterially produced PIGF affects trophoblast migration and invasion. 
Although there was a trend for the PIGF mRNA expression to be increased in pregnancies 
complicated by pre-eclampsia when compared to normotensive controls this did not reach 
statistical significance (Mann Whitney: P= 0.09) (Figure 5.4). This finding is consistent with that of 
Khaliq et al (1999) (Khaliq et al., 1999) who demonstrated utilising both protein Western blotting 
and RNA Northern blotting that placentas from women with pre-eclampsia do not significantly 
increase their production ofPIGF mRNA or protein. Interesting they demonstrated that placentas 
from women with inter-uterine growth restriction significantly increased production ofPIGF (Khaliq 
et al., 1999). They also demonstrated that hypoxia decreased and hyperoxia increased 
production PIGF from cultured trophoblast and suggested that these observations were consistent 
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with the hypothesis of Kingdom et al (1997), that placenta of fetuses with inter-uterine growth 
restriction, characterised by absent end-diastolic flow, are in a hyperoxic environment (Kingdom 
and Kaufmann, 1997). 
VEGF and PIGF form functional hetrodimers that initiate their responses through the fit-1 receptor 
(Cao et al., 1996). The observation ofClark (1998) that the mRNAs encoding VEGF and PIGF 
were not co-localised, suggests that it is unlikely that any significant production of VEGF/PIGF 
heterodimer occurs in the placenta (Clark et al., 1998a). 
5.5.2 Myometrial expression: 
Although the expression of VEGF in human myometrium has been investigated previously 
(Charnock-Jones et al., 1993) (Harriso-Woolrych et al., 1996), this is the first study to examine the 
mRNA expression of the VEGF isoforms in the maternal myometrium in non-pregnant women, 
pregnant women, and women with pre-eclampsia. This thesis demonstrated that at least hree 
VEGF isoforms are expressed by human myometrium, VEGF 121, VEGF 165, VEGF 189, and 
confirmed the findings of Charnock-Jones et al (1993) and Harrison-Woolrych et al (1995). It also 
showed that all VEGF isoforms are increased incontrol third trimester myometrium and this raises 
the possibility hormonally controlled expression. Harrison-Woolrych et at (1995) utilised an RNAse 
protection to demonstrate hat VEGF production was enhanced in the proliferative phase of the 
oestrous cycle, postulating that the ovarian steroids, oestrogen and progesterone, mediated the 
observed increased expression (Harriso-Woolrych et at., 1996). Further evidence to support this 
comes from the observation that in the endometrial cancer cell line HEC-1A, oestadiol stimulates 
VEGF mRNA production (Charnock-Jones et al., 1993). 
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Although the ovarian steroids may control VEGF production within the myometrium, yometrial 
VEGF function still remains to be fully elucidated. In early pregnancy it may enhance the uterine 
environment, through increased angiogenesis, to aid implantation of the fertilised ovum 
(Charnock-Jones et al., 1993). It has also been demonstrated that maternal serum concentrations 
of VEGF are increased in the early gestations ofnormal pregnancy and this has been postulated 
to drive the maternal cardiovascular daptations (Evans et al., 1997) (Evans et al., 1998) 
(Wheeler et al., 1999). Increased myometrial production may also increase the blood supply to 
the endometrium through vasodilatation f the uterine and myometrial vessels. It has previously 
been reported that in a rat model, VEGF causes the vasodilatation f rat uterine arteries (Ni et al., 
1997b). It would of interest o examine whether VEGF affects human myometrial resistance 
arteries in a similar manner; this may enhance our understanding of the early changes that occur 
in these vessels to allow the implantation and early development of the conceptus (Chapter 8). 
This thesis also showed that the myometrial expression of the VEGF isoforms were altered with 
pregnancy; in non-pregnant myometrium VEGF 121 predominates, however, in pregnant 
myometrium allthe isoforms are expressed in similar quantities. This may indicate that the VEGF 
isoforms have varying functional properties dependent on their physical properties, however, the 
reason for the change with pregnancy remains to be elucidated. 
Although myometrium from women with pre-eclampsia showed no overall differences in the 
expression of the VEGF isoforms when compared to control pregnant myometrium, the isoform 
expression pattern in the pre-eclampsia group returned toward the non-pregnant pattern, with 
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VEGF 121 being most abundant. This may indicate that an alteration in the ratios of VEGF in the 
myometrium is necessary for a normal pregnancy outcome. 
During the time of this thesis, frozen samples of myometrium from non-pregnant women, pregnant 
women, and women with pre-eclampsia were collected and transported on dry ice to the 
laboratory of Dr S Davidge (University of Alberta, Canada) and immunohistochemical staining was 
performed for VEGF (Figures 5.9 & 5.10). This showed that VEGF protein was present In the 
myometrium of non-pregnant women, pregnant women and women with pre-eclampsia. The 
protein expression was increased in pregnant women and paradoxically, increased further In the 
myometrium of pregnancies complicated by pre-eclampsia. 
VEGF mRNA has been shown to increase in the myometrium of pregnant women when compared 
to non-pregnant women. The increased expression may be postulated to explain the increased 
circulating concentrations that parallel gestation in the third trimester (Chapter 4). Although this is 
an interesting hypothesis t would require a cross-sectional study of VEGF plasma concentrations 
determined in uterine artery and vein samples of women undergoing Caesarean sections at 
varying estations and correlation with VEGF mRNA and protein expression. However, this would 
then be subject to sampling basis with the abnormal pregnancies contributing to the early 
gestations. 
VEGF function is also regulated by the bloavailability of VEGF receptors (fit-1 and KDR). This 
thesis demonstrated that although no significant differences in VEGF receptor expression (flt- 
1/KDR) occurred between the three study groups there was a trend for Increased expression of 
both fit-1 and KDR receptors in the myometrium of pregnancies complicated by pre-eclampsia. 
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This study confirms the finding of (Brown et al., 1997b) who, utilising in situ hybridisation, 
demonstrated that uterine smooth muscle from non-pregnant women expressed both fit-1 and 
KDR receptors. They also demonstrated that isolated myometrial smooth muscle cells 
proliferated strongly in the presence of VEGF and that this proliferation was in the same order of 
magnitude as in endothelial cells (Brown et al., 1997b). From this they postulated that VEGF was 
acting as an autocrine growth factor in these muscle cells and that alterations of the expression of 
VEGF or its receptors may play a role in the pathogenesis of tumours of the uterus (Brown et al., 
1997b). 
5.6 Summary: 
It has been shown previously that increased circulating concentrations of VEGF occur in both 
pregnancy and pre-eclampsia (Chapter 4). This chapter sought to test the hypothesis that the 
observed increased concentrations in pre-eclampsia were due to an altered production ofVEGF 
in the fetomaternal unit. Contrary to the original hypothesis the data presented in this thesis 
demonstrates that there are no differences inthe production ofVEGF by the fetomaternal unit in 
the disease of pre-eclampsia. 
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Chapter six: The vascular adaptations that occur In myometrial resistance 
vessels in pregnancy and in pregnancies complicated by pre-eclampsia: 
6.1 Introduction: 
Normal pregnancy is characterised by a fall in the blood pressure, a reduction in peripheral 
vascular resistance, and a 40% increase in the cardiac output (Duvekot et al., 1993) (Duvekot and 
Peeters, 1994) (van Oppen et al., 1996). The vasodilatation f pregnancy is also accompanied by 
an alteration in the vascular reactivity to the pressor effects of angiotensin II (Gant et al., 1973). In 
a longitudinal study Gant et al (1973) found a decreased sensitivity to infused angiotenisn ii in 
pregnant women when compared to non-pregnant controls (Gant et al., 1973). Similar findings 
were reported in women with pre-existing chronic hypertension (Gant et al., 1977). 
The mechanism for these changes has been extensively studied and it is clear that the observed 
decreases are not due to changes in plasma renin concentrations a  rapid infusions of fluid do not 
alter angiotensin II sensitivity (Matsuura et al., 1981). These observations ofGant et al (1977) 
and Matsuura et al (1981) would indicate that the hypertension i  pre-eclampsia is a delayed 
clinical manifestation f an abnormality atthe microvascular level, which is specific to pregnancy. 
Evidence to support the involvement of the endothelium comes from cell culture studies. 
Endothelial cells cultured in the presence of plasma from women with pre-eclampsia show altered 
production of endothelial products, such as nitric oxide and prostacyclin, when compared to 
plasma from control women (Lorentzen et al., 1991) (Taylor et al., 1991) (Branch et at., 1992) 
(Roberts et a!., 1992) (Baker et al., 1995b) (de Groot et at., 1995) (Baker at al., 1996a) 
(Kupferminc et al., 1996). 
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The difficulties with in vivo studies in human pregnancy have led researchers to examine the 
vascular changes that occur in pregnancy with indirect methods. These have included animal 
models and myography. Myography allows the study of vascular reactivity in ex vivo resistance 
vessels and can be used to determine the contribution of the endothelium to the observed 
changes. 
Uterine resistance vessels are juxtaposed to the developing placental bed and undergo 
considerable r modelling with pregnancy. As such it is pertinent to study these vessels when 
examining the changes that occur during pregnancy. However, there is a paucity of data into the 
effect of pregnancy on myometrial resistance vessels. This is primarily due to the technical 
difficulties of sample collection. The studies that have investigated endothelium-dependent 
relaxation in myometrial resistance arteries have utilised different vasoconstrictor (vasopressin, 
endothelin and U46619) and vasorelaxant agents (bradykinin and acetylcholine) and as such 
comparison is difficult (Svane et al., 1991) (Ashworth et al., 1996a) (Kublickiene et al., 1997), 
6.2 Aims: 
" To examine whether pregnancy alters the vasopressin responses of myometrial resistance 
arteries. 
" To examine whether pregnancy or pre-eclampsia alters endothelium dependent relaxation in 
the uterine circulation. 
" To characterise the mechanism by which these changes occur. 
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" To elucidate which vasodilator changes were to be studied when considering the interaction 
of the endothelium with Vascular Endothelial Growth Factor. 
6.3 Experimental design: 
6.3.1 Vasoconstrictors: 
6.3.1.1 Vasopressin: 
Myometrial resistance vessels were obtained from non-pregnant (n=6), pregnant (n=7) and 
women with pre-eclampsia (n=6) as described previously in Chapter 2.4.2a. Whenever, possible 
three vessels from the same patient were mounted on separate myographs. Vessels were 
normalised as described in Chapter 2.4.4. The myography protocol (Chapter 3.3.1) was then 
followed and incremental doses of vasopressin were used to cause constriction (Chapter 2.4.5.5). 
In a separate set of experiments, myometrial vessels were obtained from pregnant women (n=7). 
Two vessels were dissected out as described previously, and mounted on the same myograph. 
After mounting, the endothelium lining the vessels was removed by debridement with a human 
hair prior to experimentation. Vessels were normalised as described in Chapter 2.4.4. The 
myography protocol (Chapter 3.3.1) was then followed and incremental doses of vasopressin 
were used to cause constriction (Chapter 2.4.5.5). 
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6.3.2 Vasodilators: 
6.3.2.1 Bradykinin: 
Myometrial resistance vessels were obtained from non-pregnant (n=6), and pregnant women 
(n=7) and women with pre-eclampsia (n=6) as described previously in Chapter 2.4.2a. Whenever 
possible three vessels from the same patient were mounted on the three separate myographs. 
Vessels were normalised as described in Chapter 2.4.4. The myography protocol for vasopressin 
(Chapter 3.3.1) was then followed and incremental doses of bradykinin were used to cause 
endothelium dependent relaxation (Chapter 2.4.5.5). 
6.3.2.2 Histamine: 
Myometrial resistance vessels were obtained from non-pregnant (n=7), and pregnant women 
(n=8) and women with pre-eclampsia (n=9) and mounted as described previously. The myograph 
protocol for vasopressin (Chapter 3.3.1) was then followed and incremental doses of histamine 
were used to cause an endothelium dependent relaxation (Chapter 2.4.5.6). 
6.4 Results: 
Table 6.1,6.2 and 6.3 detail the demographics and vessel characteristics of the non-pregnant, 
pregnant controls and the pre-eclampsia group. As anticipated, systolic and diastolic blood 
pressure were significantly greater in the group of women with pre-eclampsia than the control 
pregnant or non-pregnant groups. 
Ir- 
(1) 
cu t 
I- m 
N 
E =00 
v 
- 
C 
co 
NM 
O 
FZ' 
r-. 
co cu Q: 
5= OGM) 
0) U) mE 
ES Mý 
M 
0 0 
01 
CL cc 
a C. ) 
C 
N r 
N 3 ä) 
g a (1) 
ý 
402 -0 
"to Ný "- ý Qý 
(O ö ý! N 
.... 
"D 
E 
a 
5 1 M p 
ýi 
N co 
M Ný 
M 
Ci . ý 
M ý N `ýJv 
C c cý 
aý ýp MM MN MN 
E v 
C ý_ Qý 
co 
^(/I 
ID '9 ca C: 
Z ß 
1 
RS 
ä'i 
rn 
c 
cß 
c0 
aý y-. 
c 
c 
cis 
E 
ca 
N 
.C 
N 
E 
E 
cý 
m 0 
N 
CCs 
N 
.ä co I- 
C 
N 
E O 
3 
ö 
c 0 
v 
a) E 
0 
ca ca 
C o' 
CL cu 
0 9) 
c cD 
E ö. 
g 
N3 
c N a) 
C', E 
>0 
"° 
N 
Ca 
N 
10 
V 
Z 
CL 
N 
EP 
E 
N 
C 
N 
cc 
13- 
Z 
cm 
C 
äý 
a) 
gE Sm 
2 
0 
cri 
rn N 
CC! 
. -. 
ýM 
C 
O 
0 
oý 
0 0 
cv) 
cu 
r- 
. - tV 
is 
04ý 
ci 
MM 
N 
cn - 
ni N C) 
N 
.. s 
r 
M Cý 
ýM 
`ý 
:g 
N 
PQ 
r 
C, 4 
ali 
v 
N 
N 
r O 
p' 
N 
M 
CO) 
Ui 
v v 
" L ö 
C ý 
CLLU- 
C 
W 
N 
rn 
c 
E 
cu 
E 
E 
m N 
12 N 
. 
i3 
N 
r2 
M 
Co 
CD 
Co 
N 
E 
0 
.9 Cp 
C 
N 
E 
ca co C 'y 
a.. 
E 
(a 
rL -6 O qp aO 
E `c. 
o rte,, 
N 
NO 
C, o >O 
N CU 
aý v 
v 
a 
ca 
ö 
E 
aý 
-v 
c 0 
cv D.. 
1 
0 
v 
cm 
C 
äI ý 
ý 
°º 
ýý ý 
a ýv 
"c ý 
°ý 
cgý ý op E 
Cmý 
0 
PI 
ýI ý 
m arc 
23 
a) C 
E 
Co 
Cl) 
m 
rn v 
co I 
N 
Lo 
0 
uM 
CD '-CD ö 
N tl) 
i.. i 
r 
cq 
19 
R a 
t l» M Op 
GO ý: p ý OD In 
N r' 
vý 
S o N 
N 
c'7 ý- ' v 
Ea m 
p 
O 
Q^ý 
CD 
N 
NC -i 
Ö 
M 
, 
co 
Ln `'ý IA 
ý 
v 
M 
ý f° 
4 Hi 
%i 
U 
N 
 
N 
a) 0) 
f0 
a.. 
N 
N_ 
E 
Co 
3 
"c 
ca E 
E 
co 
0 
184 
6.4.1 Vasoconstrictors: 
6.4.1.1 Vasopressin: Comparison of vessels from non-pregnant and pregnant 
women and women with pre-eclampsia: 
There were no significant differences inthe dose response curves obtained with vasopressin for 
vessels from non-pregnant, ormal pregnant women and women with pre-eclampsia (Fig 6.1), or 
the EC5o values for the three groups. However, analysis of the Emax values revealed adifference 
between the three groups. Post hoc testing demonstrated that these differences occurred 
between the non-pregnant and normal pregnant groups (E,,,; P=0.02) and between the normal 
pregnant and pre-eclampsia group (Emax; P=0.04). 
The addition of indomethacin had no significant effect on EC5o r E, º, ax values for any of the groups 
studied; non pregnant: (EC5o 
-9.1+/-0.1 Vs -9.0+1-0.1: P=0.59: E M"; P=0.12), pregnant (EC50 - 
8.9+/-0.1 Vs 
-8.9+/-0.1P=0.45: E ax: P=0.45), or women with pre-eclampsia (EC 5o -9.1+1-0.1 Vs 
-9.2+/-0.2: P=0.70: Emu: P=0.67). 
As with indomethacin alone, the addition of Indomethacin a d L-NAME caused no shift in either 
the EC 5o or E max values: non-pregnant (EC so -9.0+1-0.1 Vs -9.0+/-0.1: P=0.98: E max; P=0.59), 
normal pregnant (EC 5o 
-8.9+1-0.1 Vs -8.9+1-0.1; P=0.96; E max; P=0.87), women with pre- 
eclampsia (EC 5o -9.2+/-0.1 Vs 
-9.2+/-0.1; P=096: E max ; P=0.17). 
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The removal of the endothelium from the group of vessels from pregnant women caused a non- 
significant rightward shift of the concentration response curve (EC so ; P=. 0.6). However, analysis 
of the Em. values revealed a difference between the endothelial stripped and intact groups 
(P=0.05; paired t-test). The group of vessels, which had had the endothelium removed showed 
an enhanced Emu responses when compared to the endothelium intact group (Fig 6.2), 
Vasodilators: 
6.4.2 Bradykinin: 
6.4.2.1 Comparison of endothelium dependent relaxation i  non pregnant and 
pregnant women and women with pre-eclampsia: 
There was no statistical difference in the dose response curves obtained between myometrial 
vessels from non-pregnant and pregnant women (Fig 6.3) (p = 0.41, repeated measures analysis 
of variance (ANOVA). However, there was a marked decrease in endothelium-dependent 
relaxation to bradykinin i myometrial resistance vessels from women with pre-eclampsia when 
compared to normal pregnant women (Fig 6.3) (p = 0.002, ANOVA) (E max: P=0.002; unpaired t- 
test). 
6.4.2.2 Effect of incubation of vessels with Indomethacin: 
The addition of indomethacin had no significant effect on the relaxation to bradykinin i  vessels 
from non-pregnant (Fig 6.6) (p = 0.73, ANOVA), normal pregnant (Fig 6.7) (p = 0.90, ANOVA) or 
women with pre-eclampsia (Fig 6.8). 
Fig 6.2 
Comparison of vasopressin contraction curves in vessels from 
pregnant women with or without removal of the endothelium 
140 
1 
0 
"- 
V 
C ý. i 
X 
E 
J, 
120 
100 
80 
60 
40 
- 
20 
* 
ýk 
I 
I 
*I 
I 
Tý 
I 
Post Hoc ANOVA: P=0.05 = 
P=0.01= 
-11 -10 -9 -8 -7 
Log [Vasopressin] x10 -10 M 
Statistical comparisons: 
KEY: 
EC 50 Emax 
-0-- Stripped 
-9.3+1-0.1 141.1+/-10.1 
-- 
Intact 
-8.8+/-0.1 111.8+1-9.0 
ANOVA (factorial) 0.06 0.05 
Fig 6.3 
0 
0 
ö 
Endothelium-dependent relaxations to bradykinin in myometrial 
vessels from non-pregnant women, pregnant women and women 
with pre-ecampsia 
o 
10 
20 
30 
40 
50 
60 
70 
80 
90 
Ann i uu 1 
-12 -11 -10 -9 -8 -7 -6 -5 
Log [Bradykinin] x1010 M 
KEY: 
_#_ Non-pregnant 
0 Pregnant 
_0 Pre-eclampsia 
ANOVA (factorial) 
ANOVA (repeated measures) 
Statistical comparisons: 
ErTox 
62.30+/-5.66 
70.81+/-6.66 
29.03+/-3.61 
p 0.001 
p 0.001 
Post Hoc ANOVA: P=0.05 =* 
P=0.01= ** 
Fig 6.4 
The effect of indomethacin and indomethacin and 
L-NAME on the endothelium-dependent relaxation of 
vessels from non-pregnant women 
9 
0 
X 
0 
100 
-12 -11 -10 -9 -8 -7 -6 -5 
80 Post Hoc ANOVA: P=0.05 = ýk 
90 P=0.01= 
10 
20 
30 
40 
50 
60 
70 
Log [Bradykinin] x1010 M 
KEY: Statistical comparisons: 
Emax 
--ý- Control 58.76+/-6.61 
0 Indomethacin 65.97+/-5.07 
A 
...... ""
Indo + L-NAME 15.08+/-5.46 
ANOVA (factorial) p 0.001 
ANOVA (repeated measures) p 0.001 
Fig 6.5 
The effect of indomethacin and indomethacin and 
L-NAME on the endothelium-dependent relaxation of 
vessels from pregnant women 
0 
0 
. '.., ww 
x 
ö 
0 
10 
20 
30 
40 ' 
50 
60 
70 
80 
90 
wnn 
-1uu ., i 
-12 -11 -10 -9 -8 -7 -6 -5 
Log [Bradykinin] x1010 M 
KEY: 
Control 
- -0' - Indomethacin 
Indo + L-NAME 
ANOVA (factorial) 
ANOVA (repeated measures) 
Statistical comparisons: 
Emax 
64.92+1-9.73 
66.69+/-8.53 
59.52+1-9.54 
p 0.87 
P 0.93 
Fig 6.6 
The effect of indomethacin and indomethacin and 
L-NAME on the endothelium-dependent relaxation on 
myometrial vessels from women with pre-eclampsia 
AL 
0 
0 
x 
o 
10 
20 
30 
40 
Post Hoc ANOVA: P=0.05 =* 
P=0.01= ** 
I uu 
-12 -11 -10 -9 -8 -7 -6 -5 
50 
60 
70 
80 
90 
Log [Bradykinin] x1070 M 
Legend: Statistical comparisons: 
Emax 
--f- Control 29.01+/-6.67 
-- -0 -- Indomethacin 37.51+/-11.57 
A...... Indo + L-NAME 10.05+/-4.30 
ANOVA (factorial) p 0.009 
ANOVA (repeated measures) P 0.005 
Fig 6.7 
Endothelium-dependent relaxations to histamine of myometrial 
vessels from non-pregnant women, pregnant women and women 
with pre-eclampsia 
9 
0 
. - 
X 
ö 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
-12 
Post F 
-11 -10 -9 -8 -7 
Log [Histamine] x10-10 M 
KEY: 
Non-pregnant 
Pregnant 
_.. 
ý. 
__ 
Pre-eclampsia 
ANOVA (factorial) 
ANOVA (repeated measures) 
Statistical comparisons: 
EC 50 Emax 
-9.2+1-0.3 80.00+1-4.99 
-7.7+/-0.4 52.18+/-0.87 
-7.4+/-0.6 47.84+/-5.37 
0.03 0.006 
0.001 
Fig 6.8 
The effect of indomethacin and indomethacin and 
L-NAME on the endothelium-dependent relaxation 
obtained from vessels from non-pregnant women 
0 
0 
x 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 l 
-12 -11 -10 -9 -8 -7 
Log [Histamine] x1010 M 
KEY: 
---+- Control 
0 Indomethacin 
.......... 
A"""". 
""" 
Indo + L-NAME 
ANOVA (factorial) p 
ANOVA (repeated measures) p 
Statistical comparisons: 
EC 50 Emax 
-9.2+/-0.3 80.00+14.99 
-9.1+/-0.2 52.18+/-0.87 
-9.2+/-0.3 47.84+1-5.37 
0.98 0.08 
0.78 
186 
6.4.2.3 Effect of incubation with Indomethacin and L-NAME: 
The addition of indomethacin and L-NAME to non-pregnant vessels caused a marked ecrease in 
the endothelium dependent relaxation when compared to both control vessels and those 
incubated with indomethacin (Control Vs Indomethacin a d L-NAME incubated vessels (P= 0.001, 
ANOVA) (E 
,,, ax: P= 0.004; unpaired T-test). Indomethacin Vs Indomthacin and L-NAME 
incubated vessels (p= 0.001, ANOVA) (Emax: P= 0.001, unpaired T-test)). However, the addition 
of indomethacin and L-NAME to vessels from pregnant women did not significantly affect 
endothelium dependent relaxation. (Control Vs Indomethacin + L-NAME incubated vessels (p= 
0.58, ANOVA): Indomethacin Vs Indomethacin + L-NAME incubated vessels (p= 0.96, ANOVA) 
(Fig 6.5)). Although women with pre-eclampsia displayed a reduced endothelium dependent 
relaxation, the addition of Indomethacin and L-NAME further attenuated the observed response 
when compared to both control vessels and those incubated with indomethacin. Control Vs 
Indomethacin a d L-NAME incubated vessels (P= 0.001, ANOVA) (E max: P= 0.06; unpaired T- 
test). Indomethacin Vs Indomethacin and L-NAME incubated vessels (p= 0.006, ANOVA) (E max: 
P= 0.012, unpaired T-test) (Fig 6.6)). 
6.4.3 Histamine: 
6.4.3.1 Comparison of endothelium dependent relaxation I  non-pregnant and 
pregnant women and women with pre-eclampsia 
There was a statistical difference in the dose response curves obtained between myometrial 
vessels from non-pregnant and pregnant women (Fig 6.7) (P = 0.001, ANOVA) (E max: P= 0.001, 
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unpaired t-test). However, there were no differences in the endothelium-dependent relaxation 
from women with pre-eclampsia when compared to normal pregnant women (Fig 6.7) (P = 0.66, 
ANOVA). 
6.4.2.2 Effect of incubation of vessels with Indomethacin: 
The addition of indomethacin had no significant effect on the relaxation curve to histamine in the 
non-pregnant (Fig 6.8) (P = 0.79, ANOVA) or pregnant women (Fig 6.9) (P = 0.99, ANOVA) or 
women with pre-eclampsia (Fig 6.10) (P = 0.91, ANOVA). 
6.4.2.3 The effect of incubation with Indomethacin and L-NAME: 
The addition of indomethacin a d L-NAME had no effect on the endothelium dependent relaxation 
to histamine in the non-pregnant group of women when compared to both control vessels and 
those incubated with indomethacin alone (Control Vs Indomethacin + L-NAME incubated vessels 
(P = 0.79, ANOVA). Indomethacin Vs Indomethacin + L-NAME incubated vessels (P = 0.52, 
ANOVA) (E max: P=0.09; unpaired T-test) (Fig 6.10)). Likewise, the addition of indomethacin and 
L-NAME to pregnant vessels did not significantly effect the endothelium dependent relaxation 
when compared to both control vessels and those incubated with indomethacin (Control Vs 
Indomethacin + L-NAME incubated vessels (P= 0.57, ANOVA). Indomethacin Vs Indomethacin + 
L-NAME incubated vessels (P= 0.68, ANOVA) (Fig 6.9)). However, the addition of Indomethacin 
and L-NAME to vessels from women with pre-eclampsia c used a significant diminution of the 
endothelium dependent relaxation when compared to both control vessels and those incubated 
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with indomethacin. Control Vs Indomethacin + L-NAME incubated vessels (p= 0.001, ANOVA) (E 
max: P= 0.021; unpaired T-test). Indomethacin Vs Indomethacin + L-NAME incubated vessels (p= 
0.002, ANOVA) (E max: P= 0.022, unpaired T-test) (Fig 6.10). 
6.4.3 Sodium Nitroprusside: 
6.4.3.1 Comparison of non- endothelium dependent relaxation in pregnant and 
women with pre-eclampsia: 
The formal comparison of non-endothelium dependent relaxation of vessels to sodium 
nitroprusside from the three study groups had been done prior to the author commencing this 
study; and as no significant differences were shown it was felt that this should not be repeated 
(Ashworth, 1998), However, comparison of non-endothelium dependent relaxation between 
vessels from pregnant women and women with pre-eclampsia w s undertaken. This was used to 
demonstrate hat vessels exhibiting loss of endothelium dependent relaxation were capable of 
smooth muscle relaxation. Comparison between these two study groups howed no significant 
differences (EC5o 
-6.3+1-0.3 Vs -6.6+I-0.4; P=0.62; E rnax 82.14+1-5.02 Vs 83.33+1-2.27; P: 0.85). 
6.5 Discussion: 
This chapter will focus on the vascular alterations that occur in the myometrial resistance vessels 
with pregnancy and pre-eclampsia. The differences between the myometrial and systemic 
circulation will be discussed inChapter 10. 
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6.5.1: Vasoconstrictors: 
This thesis confirmed previous studies that, in contrast to other arteries (Katusic et al., 1984) 
(Vanhoutte et at., 1984) (Evora et at., 1993), in which relaxant responses to AVP have been 
observed, AVP induces contraction of uterine resistance vessels (Svane et al., 1991) 
(Kostrzewska et al., 1997). 
In this study myometrial vessels from non-pregnant women exposed to vasopressin showed 
significantly higher Emax values than normotensive pregnant controls, with no apparent shift in the 
EC50 values. This might have been postulated from the work of Gant et at (1973) which 
demonstrated the pressor effects of angiotensin II are decreased inpregnancy (Gant et al., 1973). 
As discussed previously pregnancy has also been shown to alter the vascular reactivity of guinea- 
pig uterine arteries to norepinephrine, phenylamine, angiotensin II, serotonin, and the 
thromboxane-memetic U46619 (Weiner et al., 1989b) (Weiner et al., 1991) (Weiner et al., 1992b) 
(Jovanovic et al., 1995c). 
This study confirms in a human in vitro system, the importance of the endothelium in the 
regulation of pressor esponses, as the removal of the endothelium from pregnant vessels 
returned their Emax value of constriction curves to vasopressin to a similar level to that of the non- 
pregnant state (Fig 6.3). Although, this thesis did not examine whether removal of the 
endothelium from non-pregnant vessels effects vasopressin responses, everal previous tudies 
have investigated this in both myometrial resistance vessels and human uterine arteries, and 
demonstrated that removal has no significant affect on the responses obtained (Jovanovic etal., 
1995c) (Ashworth, 1998). It is also well documented that, in certain blood vessels, removal of the 
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endothelium can potentiate the responses ofvascular smooth muscle to vasopressin (Katusic and 
Krstic, 1987) (Randall et al., 1988), as opposed to some other arteries which lack endothelial 
modulation (Katusic and Krstic, 1987) (Conde t al., 1991). 
Steele et al (1993) also implicated the endothelium as pivotal to the vascular adaptations that 
occur in pregnancy. They demonstrated that, although there were no differences inthe CRC for 
intact vessels, removal of the endothelium from myometrial vessels from pregnant women 
significantly enhanced the constriction responses to noradrenaline when compared with non- 
pregnant controls in a similar state, and postulated that the increased sensitivity is countered by 
an endothelium-derived r laxing factor (Steele t al., 1993). This literature and the data in this 
thesis would suggest that during pregnancy the endothelium undergoes various alterations that 
allow the modulation of smooth muscle. This effect may be hypothesised to allow increased 
control over the local blood flow to the feto-maternal unit. 
Although removal of the endothelium from pregnant vessels enhanced constrictor responses, 
these effects were not mediated through either the endothelial nitric oxide or the eicosanoid 
systems, as inhibition of these systems had no effect on the responses obtained in endothelium 
intact vessels. This is in accord with the observations of Steele et al who also demonstrated that 
the observed differences between endothelial denuded and intact pregnant myometrial vessels 
were also independent of nitric oxide (Steele et al., 1993). These results imply that the observed 
decreased in systemic vascular esistance in pregnancy may be mediated at least in part by a 
non-nitric oxide, non-elcosanoid pathway and implicates a role for the putative Endothelial Derived 
Hypoerpolarisation Factor (EDHF) in both pregnancy and pre-eclampsia. 
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EDHF, although it remains to be formally identified, has recently been demonstrated to act 
through gap junctions (Kuhberger et al., 1994) (Griffith and Taylor, 1999) (Fukuta et al., 1999) 
(Edwards et al., 1999). It is well documented that gap-junction concentrations increase in the 
myometrium of pregnant women through increased oestrogen drive (Neulen and Breckwoldt, 
1994). Moreover, it has been shown that non-pregnant myometrial vessels, which have been 
treated with oestradiol or diethylstilbestrol show reduced sensitivity to vasopressin (Kostrzewska 
et al., 1993). The effect of oestrogen may be postulated to be through alterations in the vascular 
gap junction expression, which leads to an increase in the transport of EDHF, however, this 
remains to be established. 
Although pregnancy caused myometrial vessels to display a decreased sensitivity to vasopressin; 
vessels from women with pre-eclampsia exhibited the reverse with responses shifted towards the 
non-pregnant state (Fig 6.1). These vessels were characterised by the enhancement of the Em. 
value without any significant change in the EC5o. This is in accord with the work of Allen et al 
(1989), who demonstrated increased contractile responses to vasopressin in similar vessels from 
women with pre-eclampsia when compared to normal controls (Allen et at., 1989). Allen et al 
(1989) also showed that there was an enhanced response to U46619 in vessels from women with 
pre-eclampsia. However, responses in myometrial resistance vessels from women with pre- 
eclampsia have been demonstrated to be blunted to endothelin (Wolff et al., 1996). This suggests 
that in pre-eclampsia, the responses ofmyometrial vessels to vasoconstrictor agents are similar to 
those of vessels from non-pregnant women. It could therefore be hypothesised that In pre- 
eclampsia either the endothelium fails to adapt to pregnancy or function returns toward the non- 
pregnant state. As such it would be of interest and importance to determine whether exposure to 
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VEGF enhances the responses to vasopressin from normal pregnant vessels, in a similar manner 
to vessels from women with pre-eclampsia. 
6.5.2 Bradykinin: 
In this study of myometrial resistance vessels there was no significant increase in endothelium- 
dependent relaxation to bradykinin when vessels from pregnant women were compared to non- 
pregnant controls (Fig 6.3). This confirms the findings of Ashworth et al (1999). 
The addition of indomethacin to the vessels from non-pregnant, pregnant and women with pre- 
eclampsia did not significantly alter the concentration responses curves of these vessels to 
bradykinin. However, Ashworth et al demonstrated an increase in the relative production of 
vasoconstrictor to vasodilator prostanoids in vessels from women with pre-eclampsia, although 
they were unable to characterise the nature of the change (Ashworth, 1998) (Ashworth et al., 
1999). In Chapter 3 of this thesis it was demonstrated that these results might be due to the 
protocol utilised by Ashworth et al (1998). The inhibition of eicosanoid synthesis with 
indomethacin does not only inhibit the vasodilator eicosanoids such as prostacyclin but also 
inhibits any vasoconstrictor eicosanoids originating from these blood vessels. Such eicosanoids 
could include thromboxane A2 or prostaglandin El, both of which are produced by the endothelium 
(Wetzka et al., 1996). Therefore, it can not be simply concluded from this data that prostacyclin 
has no role in the relaxatory response of these vessels to bradykinin. 
Indomethacin inhibits both the isoforms of cyclo-oxygenase, the rate-limiting enzyme responsible 
for the conversion ofarachadonic a id into prostaglandins. It 1s possible that the use of this drug 
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masked subtle alterations in the balance of the eicosanoids within vessels. Recent studies have 
demonstrated that the inducible form, COX-2, is the major isoenzyme involved in the pathological 
situations (Lora et al., 1998), it is possible that experimentation with a specific COX-2 inhibitor 
would provide different results to those observed in this study. Such a methodological approach 
may help to unravel the complex balance that exists between the various eicosanoids in normal 
pregnancy. 
When vessels from normal pregnant women were studied, the addition of both indomethacin and 
L-NAME had no significant effect on the concentration response curves to bradykinin. However, 
the addition of L-NAME and indomethacin to non-pregnant vessels ignificantly attenuated the 
vasodilator response. Although, the effect of L-NAME on its own was not studied (See Chapter 
10), it can be concluded that myometrial resistance vessels undergo specific adaptations during 
pregnancy, which appear to be mediated through the endothelium. This adaptation appears to be 
mediated through a switch in the mechanism ofvasodilatation from a predominantly nitric oxide 
system, to a non-nitric oxide, non-prostaglandin-mediated system. This adds further support to 
the hypothesis of an altered endothelial-derived factor being important in the normal pregnancy 
adaptation. The suggestion ofadaptation of the resistance vessels of the myometrium to a non- 
nitric oxide, non-prostanoid mediated relaxation has recently been confirmed by Kenny et al 
(Kenny et al., 1999a). Moreover, Gerber et al have recently shown that EDHF has an enhanced 
role in the relaxation of mesenteric vessels from pregnant rats when compared to non-pregnant 
controls (Gerber et al., 1998). 
Previous work on agonist induced vasodilatation in the same vascular bed has been unable to 
demonstrate similar differences (Ashworth et al., 1996a). There are two possible reasons for 
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these observed ifferences, Ashworth et al (1996) utilised L-NNMA as their nitric oxide inhibitor 
and vessels were stored for up to 48 hours prior to use. In pilot data (n=2) L-NNMA had no 
significant effect on endothelium-dependent relaxation in non-pregnant vessels. Therefore it may 
be postulated that the nitric oxide synthase inhibitor used by Ashworth et at (1996) was not 
effective in these vessels with this protocol. 
The stimulus for the alteration i  the vascular function during pregnancy remains to be described; 
however, possible candidates include the hormones; progesterone and oestrogen. Both hormones 
are known to have effects on the vascular endothelium and oestrogen has been shown to cause 
endothelial changes with respect to vasoconstrictor agents (Kostrzewska et al., 1993). 
Endothelium dependent relaxation to bradykinin of myometrial resistance vessels from women 
with pre-eclampsia w s attenuated in comparison to similar vessels from pregnant control women 
(Fig 6.3) and this confirms the observation of Ashworth et al (1997). Losses of endothelium 
dependent relaxation have also been demonstrated, with other vasodilators (acetylcholine, 
histamine, and bradykinin) in other vascular beds from women with pre-eclampsia, including 
omental vessels, and subcutaneous vessels (McCarthy et al., 1993a) (Oguogho et al., 1996) 
(Pascoal et al., 1998). However, this finding appears to be specific for bradykinin i  myometrial 
vessels, as the degree of endothelium-dependent r laxation to histamine remained unaltered in 
pre-eclampsia (see section 4.2). The observed generalised loss of endothelium dependent 
relaxation would suggest that this process is not mediated through a loss of receptors, but through 
a more fundamental cellular transduction system. 
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The addition of indomethacin to vessels from women with pre-eclampsia h d no significant effect 
on the relaxation to bradykinin. This differs from previous data, which has demonstrated that 
indomethacin caused enhancement of endothelium-dependent relaxation i  vessels from women 
with pre-eclampsia (Ashworth et al., 1999). The differences between these observations have 
been discussed previously (see Page 191). 
The addition of indomethacin and L-NAME attenuated the concentration response curves to 
bradykinin the vessels from women with pre-eclampsia, which would suggest that this residual 
vasodilatory capacity was due to the synthesis of nitric oxide. This is in accord with the 
observations of Ashworth et al (1999) and Kenny et al (2000), who demonstrated a similar finding 
in myometrial vessels from women with pre-eclampsia. 
Myometrial vessels, at present, appear to be unique in their responses to pregnancy and pre- 
eclampsia, when compared to other vascular beds. Unlike other vascular beds (McCarthy et al., 
1993a) (Pascoal et al., 1998), myometrial vessels undergo adaptations to pregnancy mediated 
through the endothelium. Moreover, myometrial vessels from women with pre-eclampsia appear 
to exhibit two distinct responses, firstly a loss of endothelium-dependent relaxation and secondly a
lack of adaptation of the mechanism ofvasodilatation. Therefore, it could be hypothesised that 
these changes occur, either through a failure of adaptation with a superimposed loss of 
endothelium dependent relaxation, or that there is a loss of endothelium dependent relaxation 
consequent on the return of nitric oxide mediated relaxation. However, the hypothesis of a failure 
of adaptation is not supported by the data obtained for histamine concentration response curves, 
as this demonstrates that in vessels from women with pre-eclampsia the pregnancy specific 
adaptation is not lost (Fig. 6.4). Furthermore, the loss of EDHF relaxation mediated through an 
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increase in nitric oxide is supported by the observation that there appears to be a reciprocal 
relationship between nitric oxide and EDHF (Bauersachs et al., 1996) (Bauersachs et al., 1997) 
(Randall and March, 1998). 
In view of these observations it would be of interest to determine whether exposure to VEGF 
causes normal pregnant vessels to behave in a similar manner to vessels from women with pre- 
eclampsia when exposed to bradykinin, and this is addressed in Chapter 8. 
6.5.3 Histamine 
In the myometrial resistance vessels there was a significant decrease In the degree of 
endothelium-dependent r laxation to histamine from pregnant women when compared to non- 
pregnant controls (Fig 6.7). These differences did not appear to be due to the reduction of either 
eicosanoid or nitric oxide systems (Fig 6.8). Therefore, it might be postulated that these 
differences occurred due to either the reduction in the available histamine receptors, or a 
reduction in the efficacy of the second messenger system. It has been shown that H1 receptor 
affinity increases in the myometrium of term pregnancies when compared to non-pregnant 
controls; this increased affinity occurs with a concomitant decrease in the number of receptors 
available for binding (Gonzalez et al., 1994). 
However, histamine mediated endothelium dependent relaxation was not reduced in vessels from 
women with pre-eclampsia. It was also intriguing to note that the addition of indomethacin a d L- 
NAME attenuated the relaxatory responses to both bradykinin and histamine in the vessels from 
women with pre-eclampsia when these were compared to control pregnant vessels (Fig 6.6 & 
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6.10). This would suggest that the residual vasodilatory capacity in vessels from women with pre- 
eclampsia is due to the increased synthesis of nitric oxide. 
The role of endothelial-derived nitric oxide in pre-eclampsia is far from certain. Evidence for 
decreased production is weak (reviewed inChapter one) and there is accumulating evidence that 
nitric oxide may actually be increased in this condition (Smarason et al., 1997). It has recently 
been proposed that increased nitric oxide in the presence of oxidative stress could lead to 
peroxynitrite formation and subsequent endothelial cell dysfunction (Roggensack et al., 1999). 
Peroxynitrite is an oxidant formed by the reaction of nitric oxide and superoxide anions (produced 
under conditions of oxidative stress) (Radi et al., 1991). This reaction is approximately three times 
faster than the reaction rate of superoxide anions with superoxide dismutase, therefore there is a 
greater propensity for the reaction to favour peroxynitrite formation even if superoxide dismutase 
is present (McBride and Brown, 1997). The mechanism of peroxynitrite formation could either: 
reduce the availability of nitric oxide to act as a vasorelaxant, or result in peroxynitrite acting on 
the vasculature as a pro-oxidant 
In addition, peroxynitrite r acts with tyrosine residues in proteins, a process that could affect 
tyrosine phosphorylation/dephosphorylation reactions involved in signal transduction (Darley- 
Usmar and Halliweli, 1996). The formation and action of peroxynitite can be detected by 
immunohistochemical localisation of nitrotyrosine residues in tissues. Moreover, Increased 
nitrotyrosine immunostaining in the placental terminal and stem villous vessels of women with 
pregnancies affected by pre-eclampsia and/or IUGR as compared with normal pregnant controls 
has been described (Myatt et al., 1996). Peroxynitrite may have additional direct damaging 
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effects on cells. Peroxynitrite has been shown to mediate apoptosis, along with cell necrosis 
(Sandau et ah, 1997). Changes in cell viability either by necrosis or apoptosis could then result in 
increased permeability of the endothelium and thus the loss of fluid from the intravascular space 
that is observed in some women with pre-eclampsia. 
In an experimental model of oxidative stress, such as the cholesterol-fed rabbit, oxidative 
inactivation of nitric oxide contributes to the vascular pathology (Palombo et al., 1999) (Gerber et 
al., 1999). Whether peroxynitrite, and thus inactivation of nitric oxide, contributes to the maternal 
vascular pathologies of pre-eclampsia is not known. However, placental production of nitric oxide 
is increased in pregnancies complicated by pre-eclampsia. This has been shown by various 
method including indirect immunostaining of nitric oxide synthetase enzyme (Rutherford et al., 
1995), and the direct measurement itric oxide from umbilical arterial blood sampled after delivery 
(Lyall et al., 1996). These increases in nitric oxide synthesis have been shown to be through 
increased production of endothelial nitric oxide synthetase (Nasiell et al., 1998), and that 
increased production occurs in the terminal and stem villous vessels (Myatt et al., 1997). 
Similarly, Roggensack et al have recently reported the presence of Increased nitrotyrosine 
staining of the peripheral vascular endothelium ofwomen with pre-eclampsia ascompared with 
pregnant controls (Roggensack et al., 1999). In addition, they also found an increased level of 
eNOS together with decreased levels of superoxide dismutase inthe vasculature, suggesting that 
peroxynitrite is involved in endothelial dysfunction i pre-eclampsia. Furthermore, during the time 
of this thesis frozen samples of myometrium from non-pregnant women, pregnant women, and 
women with pre-eclampsia were collected and transported on dry Ice to the laboratory of Dr S 
Davidge (University of Alberta, Canada) where immunohistochemical staining was performed for 
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nitrotyrosine r sidues (Fig 6.11 & 6.12). This again shows that in women with pre-eclampsia 
there is increased staining for nitrotyrosine r sidues, further implicating nitric oxide in the 
pathophysiology of this disease. 
6.6 Summary: 
In this chapter the vasoconstrictor responses to vasopressin i  non-pregnant, pregnant and 
vessels from women with pre-eclampsia have been characterised. It has been shown that in 
pregnant myometrial vessels there is blunted response to vasopressin and that in vessels from 
women with pre-eclampsia this adaptation either does not occur or is lost with the onset of 
disease. It also demonstrates that this effect is independent of both eicosanoids and nitric oxide, 
implicating indirectly a role of endothelial derived hyperpolarizing factor. 
Data presented in this thesis clearly demonstrates that pregnancy and pre-eclampsia are 
associated with alterations in endothelial dependent relaxation. It also demonstrates that these 
changes may be mediated through the alteration in the reciprocal relationship between NO and 
EDHF. 
Data presented in this chapter also show that when the interaction of the endothelium with 
Vascular Endothelial Growth Factor and plasma (Chapter 8) are investigated, the effect that these 
have with the endothelium on the bradykinin response should be considered. 
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Chapter Seven The vascular reactivity adaptations that occur in omental 
resistance vessels in normal pregnancy and pregnancies complicated by pre- 
eclampsia: 
7.1 Introduction: 
Several studies have demonstrated that systemic small vessel physiology is altered in pre- 
eclampsia. However, there is no consensus as to how these changes occur. Recent evidence 
may partially explain this with the suggestion that the vasoconstrictor used to induce vessel tone 
affects the mechanism ofvasodilatation (Pascoal nd Umans, 1996) (Wallerstedt and Bodelsson, 
1997). It is also evident that the vascular bed studied alters the results obtained (Ashworth et al., 
1996b). To date no study has established whether there are differences in the vasodilator 
responses in which the same agent induces tone in systemic vessels in normal pregnancy and 
pre-eclampsia. 
7.2 Aims: 
" 
To characterise the vasoconstrictor responses from omental resistance vessels from non- 
pregnant and pregnant women and women with pre-eclampsia. 
9 To characterise the mechanism by which the different vasodilators cause relaxation i  human 
omental vessels. 
" To examine whether normal pregnancy or pre-eclampsia alters endothelium dependent 
relaxation in the systemic circulation. 
" To elucidate which of these changes hould be studied when considering the interaction of 
the endothelium with Vascular Endothelial Growth Factor and plasma. 
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7.3 Experimental design: 
7.3.1 Bradykinin: 
Omental resistance vessels were obtained from non-pregnant ( =6) and pregnant women (n=10) 
and women with pre-eclampsia (n=6) as described previously in Chapter 2.5.2 b (Table 7.1). 
When ever possible three vessels from the same patient were mounted on separate myographs. 
Vessels were normalised as described inChapter 2.5.4. The myography protocol (Chapter 3.3.1) 
was then followed and incremental doses of bradykinin were used to cause endothelium 
dependent relaxation (Chapter 2.5.5.5). In a separate set of experiments omental vessels were 
obtained from pregnant women (n=4). Four vessels were mounted on separate myographs, one of 
these vessels acted as both a time and internal control, while the other three were incubated with 
varying doses of L-NAME (1x10-4 M, 3x10-4 M, and 1x10-3 M), 
7.3.2 Acetylcholine: 
Omental resistance vessels were obtained from non-pregnant (n=4) and pregnant women (n=7), 
and women with pre-eclampsia (n=6) (Table 7.2), and mounted as described previously. The 
myograph protocol (Chapter 3.3.1) was then followed and incremental doses of acetylcholine 
were used to cause an endothelium dependent relaxation (Chapter 2.5.5.6). 
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7.4 Results: 
7.4.1 Vasopressin 
7.4.1 Vasopressin: Comparison non-pregnant, pregnant and women with pre- 
eclampsla 
Analysis of the vasopressin dose response curves obtained from non-pregnant, pregnant and 
women with pre-eclampsia revealed asignificant difference (P=0.03; repeated measure ANOVA) 
(Fig 7.1). ANOVA Post hoc testing demonstrated that there was a significant difference between 
vessels from normal pregnant women and women with pre-eclampsia (P=0.001) and between 
vessels from non-pregnant women and women with pre-eclampsia (P=0.003), however there was 
no difference between on-pregnant women and pregnant women. Further analysis of the EC5o 
values found significant differences (non-pregnant (-8.5+1-0.1) Vs pregnant (-8.5+/-0.1) Vs pre- 
eclampsia (-8.8+1-0.1); P=0.004), while no differences in the Emax were noted (non-pregnant 
(80.65+/-6.55) Vs pregnant (80.41+/-3.76) Vs pre-eclampsia (89.43+1-3.81); P=0.30). Post hoc 
analysis of the EC5o values demonstrated differences between the normal pregnant and pre- 
eclampsia groups (P=0.009) and the non-pregnant and pre-eclampsia group (P=0.011). 
7.4.1.2 Effect of incubating with Indomethacin a d indomethacin/L-NAME: 
The addition of indomethacin to the vessels had no significant effect on the concentration 
response curves for the normal pregnant women and the women with pre-eclampsia (Figs 7.3 
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& 7.4). However, its addition to vessels from non-pregnant women caused a leftward shift in the 
response curves (ANOVA; P=0.09), without an alteration the EC5o or the Emax values (Fig 7.2). 
The addition of indomethacin and L-NAME significantly effected the CRC of vessels from women 
with pre-eclampsia, shifting the EC50 (-8.7+1-0.2 Vs 
-9.1 +1-0.1; P=0.019) to the left without altering 
the Emax (91.52+/-3.93 Vs 97.28+/-5.43; P=0.4) (Fig 7,4). Although the addition of Indomethacin/L- 
NAME affected the pre-eclampsia group it had no significant effect on the other two groups (see 
Figs 7.2 & 7.3). 
7.4.1 Bradykinin: 
7.4.1.1 Comparison of endothelium dependent relaxation from vessels from non- 
pregnant and pregnant women and women with pre-eclampsia: 
There was no statistical difference in the dose response curves obtained between omental 
vessels from non-pregnant, pregnant and women with pre-eclampsia (P=0.96) (Fig 7.5). 
7.4.1.2 Effect of incubating with indomethacin: 
The addition of indomethacin had no significant effect on the relaxation to bradykinin i  the non- 
pregnant group (Fig 7.6) (p = 0.98, ANOVA), the pregnant group (Fig 7.7) (p = 0.71, ANOVA), the 
pre-eclampsia group (Fig 7.8) (p = 0.48, ANOVA). 
Fig 7.4 
Comparison of CRC for vasopressin for omental vessels from 
women with pre-eclampsia in the presence of indomethacin 
and indomethacin and L-NAME 
140 
120 
lz 
pasq 100 
80 
Zog, 
O 
60 
x 
cý! 
E 40 
ö12 
20 oc ANOVA: P=0.05 =* 
P=0.01= ** 
0i 
, 
-11 -10 -9 -8 -7 
Log [Vasopressin] x10 -10 M 
KEY: 
--1b- Control 
--0-- Indomethacin 
A""". Indo + L-NAME 
Statistical comparisons: 
EC 50 Emax 
-8.8+/-0.1 89.43+/-3.33 
-8.7+/-0.2 91.52+/-3.93 
-9.1 +/-0.1 97.28+/-5.43 
ANOVA (factorial) p 0.049 0.46 
ANOVA (repeated measures) p 0.019 
Fig 7.5 
9 
0 .- 
Comparison of CRC for bradykinin in omental vessels from non- 
pregnant women, and pregnant women and women with 
pre-eclampsia 
IVV I 
-12 -11 -10 -9 -8 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
-7 -6 -5 
Log [Bradykinin] x1010 M 
KEY: 
Non-pregnant 
Pregnant 
_, 
ý.. 
_ 
Pre-eclampsia 
ANOVA (factorial) 
ANOVA (repeated measures) 
Statistical comparisons: 
EC 50 Emax 
-8.1+/-0.2 88.24+1-4.29 
-8.5+/-0.3 93.79+1-1.39 
-7.7+/-0.3 87.73+1416 
p 0.20 0.36 
p 0.96 
Fig 7.6 
The effect of indomethacin alone and indomethacin and 
L-NAME on the endothelium-dependent relaxation of 
non-pregnant omental vessels 
0 
0 . '.., 
I rd X 
ed 
ö 
iuu 
-12 -11 -10 -9 -8 -7 
o 
10 
20 
30 
40 
50 
60 
70 
80 
Post 
90 
-6 -5 
Log [Bradykinin] x1010 M 
KEY: 
_., 
&_ Control 
Indomethacin 
Indo + L-NAME 
ANOVA (factorial) p 
Statistical comparisons: 
EC50 Emax 
-7.9+/-0.3 88.24+/4.29 
-8.0+/-0.5 85.32+/-5.07 
-6.5+/-0.3 65.13+1-5.09 
0.01 0.008 
ANOVA (repeated measures) p 0.001 
-'- 'TT 
Fig 7.7 
The effect of indomethacin alone and indomethacin a d 
L-NAME on the endothelium-dependent relaxation of 
pregnant omental vessels 
1: ý O 
"r-, 
X 
0 
iuu 
-12 -11 -10 -9 -8 -7 -6 -5 
Log [Bradykinin] xl 1° M 
0 
........... 
a. 
10 
20 
30 
40 
50 
60 
70 
80 
Post Hoc ANOVA: P=0.05 = 
90 P=0.01= 
A f% f% 
KEY: 
-f- Control 
-ý-- Indomethacin 
Indo + L-NAME 
ANOVA (factorial) p 
Statistical comparisons: 
EC 50 Emax 
-8.6+1-0.1 93.79+/-1.39 
-8.7+1-0.1 93.36+/-2.08 
-8.8+/-0.1 67.13+/-5.27 
0.004 0.001 
ANOVA (repeated measures) p 0.001 
Fig 7.8 
The effect indomethacin alone and indomethacin and 
L-NAME on the endothelium-dependent relaxation on 
omental vessels from women with pre-eclampsia 
9 
O 
X 
10 
20 
30 
40 
50 
60 
70 
80 
Post Hoc ANOVA: P=O 
Vu 
100 
-12 -11 -10 -9 -8 -7 -6 -5 
Log [Bradykinin] x1010 M 
KEY: 
--ý - Control 
--- 
Indomethacin 
Indo + L-NAME 
ANOVA (factorial) p 
Statistical comparisons: 
EC 50 Emax 
-7.7+/-0.3 87.73+/-4.16 
-7.3+1-0.4 84.39+/-4.18 
-5.8+/-0.4 55.29+/-11.6 
0.008 0.001 
ANOVA (repeated measures) p 0.002 
r=u. u1= ** 
204 
7.4.1.3. Effect of incubating with indomethacin a d L-NAME: 
The addition of L-NAME and indomethacin caused a marked decrease in the endothelium 
dependent relaxation in all three groups studied, when compared to both control vessels and 
those incubated with indomethacin. 
Non-pregnant: Control Vs L-NAME and indomethacin incubated vessels (p= 0.008, ANOVA) (E 
max 88.24+/- 4.29 Vs 65.13+1- 5.09: p= 0.006; unpaired T-test). Indomethacin Vs L-NAME and 
indomethacin i cubated vessels (p= 0.009, ANOVA) (E max 85.32+1-5.07 Vs65.13+/-5.09: p= 
0.02, unpaired T-test). 
Pregnant: Control Vs L-NAME and indomethacin incubated vessels (p= 0.001, ANOVA) (E max 
. 
93.79+/- 1.39 Vs 67.13+/- 5.21: p= 0.009; unpaired T-test). Indomethacin Vs L-NAME and 
indomethacin incubated vessels (p= 0.001, ANOVA) (E max 93.36+1-2.08 Vs 67.13+/-5.27: p= 
0.02, unpaired T-test). 
Pre-eclampsia: Control Vs L-NAME and indomethacin incubated vessels (p= 0.001, ANOVA) (E 
max 29.01+/- 6.67 Vs 10.05+/- 4.30: p= 0.06; unpaired T-test). Indomethacin Vs L-NAME and 
indomethacin cubated vessels (p= 0.006, ANOVA) (E max 37.51+/-11.57 Vs 10.05+1-4.30: p= 
0.012, unpaired T-test). 
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7.4.1.4 The dose response of vessels from pregnant women to L-NAME in the 
presence of indomethacin: 
All three concentrations of L-NAME utilised caused a significant reduction in the endothelium 
dependent relaxation to bradykinin (Fig 7.9) (p= 0.006; ANOVA), although, there were no 
demonstrable differences between vessels that were incubated with the incremental 
concentrations of L-NAME (p= 0.93; ANOVA). 
7.4.2 Acetylcholine: 
7.4.2.1 Comparison of endothelium dependent relaxation in omental vessels from 
non pregnant and pregnant women and women with pre-eclampsia: 
A comparison of the three groups demonstrated significant differences between the dose 
response curves obtained with acetylcholine ((Fig 7.10) (p = 0.001), repeated measures analysis 
of variance (ANOVA)). Post hoc testing revealed these differences to be between the pre- 
eclampsia group and the other two study groups (pregnant Vs pre-eclampsia: E max; P=0.001). 
7.4.2.2 Effect of incubation with Indomethacin: 
The addition of indomethacin had no significant effect on the relaxation to acetylcholine in the 
non-pregnant group (Fig 7.11) (P = 0.62, ANOVA), the normal pregnant group (Fig 7.12) (P = 
0.75, ANOVA), or the pre-eclampsia group (Fig 7.13) (P = 0.99, ANOVA). 
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7.4.2.3 Effect of incubating with Indomethacin a d L-NAME: 
In a similar manner to the effect of indomethacin, the addition of indomethacin and L-NAME 
caused no change in the relaxation profiles in non-pregnant (P=0.23), pregnant (P= 0.92), and 
women with pre-eclampsia (P=0.63) 
7.4.4 Sodium Nitroprusside: 
7.4.4.1 1 Comparison of endothelium dependent relaxation in non-pregnant, 
pregnant and women with pre-eclampsia 
Comparison of non-endothelium dependent relaxation between vessels from normal pregnant 
women and women with pre-eclampsia howed no significant differences (P=0.93, ANOVA). 
7.5 Discussion: 
7.5.1 Vasoconstrictors: 
7.5.1.1 Vasopressin: 
Pressor responses to angiotensin II in pregnancy are reduced both in humans (Gant et al., 1973), 
and sheep (Rosenfeld and Gant, 1981), a finding that appears to be universal to all animals 
studied (Joels and Humphreys, 1985) (Jansakul et al., 1990) (Ahokas et al., 1991) (Ahokas and 
Sibai, 1992) (Ramsay et al., 1992) (Ramsay et al., 1993) (Allen et al., 1994) (Hines et al., 1994). 
Responses in pregnant rats to vasopressin have also been shown to be decreased when 
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compared to non-pregnant animals (Hines et al., 1994), however the responses to vasopressin of 
human pregnant women remains to be fully elucidated. 
This thesis confirms the findings of Pascoal et at (1998) that during pregnancy, human omental 
vessels undergo no alteration in their response to vasopressin when compared to non-pregnant 
vessels (Pascoal and Umans, 1996). Similar findings have been also been reported in both 
animal and human studies of different systemic vascular beds. Norepinepherine Induced 
contractions of human pregnant subcutaneous resistance vessels also remain unchanged with 
pregnancy (McCarthy et al., 1993b) (Knock and Poston, 1996) (Van de Voorde et al., 1997). This 
is in sharp contrast to the data from vessels obtained from pregnant myometrium which undergo 
dramatic changes in endothelial response to various vasoconstrictor agents; these differences 
have already been discussed inChapter 6and will not be dwelt on here. 
The addition of indomethacin, or indomethacin and L-NAME, to the non-pregnant and pregnant 
vessels had no effect on the concentration response curves to vasopressin. This is similar to 
previously reported findings in human myometrial vessels constricted to vasopressin (Chapter 6) 
and noradrenaline (Steele et al., 1993), and systemic subcutaneous vessels constricted to 
noradrenaline (McCarthy et al., 1993b). 
Human and animal studies uggest that pregnancy is clearly associated with an alteration in the 
basal release of endothelium-derived products. These effects are not due to alterations in either 
nitric oxide or eicosanoid synthesis, as inhibition of these pathways caused no differences 
between pregnant and non-pregnant vessels in either animal or human vessels (Fig 7.1) (Chapter 
6) (Davidge and McLaughlin, 1992) (Steele et al., 1993) (Kim et al., 1994). As such, these 
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observations further support a significant role for the yet to be identified endothelial derived 
relaxing factor in the vascular changes associated with pregnancy. 
Omental vessels from women with pre-eclampsia showed enhanced constrictor responses to 
vasopressin when compared to normal pregnant controls (Fig 7.1), an observation that has also 
been reported by Pascoal et al (1998). Similar findings have been reported in myometrial vessels 
(Chapter 6) (Allen et al., 1989), subcutaneous vessels (McCarthy et al., 1993b) and inferior 
epigastric arteries (Oguogho et al., 1996). These observations from various non-uterine vascular 
beds of human pregnant women with pre-eclampsia support the hypothesis that there is an 
alteration in endothelial function that causes the clinical manifestation of this disease. The 
generality of this observation throughout the human system would also support the hypothesis of 
Roberts et al (1989), that a blood borne factor(s) causes the alteration in endothelial function 
(Roberts et al., 1989) (Roberts et al., 1991). 
The addition of the eicosanoid inhibitor indomethacin to omental vessels from pregnant women 
and women with pre-eclampsia c used no significant alterations in the concentration response 
curves to vasopressin (Fig 7.3 and 7.4). However, the addition of both indomethacin and the nitric 
oxide inhibitor, L-NAME, to the vessels from women with pre-eclampsia c used a significant 
leftward shift in their response, a shift that was not observed in vessels from the normal control 
group (Fig 7.3 and Fig 7.4). This suggests that there is an increased basal release of nitric oxide 
in vessels from women with pre-eclampsia. Smarason et at (1997) have recently reported that 
plasma levels of nitric oxide are increased in pre-eclampsia (Smarason et al., 1997) and several 
studies including this thesis have suggested that peroxynitrites are increased in various tissues in 
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women with pre-eclampsia (Myatt et al., 1996) (Roggensack et al., 1999) (Kossenjans et at., 
2000) (Chapter 6). 
7.5.2 Vasodilators: 
7.5.2.1 Bradykinin: 
This study is in accord with several other studies that have demonstrated relaxation to bradykinin 
(Ashworth et al., 1996b) (Pascoal and Umans, 1996) (Ashworth et al., 1996c) (Pascoal et al., 
1998) and acetylcholine in omental vessels (Pascoal and Umans, 1996) (Pascoal et at., 1998). 
However, the maximal response obtained to bradykinin differs between studies. This study 
obtained relaxations ofapproximately 70-80%, which is similar to those obtained by Ashworth et 
at, whereas Pascoal et al reported 100% relaxations. Moreover, analysis of the EC5o values 
between the various tudies demonstrates marked ifferences, Pascoal et al did not calculate 
EC5o values, however analysis of their presented ata suggests an EC5o value of approximately (-) 
7x10-10M. However, this study and that of Ashworth et al report EC5o values of (-) 9 x10-10M. 
Discrepancies in these studies may have come from differences In the passive diameter of the 
vessels; this study and that of Ashworth et al (1996) used passive diameters that corresponded to 
90% of the calculated diameter at 100mmHg, whereas Pascoal et al (1998) used a passive 
diameter that corresponded to the diameter at 100mmHg. McPherson et al have demonstrated 
that increasing of the passive diameter causes a rightward shift In the ECso values to the 
contractile agent methaxamine In rat mesenteric vessels (McPherson, 1992). Therefore, it could 
be postulated that the tension that the vessel is under might affect he vasodilator responses in a 
similar manner. 
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Data presented in this thesis show that relaxation to bradykinin is similar in vessels from normal 
pregnant and non-pregnant women (Fig 7.5). These observations confirm those published by 
Pascoal et al (1998) (Pascoal and Umans, 1996) (Ashworth et al., 1996b). Human uterine 
resistance vessels have been demonstrated to show no differences in bradykinin mediated 
relaxations between pregnant and non-pregnant women (Ashworth et al., 1997) (Chapter 6). 
However, studies from human subcutaneous vessels are more controversial; Knock et al (1996) 
reported enhanced relaxation to bradykinin from vessels obtained from pregnant women when 
compared to those from non-pregnant women (Knock and Poston, 1996), but, in a similar study 
Van de Voorde et al (1996) were unable to demonstrate any significant differences in relaxation 
between the two study groups (Van de Voorde et al., 1997). The observed differences inthese 
studies may be due to differences inprotocol. Van de Voorde t al (1997) utilised norepinephrine 
in depolarised [30 mmol K+] conditions to induce contractions. It is now well documented that 
varying extra-cellular potassium concentrations effectively separates nitric oxide and EDHF 
mediated relaxation (Adeagbo and Triggle, 1993); in such conditions EDHF relaxation would be 
abolished. Knock et at (1996) utilised the same vasoconstrictor agent without partial 
depolarisation a d demonstrated an increase in relaxation in pregnant vessels. 
Pascoal et al demonstrated that responses were independent of both eicosanoids and nitric oxide 
(Pascoal and Umans, 1996) (Pascoal et al., 1998). This is in contrast to the results of this thesis 
where the three vessel groups studied displayed a varying degree of nitric oxide mediated 
relaxation (Fig 7.6,7.7,7.8,7.9). These differences may have occurred for several reasons. 
Firstly, vessel size: it is well documented that smaller diameter vessels display proportionally 
greater EDHF mediated relaxation (Woolfson a d Poston, 1990) (Hasunuma et al., 1991) (Mugge 
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et al., 1991) (Nagao et al., 1992) and this study utilised vessels that were of a two fold greater 
diameter than those used by Pascoal et al (412 Vs 210µm). Secondly, the passive diameter of 
the vessel during experimentation may effect the results as stated previously. The EC5o values of 
the L-NAME exposed pregnant and non-pregnant vessels were in the order of (") 6.6 x 10-10M (Fig 
7.6 and 7.7) and in the study of Pascoal et al the EC5o values with and without a nitric oxide 
synthase inhibitor were approximately (-) 7.0 x 10.10 M. From this it could be hypothesised that 
vessels at a higher passive diameter (under greater tension) require greater concentrations of 
bradykinin to initiate relaxation, and therefore the bradykinin concentrations are above those that 
mediate relaxation through nitric oxide. This hypothesis was not formally tested. 
With regard to pregnancy, unlike myometrial vessels, omental vessels displayed no significant 
increase in the proportion of non-eicosanoid, non-nitric oxide mediated relaxation (EDHF) 
(P=0.88). However, it might be postulated that in these vessels the nitric oxide synthetase 
enzyme had not been adequately inhibited. This hypothesis was tested through the dose 
response to varying concentrations of L-NAME. The results demonstrated that doubling the 
concentration f L-NAME had no further effect the rightward shift of the CRC and suggest further 
that EDHF is important in the relaxation of human vessels (Fig 7.8). 
Although data from animal research suggests that the decrease in peripheral resistance in normal 
pregnancy might be mediated be enhanced nitric oxide mediated relaxation (Hull et al., 1992) 
(Matsumoto et al., 1992) (Chu and Beilin, 1993), the observations of this thesis on omental and 
myometrial (Chapter 6) vessels provides no evidence to support this hypothesis. On the contrary 
the observations ofmyometrial resistance vessels uggest that there is In fact a reduction In the 
nitric oxide mediated relaxation during pregnancy (Chapter 6). Similar resistance to nitric oxide 
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blockade has also been reported in subcutaneous resistance vessels (Knock and Poston, 1996) 
(Van de Voorde et al., 1997). The observations of this thesis and the observed ifferences 
between the reports of Knock et al (1996) and Van de Voorde et al (1997) would Imply that 
increased EDHF, not nitric oxide, mediated relaxation is important in human pregnancy 
adaptation. 
Omental vessels, unlike myometrial vessels, displayed no adaptations to pregnancy through an 
increase in EDHF mediated relaxation. Furthermore, omental vessels displayed no significant 
loss of endothelium dependent relaxation in pre-eclampsia, a finding in keeping with that of 
Pascoal et al (1996). Omental vessels from women with pre-eclampsia, in a similar manner to 
vessels from the myometrium, displayed an increase in the proportion of nitric oxide mediated 
relaxation when compared to normal control vessels (Fig 7.9) (P=0.028). This again suggests that 
in pre-eclampsia there is a compensatory up-regulation f nitric oxide mediated relaxation. This 
finding of an increased release of nitric oxide on stimulation is in keeping with the observation that 
there is an increase in the basal release of nitric oxide in vessels from women with pre-eclampsia 
(Fig 7.4). Further support for this comes from Roggensack et al (1999) who reported increased 
nitrotyrosine residues and eNOS in the vascular endothelium of women with pre-eclampsia 
(Roggensack et al., 1999) (see Chapter 6). Whether this Increased nitric oxide component is 
detrimental tovessel function remains to be elucidated. 
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7.5.2.2 Acetylcholine: 
This study demonstrates that omental vessels constricted with vasopressin displayed 
endothelium-dependent r laxation to acetylcholine (Fig 7.10). This is in accord with others 
studies that have examined acetylcholine r sponses in the omentum (Pascoal and Umans, 1996) 
(Pascoal et at., 1998). However, omental vessels constricted with U46619 have been shown to 
undergo neither contraction nor relaxation to the same doses of acetylcholine [1x10-9 
-1x10-4 M] 
(Wallerstedt and Bodelsson, 1997), a result which may suggest that the choice of vasoconstrictor 
used is important to the results obtained. Evidence to support this comes from this thesis where 
myometrial vessels contracted with vasopressin also showed no endothelial dependent relaxation 
to acetylcholine despite the presence of a functioning endothelium (Chapter 3) whereas vessels 
constricted to noradrenaline showed a 30% endothelial dependent relaxation to acetylcholine 
(Kublickiene, 1998). However, the vessel size may prove to be a determinant to the amount of 
relaxation obtained. Pascoal et al (1996) obtained 100 % relaxation in vessels that were in the 
region of 200µm, this thesis obtained 70% in vessels that were in the region of 4004m, and 
Wallerstedt et al (1997) obtained no relaxation in vessels that were greater than 600µm. This 
suggests that as vessels diverge down the vascular tree they become more responsive to 
acetylcholine due to an increase in available receptors. 
Although omental vessel endothelial dependent relaxation to acetylcholine has been 
demonstrated in this thesis, as with the responses to bradykinin, concentration response curves 
were unaltered with pregnancy (Fig 7.10). Moreover, both non-pregnant and pregnant vessels 
relaxation is independent of eicosanoids and nitric oxide, implicating a possible role for EDHF (Fig 
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7.11 & 7.12). Pascoal et al (1996) also showed similar esults with acetylcholine when using a 
similar method to that used in this thesis. 
Omental vessels are utilised in humans as representative of mesenteric vascular system, 
however, animal studies of mesenteric vessels have produced very different results. In 
pregnancy, animal models have demonstrated nhanced endothelium dependent relaxation to the 
agonists acetylcholine and bradykinin in small resistance arteries from rats (Davidge and 
McLaughlin, 1992) (Pascoal et al., 1995) (Learmont et al., 1996). In common with the non- 
pregnant state (Garland and McPherson, 1992) small arteries from pregnant rats (Pascoal et al., 
1995) usually show persistent relaxation to acetylcholine and bradykinin when nitric oxide and 
prostacyclin synthesis are inhibited. In non-pregnant animals this relaxation has been attributed 
to EDHF (Garland and McPherson, 1992). Although, studies have suggested that EDHF is 
increased in pregnancy (Pascoal and Umans, 1996) (Bobadilla et al., 1997) neither of these 
directly demonstrated the presence of EDHF by inhibition through partial depolarisation or 
measurement of smooth muscle hyperpolarision. Recently, Gerber et al demonstrated that the 
increased response to acetylcholine in pregnant mesenteric vessels is mediated through EDHF 
production. They demonstrated, utilising the technique of wire myography, that pregnant 
mesenteric vessels had enhanced relaxation over non-pregnant controls in the presence of an 
eicosanoid inhibitor, a nitric oxide synthetase inhibitor, and the soluble guanylate cyclase Inhibit 
oxidiazole quinoxalin (ODQ). However, when both vessels from non-pregnant and pregnant 
animals were partially depolarised with 25 mmol K+ the relaxation was attenuated. This 
demonstrates that in mesenteric vessels, the enhanced relaxation of pregnancy may be mediated 
through increased EDHF (Gerber et al., 1998). 
215 
Experimental evidence from both intact issues and cell culture support a role for gap junctions in 
EDHF cell-cell communication a d control of arterial function (Little et al., 1995) (Chapter 1). With 
regard to human pregnancy Kenny et al have recently demonstrated that isolated myometrial 
vessels contracted with vasopressin and relaxed to bradykinin are resistant to eicosanoid and 
nitric oxide blockade, but that the additional presence of 18-alpha glycyrrhetinic acid, a gap 
junction uncoupler (Taylor et al., 1998), completely abolishes the relaxation. This would imply that 
in myometrial vessels that EDHF responses are of considerable Importance (Kenny et al., 1999a). 
This thesis (Chapter 6) has also demonstrates that myometrial vessels alter their endothelium 
dependent relaxation with pregnancy in favour of EDHF. Therefore, this would concur with the 
data of Dantas et al (1999) that gap junction play an integral role in the vascular pregnancy 
adaptation response (Dantas et al., 1999). Whether, this increase in gap junction mediated 
relaxation occurs in vessels in the systemic irculation remains to be elucidated. 
Acetylcholine also displayed a loss of endothelium dependent relaxation in vessels from women 
with pre-eclampsia and confirms the results of Pascoal et al (1996). The addition of eicosanoid or
nitric oxide synthase inhibitors had no significant effect on the concentration response curves and 
demonstrates that in this vascular bed the acetylcholine-mediated relaxation may be mediated 
exclusively through EDHF. Evidence to support this comes from Pascoal et al (1996) who also 
demonstrated that vessels constricted with vasopressin were unaffected by nitric oxide or 
eicosanoid synthetase inhibitors when relaxation occurs with acetylcholine. 
The gross mechanisms of vasodilatation have been characterised In omental vessels to 
bradykinin and acetylcholine. Bradykinin appears to mediate its relaxation predominately through 
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nitric oxide with a small EDHF component. In contrast acetylcholine mediates its relaxation 
exclusively through EDHF. 
Omental vessels how no endothelial-mediated alterations with pregnancy; this may in part be 
due to their anatomical placement. It could be hypothesised that vessels that are required to 
accommodate and supply the growing conceptus would undergo greater adaptations to 
pregnancy than those that have little to due with peripheral vascular esistance, Another 
important vascular bed that receives a large increase in the blood flow during pregnancy is the 
kidneys, however, the inaccessibility of these vessels in the human patients precludes then from 
in vitro study. 
Although omental vessels show no adaptations to pregnancy they undergo alteration in 
endothelial function with pre-eclampsia which may be mediated through an imbalance in nitric 
oxide and EDHF. These include an increased pressor response to vasopressin that is 
independent of elcosanoids, but Is dependent unpon increased nitric oxide (Fig 7.2,7.3 & 7.4). 
Endothelium-dependent r laxation is also altered in omental vessels in women with pre- 
eclampsia; a loss of endothelium-dependent r laxation to acetylcholine was found through a 
decrease in presumed-EDHF mediated relaxation. In vessels exposed to bradykinin, there is a 
decrease in EDHF mediated relaxation and an increase in nitric oxide mediated relaxation. This 
reciprocal decrease in EDHF and Increase in nitric oxide mediated relaxation has been well 
documented (Randall and March, 1998). It might be postulated that the loss of endothelium- 
dependent relaxation to acetylcholine is through an Increase In the production of nitric oxide, 
which attenuates the EDHF response, but these vessels are incapable of vasodilation through 
nitric oxide when stimulated with these agonists. Evidence for Increased nitric oxide in these 
217 
vessels in the disease of pre-eclampsia comes from Roggensack et al who demonstrated a 
increase in endothelial staining for peroxynitrite and eNOS in these vessels (Roggensack et al., 
1999). 
The lack of adaptation to pregnancy in these vessels and the observed alteration in endothelial 
function in pre-eclampsia further enhance the hypothesis that there is a circulating factor in the 
blood of women with pre-eclampsia that causes this alteration and it is not a failure of maternal 
adaptation. The nature of this circulating factor remains to be elucidated, however, it has been 
recently demonstrated that chronic exposure to the pro-inflammatory cytokine TNFa causes rabbit 
carotid and porcine coronary vessels to lose EDHF mediated relaxation through the upregulation 
of nitric oxide (Kessler et al., 1999). Whether this is also the case in humans or whether other 
cytokines affect vascular function remains to be studied (see Chapter 8). 
7.6 Summary: 
In this chapter the vasoconstrictor responses to vasopressin in non-pregnant, pregnant and 
vessels from women with pre-eclampsia have been characterised. It has been shown that in 
pregnancy there were no blunted responses to vasopressin. This thesis has also demonstrated 
an enhanced response to vasopressin in vessels from women with pre-eclampsia and that basal 
release of nitric oxide appears to be increased as a method of off-setting this response. The data 
presented here suggest that in human pregnancy less adaptation occurs in human omental 
vessels than in myometrial vessels. This may represent the fact that these vessels have less 
involvement i  the physiology ofpregnancy than myometrial vessels. 
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Data presented in this thesis clearly demonstrate that pregnancy is not associated with 
alterations in endothelial dependent relaxation, but that pre-eclampsia dramatically alters 
endothelium dependent relaxation in the systemic irculation. It also demonstrates that these 
changes may be mediated through the alteration in the reciprocal relationship between NO and 
EDHF, in favour of nitric oxide that reduces that EDHF response. 
Data presented in this chapter also show that when the interaction of the endothelium with 
Vascular Endothelial Growth Factor and plasma [Chapter 8] are investigated, the effect that these 
have with the endothelium on the acetylcholine r sponse should be considered. 
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Chapter eight: The interaction of vascular endothelial growth factor (VEGF) 
and plasma from women with pre-eclampsia with the endothelium in an in 
vitro model. Evidence that VEGF is implicated in the pathogenesis of pre- 
eclampsia: 
Graphs 8.14,8.15,8.16 and 8.20 were obtained by collaboration with Dr Richard Hayman. 
8.1 Introduction: 
There is accumulating evidence for a pathogenic model of pre-eclampsia, whereby adeficiency in
the trophoblast invasion of the placental bed spiral arteries leads to a poorly perfused feto- 
placental unit. This results in secretion of a factor(s) into the maternal circulation which causes 
'activation' of the vascular endothelium; the clinical syndrome results from widespread changes in 
endothelial cell function (see Chapter 1). However, the nature of the circulating factor(s) and the 
mechanism by which the endothelium is activated, are as yet undetermined. 
There is much circumstantial evidence to support the hypothesis that placental-derived VEGF 
mediates the endothelial ctivation of pre-eclampsia. A detailed review of VEGF has been carried 
out in Chapter 1 and its biological functions will not be discussed further. However, VEGF is 
increased in the plasma of women with pre-eclampsia when compared to normotensive pregnant 
controls (Chapter 4). In chapter 6 it was demonstrated that myometrial resistance vessels from 
women with pre-eclampsia had an increased response to vasopressin and an attenuated 
response to bradykinin. Ithas also been previously demonstrated that normal myometrial vessels' 
responses to bradykinin are altered after incubation with plasma from women with pre-eclampsia 
in a manner which is similar to vessels obtained from women with pre-eclampsia (Ashworth et al., 
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1998). In Chapter 7 omental vessels (as representative of the peripheral vascular system) were 
also shown to have a specific loss of endothelium dependent relaxation to acetylcholine. 
Therefore it was considered interesting to investigate whether plasma nd VEGF could initiate 
similar esponses to those obtained from myometrial nd omental vessels from women with pre- 
eclampsia. 
8.2 Aims: 
" To investigate whether VEGF causes a constrictor response to myometrial nd omental 
resistance vessels. 
" 
To use an ex vivo myographic model to investigate whether VEGF and plasma were capable 
of altering the behaviour of normal myometrial vessels to vasopressin and bradykinin i  a 
similar manner to pre-eclampsia. 
" 
To use an ex vivo myographic model to investigate whether VEGF and plasma were capable 
of altering the behaviour of normal omental vessels to vasopressin and acetylcholine in a 
similar manner to vessels from women with pre-eclampsia. 
" 
To investigate the mechanism of action of VEGF on myometrial nd omental resistance 
vessels 
8.3 Experimental design: 
A 16-hour incubation period (overnight) was used for the majority of the interactions investigated 
in this study. This was chosen as previous work in our laboratory had demonstrated this to be an 
effective time period for reproducible r sults. As a consequence, 1 lu heparin/ml was added to all 
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the tubes in order to prevent the formation of a fibrin clot in those mixtures to which plasma had 
been added. 
In all the studies where plasma was required individual patient's plasma was used except in the 
experiment where VEGF was removal from the plasma with the use of Dynal beads. In this 
experiment pooled plasma was utilised as the cost of removing the VEGF from individual samples 
was deemed to be too expensive. Pooled plasma had been demonstrated to have a comparable 
effect as individual sample (Hayman, 1999). 
8.3.1: The direct effect of VEGF on myometrial resistance vessels: 
Myometrial resistance vessels were obtained from pregnant women (n=4) as described previously 
in Chapter 2.5.2a. Vessels were mounted and normalised as described in Chapter 2.5.4. The 
myography protocol (Chapter 3,3.1) was then followed and incremental doses of vasopressin 
were used to confirm that the vessel was capable of constriction (Chapter 2.5.5.5). The vessel 
was then washed as previously described. Once it had returned to the base line incremental 
doses of VEGF (0.1 nM 
-5nM) were added. 
In separate xperiments myometrial vessels were obtained from non-pregnant ( =3) and pregnant 
(n=2) women as described previously in Chapter 2.5.2a. Vessels were mounted and normalised 
as described in Chapter 2.5.4. The myography protocol (Chapter 3.3.1) was then followed and 
incremental doses of vasopressin were used to cause a constriction (Chapter 2.5.5.5); once a 
steady a state constriction had been obtained vessels were exposed to Incremental doses of 
bradykinin toconfirm presence of the endothelium. Vessels were then washed with PSS (Chapter 
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2.5.5.5) and allowed to return to a base line. Once a base line was maintained, vessels were 
again contracted with vasopressin and this time VEGF in incremental doses was added to the 
chamber solution (0.1 nM 
-5nM). 
8.3.2: The effect of incubation with vascular endothelial growth factor and 
placental growth factor on endothelium dependent resistance artery 
behaviour from non-pregnant and pregnant women. 
Myometrial vessels from normal pregnant (n=l0) and non-pregnant women (n=6) were incubated 
overnight with 5 nmol VEGF and compared to control vessels. In separate xperiments vessels 
were obtained from normal pregnant (n= 5) and non-pregnant women (n= 10) and incubated 
overnight in the presence or absence of 5nmol PIGF. 
8.3.3: The effect of concentration of vascular endothelial growth factor on 
endothelium dependent resistance artery behaviour. 
Myometrial vessels from normal pregnant women (n=6) were collected as described previously 
(Chapter 2). At least four vessels were dissected from each sample; vessels were then randomly 
divided into four groups and placed in cold oxygenated PSS for overnight storage (Chapter 2). 
VEGF (5nM, 0.5nM, 0.05nM) was then added to the PSS solution in three of the groups by a 
technician, so that the investigator was blinded to which VEGF concentration had been added to 
each vessel; one vessels remained without VEGF to act as an internal control. After the 
experimental protocol (Chapter 3.2.1) was completed the results were analysed and the VEGF 
concentrations revealed. 
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8.3.4: The effect of time of incubation with vascular endothelial growth factor 
on endothelium dependent resistance artery behaviour. 
Myometrial vessels were obtained from a total of 18 normal pregnant women as described in 
Chapter 2. Myometrial vessels were incubated with VEGF (0.5nM) for three different ime 
periods; one-hour, two-hour and sixteen-hours (overnight). Those vessels in the one hour 
protocol (n=6) were dissected, mounted and normalised as described in Chapter 2. VEGF 
(0.5nM) was then added to the myography chamber and the vessels Incubated as the 
temperature was raised to 370C over a1 hour period. Vessels in the two-hour protocol were also 
dissected and mounted as in Chapter 2. VEGF (0.5nM) was added to the myography chamber 
and the vessels incubated as the temperature was raised over 1 hour, after equilibration the PSS 
was replaced with fresh heated PSS containing VEGF and the vessels were left for a further 1 
hour before commencing the experimental protocol (Chapter 3). Vessels in the sixteen-hour 
protocol were dissected and randomly divided into two groups and placed in cold oxygenated PSS 
for storage overnight (Chapter 2). VEGF was then added to the PSS solution as described in 
Chapter 8.3.3. 
8.3.5: The effect of parity on vascular endothelial growth factor's effect on 
endothelium dependent resistance artery behaviour. 
To examine whether parity affected the endothelial response to VEGF, vessels from primiparous 
(n=8) and multiparous (n=7) women were obtained from myometrial biopsies. These were 
incubated overnight (Chapter 3) in the presence or absence of VEGF (0,5nM). 
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8.3.6: The effect of repeated concentration response curves (CRC) to 
bradykinin on the endothelial interaction with vascular endothelial growth 
factor. 
Vessels were obtained from myometrial biopsies from pregnant women (n=6) as described In 
Chapter 2. Vessels were than allocated into two groups and Incubated overnight in the presence 
or absence of VEGF (0.5nM) (Chapter 3). After incubation vessels were mounted and normalised 
(Chapter2). These were then constricted with vasopressin a d concentration response curves for 
bradykinin obtained; atotal of four CRCs were produced for each vessel. 
8.3.7: The effect of plasma from women with pre-eclampsia on endothelium- 
dependent resistance artery behaviour. 
At least three myometrial resistance vessels were obtained from pregnant (n=13) as described 
previously in Chapter 2.5.2a. Vessels were randomly allocated into three groups and stored 
overnight (Chapter 2.5.6) in either the presence of 2% normotensive plasma, 2% plasma from 
women with pre-eclampsia, or no plasma (Ashworth et al., 1998). Following incubation, vessels 
were mounted and normalised as described in Chapter 2.5.4. The myography protocol (Chapter 
3.3.1) was then followed in which incremental doses of vasopressin were used to cause 
constriction and incremental doses of bradykinin were used to cause relaxation (Chapter 2.5.5.5). 
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8.3.8: The effect of antibody to VEGF on endothelium dependent resistance 
artery behaviour. 
To determine whether VEGF in the plasma of women with pre-eclampsia w s responsible for the 
alterations in endothelial function seen using this bioassay technique, vessels from 8 patients 
were incubated overnight with either 0.5 nmol VEGF, 2% plasma from women with pre-eclampsia 
or 2% plasma from normal pregnant women, each in the presence or absence of 250 lu 
monoclonal ntibody to VEGF (R&D, UK, Abingdon). Similar sized myometrial resistance arteries 
from normal pregnant women (n=8) were divided into 6 groups, thus ensuring comparable v ssels 
within each group. 
8.3.9: The effect of anti-Flt-1 and anti-KDR antogonists on endothelium 
dependent resistance artery behaviour produced by VEGF and plasma. 
We next sought to determine which VEGF receptor was responsible for the alteration in 
endothelial function seen using our bioassay technique. Pregnant vessels (n=6) were incubated 
in the presence of VEGF (1.0 nM), with either anti-Fit-1 (10ng/ml) or anti-KDR (10ng/ml) 
antagonists (Generously supplied by Professor AAhmed, University of Birmingham). In separate 
experiments, vessels were incubated with normal pregnant plasma nd plasma from women with 
pre-eclampsia in the presence or absence of ant-Fit-1 antibody (10ng/ml). 
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8.3.10: The effect of Dynabead® removal of VEGF from plasma from women 
with pre-eclampsia on endothelium dependent resistance artery behaviour. 
In order to establish whether VEGF exerts a direct effect upon vessel behaviour or whether the 
uncharacterised factor(s) exert their effect by inducing endogenous production /or release of 
VEGF, plasma from women with pre-eclampsia w s treated with anti-VEGF coated Dynabeads® 
(Dynal® treated plasma) (Chapter 2). 
Similar sized myometrial resistance arteries from normal pregnant women (n=6) were divided into 
3 groups, thus ensuring comparable vessels within each group. These vessels were then 
incubated overnight with either 2% plasma from women with pre-eclampsia, 2% plasma from 
normal pregnant women, or 2% Dynal® treated plasma (Chapter 3). 
8.3.11: Effect of Indomethacin and L"NAME on vessels incubated with VEGF 
and appropriate time controls: 
As described in Chapter 3, the altered concentration response curves of myometrial vessels from 
women with pre-eclampsia returned towards the response curves of control vessels with repeated 
exposures to vasopressin and bradykinin accompanied by washing with PSS. Protocols were 
thus designed to allow for this when the interaction of VEGF with the endothelium were 
investigated (Chapter 3.2.2). Vessels from normotensive pregnant women (n=6) at term were 
obtained as in Chapter 2. Vessels were divided into three groups and all were exposed to VEGF 
(0.5 nM) for sixteen hours (Chapter 2). After sixteen hours Incubation With VEGF vessels were 
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mounted and normalised on separate Mulavny wire myographs. One-concentration response 
curve for vasopressin and bradykinin was obtained for each vessel. After this vessels were 
allocated to one of the three experimental groups: indomethacin alone, indomethacin and L- 
NAME or control. 
8.3.12: Effect of plasma incubation on the CRC for acetylcholine obtained 
from omental resistance vessels; 
In order to confirm that the observed effects of plasma and VEGF were not limited to the 
myometrium, experiments were initially designed to investigate he effect of plasma on omental 
vessels. It was felt that if plasma demonstrated a response, then VEGF responses would be 
investigated. In Chapter 7 it was demonstrated that omental vessels from women with pre- 
eclampsia lost endothelium dependent relaxation to both acetylcholine. Omental vessels were 
collected from normal pregnant women (n=6) as described in Chapter 2. One vessel was 
dissected out in cold PSS, this was then divided into three separate sections. These were then 
stored for 16 hours at 40C in separate sterilin tubes (Chapter 2). A member of the technical staff 
then added 2% plasma from either normal pregnant women or women with pre-eclampsia to two 
of the sterilin tubes; the third vessel section was also stored over 16 hours without plasma. After 
incubation vessels were mounted and experimented onas described in Chapter 3. 
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8.4 Results: 
Table 8.1and 8.3 detail the demographics and vessel characteristics of the non-pregnant, 
pregnant controls and the pre-eclampsia group. Table 8.2 and 8.4 detail the patient 
demographics for the plasma samples used. As anticipated, systolic and diastolic blood pressure 
were significantly greater in the group of women with pre-eclampsia than the control pregnant or 
non-pregnant groups. 
8.4.1: The direct effect of VEGF on myometrial resistance vessels: 
The addition of vasopressin to myometrial vessels produced a dose dependent contraction. 
Although the vessels utilised had demonstrated a constrictor response, the incremental addition of 
VEGF to these vessels produced no demonstrable response (Fig 8.1). 
The addition of incremental doses of VEGF to pregnant vessels caused non significant relaxation 
in vasopressin constricted vessels. However, the addition of VEGF to non-pregnant vessels 
caused a vasodilatation f these vessels (Fig 8.2). 
8.4.2: The effect of incubation with vascular endothelial growth factor and 
placental growth factor on endothelium dependent resistance artery 
behaviour from non-pregnant and pregnant women. 
Myometrial vessels from normal pregnant women which were incubated with 5 nmol VEGF 
showed significantly increased responses to vasopressin over control vessels (ANOVA: P=0.02) 
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(Figure 8.3). Sub-analysis of the data, revealed that the observed increase, occurred only in the 
maximum contraction obtained (E max P=0.04) and there was no shift in the EC5o value (-9.5+1-0,1 
Vs 
-9.3+/-0.2: P=0.4). In contrast, vessels from non-pregnant women, which were exposed to 
VEGF exhibited no differences in their contractile responses when compared to control vessels 
(P=0.92) (Figure 8.4). 
A significant reduction was also noted in bradykinin-induced en othelium dependent relaxation I  
vessels incubated with 5 nmol VEGF (p < 0.0001 Figure 8.5). Once again the observed effect of 
VEGF was demonstrated to be pregnancy specific; no differences were found between non- 
pregnant myometrial vessels incubated with VEGF and controls (P=0.85) (Figure 8.6). The 
addition of PIGF to either pregnant or non-pregnant vessels produced no differences in 
bradykinin-induced en othelium dependent relaxation (Figure 8.7 and 8.8). 
8.4.3: The effect of concentration of vascular endothelial growth factor on 
endothelium dependent resistance artery behaviour: 
VEGF was found to act in a dose dependent manner; asignificant reduction in bradykinin-induced 
endothelium dependent relaxation was found in vessels incubated with 5 nmol and 0.5 nmol 
VEGF when compared with vessels incubated in 0.05 nmol VEGF and without VEGF (p< 0.01). 
There was no significant difference between the effects of the 5 nmol and 0,5 nmol 
concentrations, nor differences between the effects of 0.05 nmol concentration and no VEGF 
(Figure 8.9). 
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8.4,4: The effect of time of incubation on vascular endothelial growth factor on 
endothelium dependent resistance artery behaviour: 
VEGF was found to act in a time dependent manner, with a significant reduction in endothelial 
dependent relaxation only occurring after sixteen-hour periods of incubation (Figure 8.10). 
8.4.5: The effect of parity on vascular endothelial growth factors' effect on 
endothelium dependent resistance artery behaviour. 
The observed effect of VEGF on pregnant myometrial resistance vessel behaviour was 
independent of the parity of the patients from whom the vessels were taken (Figure 8.11 and 
8.12). 
8.4.6 The effect of repeated washing of vessels after incubation with vascular 
endothelial growth factor: 
The effect of incubation of vessels with VEGF was reversible; the endothelium-dependent 
relaxation to bradykinin being restored following sequential washing of VEGF from the vessels 
and repeated concentration response curves to bradykinin (Fig 8.13). 
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8.4.7: The effect of incubation with plasma from women with pre-eclampsia on 
endothelium dependent resistance artery behaviour. 
As noted previously (Ashworth et al., 1998), there was a significant reduction in endothelium- 
dependent relaxation when vessels were incubated with plasma from women with pre-eclampsia 
as compared with vessels incubated in 2% plasma from normal pregnant women or without 
plasma (P < 0.0001) (Fig 8.14). 
8.4.8: The effect of antibody to VEGF on endothelium dependent resistance 
artery behaviour: 
Incubation of vessels with both 0.5 nmol VEGF and 2% plasma from women with pre-eclampsia 
resulted in a marked attenuation of relaxation when compared to control vessels and those 
incubated with 2% plasma from normal pregnant women (p<0.0001) (Fig 8.15 and 8.16). There 
was no significant difference between the relaxation oted in those vessels incubated in 2% 
plasma from women with pre-eclampsia and those incubated in 0.5 nmol VEGF. The effect of 
VEGF / plasma from women with pre-eclampsia w s significantly altered following the addition of 
VEGF antibody, such that vessel incubated with 2% plasma from women with pre-eclampsia and 
those incubated with 0.5 nmol VEGF exhibited adegree of endothelium dependent relaxation that 
approached that seen In vessel incubated in 2% plasma from normal pregnant women (Fig 8.15 
and 8.16). 
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There was no significant alteration in the degree of endothelium dependent relaxation in vessels 
incubated in 2% plasma from normal pregnant women, either with or without the addition of 
antibody to VEGF (Figure 8.16). 
8.4.9: The effect of anti-Fit-I and anti-KDR antogonists on endothelium 
dependent resistance artery behaviour. 
The presence of KDR receptor antibody had no effect on the VEGF response (P>0.05) (Fig 8.17). 
The presence of the anti-Fit-1 receptor antagonist returned the endothelium-dependent relaxation 
to normal, in spite of the presence of VEGF (P< 0.05) (Fig 8.18). Vessels exposed to the plasma 
of women with pre-eclampsia in the presence of the anti-fit-1 antibody exhibited normal relaxation 
(Fig 8.19). 
8.4.10: The effect of Dynabead® removal of VEGF on endothelium dependent 
resistance artery behaviour: 
Incubation of vessels with both Dynal® treated plasma and 2% plasma from women with pre- 
eclampsia resulted in a marked attenuation of relaxation when compared to vessels incubated 
with 2% plasma from normal pregnant women (p<0.0001). There was no significant difference 
between the relaxation oted in those vessels incubated in 2% plasma from women with pre- 
eclampsia nd those incubated inDynal® treated plasma (Fig 8.20). 
Dr F Anthony measured the concentration f VEGF in our samples using a radio-immuno-assay 
technique (RIA) (Chapter 2). Levels of VEGF were 0.16 nmol In the pooled normal pregnant 
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plasma, 0.22 nmol in the pooled plasma from women with pre-eclampsia and 0.16 nmol in the 
Dynal® treated plasma. 
8.3.11: Effect of Indomethacin and L-NAME on vessels incubated with VEGF 
and appropriate time controls: 
The addition of indomethacin had no significant effect on the bradykinin concentration response 
curve of vessels incubated with VEGF (Figure 8.21). However, the addition of indomethacin and 
L-NAME to vessels exposed to VEGF caused a marked ecrease in the endothelium dependent 
relaxation when compared to both control vessels and those incubated with indomethacin (Figure 
8.21) 
8.3.12: Effect of plasma incubation on the CRC for acetylcholine obtained 
from omental resistance vessels: 
When omental vessels from normal pregnant women which were incubated with 2% plasma from 
control pregnant women, 2% plasma from women with pre-eclampsia and no plasma were 
studied, there were no significant differences in theS endothelium dependent relaxation to 
acetylcholine between the three groups (ANOVA: P=0.83) (Fig 8.22). 
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8.5 Discussion: 
Maternal hypertension and proteinuria define pre-eclampsia. Maternal diastolic and systolic blood 
pressure (Kupferminc et al., 1997b) (Chapter 4), and the increased total peripheral resistance 
associated with pre-eclampsia (Bosio et al., 2001), have all been shown to correlate with plasma 
VEGF concentrations. VEGF is also well documented to cause an increase in vascular 
permeability (Senger et al., 1986) (Connolly et at., 1989a) (Wu et at., 1996) (Wu et at., 1999) 
(Tilton et al., 1999), and has been implicated in the renal disease proteinuria (Uchida et al,, 1994) 
(Shulman et al., 1996), both of which are also associated with pre-eclampsia. The literature data 
and the data shown in Chapter 4 led to the hypothesis that °VEGF may act directly upon the 
endothelium or vascular smooth muscle to cause vasoconstriction of vessels". 
Although VEGF is increased in pre-eclampsia (Chapter 4) (Baker et al., 1995a) (Kupferminc et al., 
1997b) (Bosio et at., 2001), contrary to the original hypothesis no direct vasoconstrictor effect was 
evident upon its addition to either human myometrial or omental vessels (Figure 8.1 and 8.20). 
Neither did VEGF cause a vasodilator esponse in pregnant myometrial vessels; however, it 
appeared to produce a vasodilator esponse in non-pregnant vessels (Fig 8.2). This study thus 
demonstrated conclusively that VEGF is incapable of causing an endothelial or non-endothelial 
dependent contraction in either human myometrial or systemic vessels. In view of this data, an 
alternative hypothesis was formulated to explain the observation that plasma VEGF 
concentrations correlation with blood pressure (Chapter4) and increased peripheral resistance 
(Bosio et al., 2001). 
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Data from this thesis (Chapter 6& 7) and the previous tudies uggest that a significant proportion 
of human myometrial nd omental resistance vessel relaxation, during pregnancy, is mediated 
through EDHF (discussed inChapter 6 and 7) (McCarthy et al., 1993a) (McCarthy et al., 1993b) 
(Knock and Poston, 1996). Endothelial production ofnitric oxide and EDHF have been shown, in 
vitro, to exhibit a reciprocal relationship (Bauersachs et al., 1996) (Randall and March, 1998). 
Recently, VEGF has been shown to increase the production of nitric oxide from various cultured 
endothelial cells (Ku et al., 1993) (Ahmed et al., 1997) (Tsurumi et al., 1997) (Ni et al., 1997a) 
(Kroll and Waltenberger, 1998) (Hood et al., 1998) (Tilton et al., 1999) (He et al., 1999). The 
reciprocal relationship ofnitric oxide and EDHF, and the observation that VEGF increases nitric 
oxide production led to the development of an alterative hypothesis: "that VEGF by its direct 
action upon the endothelium cause an alteration in endothelial nitric oxide production, which leads 
to the altered vascular reactivity that is characteristic of pre-eclampsia (Chapter 6and 7)". 
In Chapter 6 it was demonstrated that myometrial vessels from women with pre-eclampsia 
displayed enhanced responses vasopressin. This study shows that extended incubation of 
myometrial vessels with VEGF enhances the contractile responses to vasopressin, and in a 
similar manner to the behaviour of vessels from women with pre-eclampsia, the enhancement of 
the Emax value was not accompanied by a significant shift in the EC50 value (Fig 8.3). These 
observations implicate a possible alteration in endothelial function, and although this was not 
formally tested, it may also be postulated that this occurs through an alteration in endothelial 
EDHF release. The unaltered EC5o suggests that these observations are not mediated through 
any increases in the receptor density, as this would cause a shift In the EC 5o, and are more likely 
to be due to either increases in downstream secondary messengers or a decrease In an 
reciprocal vasodilator. 
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This study confirms the finding of Ashworth et al (1998) that plasma from women with pre- 
eclampsia, on extended incubation with normal pregnant myometrial vessels, alters their vessel 
function in a direction that is similar to vessels from women with pre-eclampsia (Ashworth et al., 
1998). The results in this thesis also demonstrate that extended incubation with VEGF causes a 
loss of endothelium dependent relaxation and this mimics the previously reported effect of plasma 
from women with pre-eclampsia onmyometrial vessel behaviour (Ashworth et al., 1998). VEGF 
was also shown to produce its effect in dose dependent manner (Fig 8.10), which was reversible 
upon washing with PSS (Fig 8.12). 
It was demonstrated VEGF acted in a dose dependent manner at concentrations of 500 pmol or 
greater, but exerted no significant effect at 50 pmol or lower. This represents an effect at 
concentrations of VEGF 50 times that found in 2% pre-eclamptic plasma. In vivo, the mean 
circulating level of VEGF has been estimated to vary between 10 pmol (Baker et al., 1995a) and 
720 pmol (Sharkey et al., 1996). In the pool utilised in this study we measured the levels of VEGF 
to be between 157 pmol and 220 pmol (Chapter 4). Although the concentration f VEGF in our 
2% plasma samples is significantly less than utilised in our VEGF experiments, it is possible that 
dilution of plasma results in the release from its binding protein(s) of the free / bioactive 
component, the consequence of this could be the maintenance of the level of the active factor in 
the same range as in undiluted plasma. Evidence to support this comes from Davidge t al 
(1996) who fractionated plasma from women with pre-eclampsia and showed that it contained a 
factor that produced higher prostacyclin levels In cell culture experiments han unfractionated 
plasma (Davidge t at., 1996a). Moreover, the circulating level of VEGF remains a contentious 
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issue, depending upon the assay utilised (discussed in Chapter 4) and may be higher than 
previously cited values. 
Alternatively our results can be explained by assuming that it is the concentration f VEGF at the 
endothelial surface that determines effect. If factor(s) within the plasma, such as IL-1 a (Ben-Av et 
at., 1995), IL-6 (Cohen et at., 1996), TNF-a (Ryuto et al., 1996) and nitric oxide, which are 
documented tobe increased inpre-eclampsia, induce the release of VEGF from the endothelium, 
local concentrations may well achieve parity with the concentrations of VEGF alone that we 
employed in our bioassay. 
Evidence to support the hypothesis that VEGF is pivotal to the pathogenesis of pre-eclampsia 
comes from a recent report that the intravenous injection of VEGF into guinea-pigs causes a pre- 
eclampsia-like syndrome (Hunter, 2000) (see Chapter 4). This shows, in accord with the in vitro 
data of this thesis, that both guinea pig and human myometrial vessels have to be primed by 
pregnancy to react to VEGF in such a deleterious fashion (See Chapter 4). 
The hypothesis that cytokines may act in this manner is also supported by reports that blunted 
endothelium-dependent relaxation to various receptor dependent agonists, including 
acetylcholine, bradykinin and substance P, occurs on exposure to the cytokines TNF a and II 
-1 
(Aoki et al., 1989) (Greenberg et al., 1993). TNF a and II-1 have also recently been shown to 
cause a reduction in EDHF mediated relaxation in both rabbit and porcine coronary arteries 
through the up-regulation of nitric oxide (Kessler et al., 1999). In the study, of Kessler et al, 
(1999) the interaction of TNFa with the endothelium was time dependent requiring incubation 
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times of up to sixteen hours (Kessler et al., 1999). In a similar manner, the effect of VEGF on 
myometrial vessel function was also shown to be time dependent with alterations in endothelial 
function occurring at sixteen-hours. Shorter VEGF incubation times left endothelial cell function 
effectively unaltered (Figure 8.9). The lack of effect of the short-term treatment suggests that the 
effect is unlikely to be caused by the direct effect of VEGF receptor dependent signal transduction 
pathway on the agonist stimulated biosynthesis of EDHF. Although VEGF required extended 
incubation times, Hayman et al, 2000 have demonstrated that 2% plasma from women with pre- 
eclampsia is capable of altering myometrial endothelial function within one hour (Hayman et al., 
2000). If VEGF is one factor in the plasma of women with pre-eclampsia that causes alterations 
in endothelial function, then it may be hypothesised that there are increased concentrations of 
chemicals that act synergistically with VEGF, or enhance the expression of VEGF and its 
receptors, and thus reduce the exposure time required of plasma. 
This study has shown that when vessels are Incubated with VEGF, the attenuated endothelial 
dependent relaxation is reversible, as the degree of vessel relaxation increased with sequential 
washing of the vessel with physiological salt solution (Fig 8.10). This Indicates that the 
endothelium is undamaged by exposure to VEGF. The study of Kessler et al (1997) also 
demonstrated that once the cytokine response was withdrawn endothelium dependent relaxation 
returned to normal (Kessler et al., 1997). 
Whether the endothelium dependent effect of VEGF Is generalised oris specific to the vasodilator 
bradykinin remains to be elucidated and this requires further investigation, Determination f its 
generality may well enhance our understanding of the mechanism of action of VEGF. 
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The pregnancy-specific nature of pre-eclampsia suggests that any factor involved in the 
pathogenesis hould have an effect that is also pregnancy specific. VEGF fits with this 
observation; the alteration in myometrial resistance vessel function was only demonstrable on 
incubation with vessels from normal pregnant women (Fig 8.4 & 8.5). The pregnancy specific 
nature of VEGF is further supported by the observation by Hunter et al (2000). These differences 
probably represent a pregnancy-associated change in the vessel physiology, however, the precise 
mechanism for this change remains to be determined. 
It is clear from the data presented in this thesis that VEGF itself does not cause the endothelial 
changes that are associated with pregnancy (Fig 8.3). However, it has been shown that non- 
pregnant myometrial vessels, which have been treated with oestradiol r diethylstilbestrol show 
reduced sensitivity to vasopressin, in a manner that resembles pregnant vessels (Kostrzewska et 
al., 1993). Therefore it might be postulated that oestrogens sensitise the endothelium to the 
adverse ffects of VEGF. This could also explain the apparent lack of effect that VEGF has on 
non-pregnant myometrial vascular function (Fig 8.3 & 8.5) and in other pathological conditions 
where circulating concentrations are increased (Hyodo et al., 1998) (Jinno et al., 1998) (Duque et 
al., 1999). 
It has also been demonstrated that the loss of endothelium dependent relaxation observed on 
incubation with plasma from women with pre-eclampsia c n be inhibited with the addition of 
antibodies to VEGF and a specific anti-fit-1 receptor antibody. This provides the strongest upport 
for our hypothesis that VEGF Is integral to the pathogenesis of pre-eclampsia. it is important to 
note that although the addition of VEGF antibody significantly increased the vessel relaxation In 
those vessels incubated in 2% plasma from women with pre-eclampsia, vessel behaviour was not 
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completely restored to normal. There remained a significant attenuation ofendothelium dependent 
relaxation in these vessels when compared to those with 0.5 nmol VEGF + antibody, and those 
incubated with 2% plasma from normal pregnant women. These results may have occurred due 
be the monoclonal ntibody used only binding to certain of the VEGF isoforms. An alternative 
explanation is that there was a contribution offactor(s) other than VEGF to the effect of plasma 
from women with pre-eclampsia onthe vessel behaviour. Moreover, the results of our Dynabead® 
treatment of plasma from women with pre-eclampsia suggest that the circulating factor(s) may 
partially exert its effects through VEGF produced within the locality of the vascular endothelium. 
The RIA measurement of VEGF in our samples indicates that treatment of plasma from women 
with pre-eclampsia with anti-VEGF coated Dynabeads® only removed asmall amount of VEGF. It 
was significant that treatment reduced the levels of VEGF to those seen in the plasma of normal 
pregnant women. However, further extraction of VEGF from the plasma is likely to be hampered 
by highly complex interactions with binding proteins (such as soluble fit), and as a consequence, 
complete denudation of VEGF from plasma by immunoadsorption would be extremely difficult. It is 
possible that not only does VEGF exert its effects locally in the vascular endothelium, but that 
VEGF exists in a "free" bioactive form, and in a "bound" inactive reservoir. Published evidence to 
support this hypothesis comes from Anthony et al who have shown that there may be binding 
proteins that affects measurement of VEGF (Anthony et al., 1997). The fit-1 receptor antagonist 
completely inhibited the effect of the plasma from women with pre-eclampsia strongly suggesting 
that the fit-1 receptor is the final common mediator in this pathological process. 
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Human pregnancy is marked by increased amounts of soluble fit-1 receptor (Chamock-Jones et 
al., 1997) (Clark et al., 1998a) (Banks et al., 1998). Clark et al have demonstrated that 
trophoblast cells contain mRNA which encodes this soluble form of the VEGF receptor (soluble fit) 
and that this protein is a potent antagonist ofVEGF (Clark et al., 1998a). It can be hypothesised 
that an alteration in the equilibrium of soluble fit receptor and VEGF in pre-eclampsia would 
diminish the endothelium-dependent response to bradykinin. It will therefore be interesting and 
important to investigate he interaction of VEGF with the soluble fit-1 receptor in pregnancy and 
pregnancies complicated by pre-eclampsia. 
The VEGF family includes five VEGF isoforms and the homologous placental growth factor (PIGF) 
which shares the VEGF receptor system. The VEGF185 isoform used in our studies binds to both 
receptors, whereas VEGF12I has a greater affinity to KDR and PIGF to fit-1 (Masabum, 1993). 
Kendel et al (1994) demonstrated that like VEGF, PIGF was capable of binding to the fit-1 
receptor but was unable to bind the KDR receptor system (Kendall et al., 1994). 
Although VEGF appears to have an affect on myometrial vessel function through the fit-1 
receptor, incubation with PIGF caused no reduction In endothelium dependent relaxation i  either 
pregnant or non-pregnant vessels. Park et al (1994) showed that PIGF, although capable of 
binding to the fit-1 receptor, was unable to Initiate a stimulus via tyrosine phosphorylation (Park et 
al., 1994). However, non- bacterial PIGF has been demonstrated to have a high mitogenic effect 
on cultured endothelial cells through the fit-1 receptor system (Ziche et al., 1997). The apparent 
lack of PIGF activity on myometrial vessels may well be due to the use of human recombinant 
PIGF in these experiments, however, PIGF with carbohydrate moieties is not available 
commercially and the author was unable to obtain any from Ziche et al. Although possibly 
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artefactual, it would be interesting and important to examine the possible Interactions of VEGF 
and PIGF in this myometrial vessel model. 
In this study, the addition of indomethacin did not significantly alter the endothelium dependent 
relaxation of vessels from normal pregnant women incubated with VEGF (Fig. 8.21). However, 
the presence of an inhibitor of nitric oxide synthetase (L-NAME), in addition to an inhibitor of 
cyclooxygenase, significantly attenuated the endothelium dependent relaxation in normal 
pregnant vessels that were incubated with VEGF (Fig 8.21). As observed in Chapter 6, normal 
pregnant vessel responses to bradykinin are resistant to the addition of an nitric oxide synthetase 
and cyclooxygenase inhibitor. The observed attenuation of relaxation i  vessels incubated with 
VEGF suggests that the relaxation in these vessels is primarily dependent on the release of nitric 
oxide, with little contribution from EDHF. In this respect the theses observations mimic those 
seen in myometrial vessels from women with pre-eclampsia (Chapter 6) (Ashworth et al., 1997). 
Therefore, it could be postulated that these changes occur, either through a disruption of EDHF 
mediated responses with the compensatory increase in nitric oxide mediated relaxation, or that 
there is a loss of endothelium dependent relaxation consequent to the upregulation ofendothelial 
nitric oxide. These hypothesises were not formally tested, but could be achieved via similar 
methodology to this thesis. 
8.6 Summary: 
This study demonstrated that VEGF is incapable of causing a constrictor response to myometrial 
and omental resistance vessels, but paralleled the effects of plasma from women with pre- 
eclampsia on vessel behaviour, at a concentration similar to those found in vivo (0.5 nmol). This 
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study also shows that in a similar manner to vessels from women with pre-eclampsia, VEGF 
causes a compensatory increase in nitric oxide mediated relaxation in myometrial vessels. 
However, antibodies to VEGF only partially block the interaction of plasma from women with pre- 
eclampsia with the vascular endothelium, this suggests that there are additional factors involved in 
the endothelial dysfunction seen in the bioassay technique. 
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Chapter Nine: The effects of vascular endothelial growth factor on four 
endothelial cell types: 
9.1 Introduction: 
A number of studies have demonstrated that serum or plasma from women with pre-eclampsia 
causes activation of endothelial cells in vitro (Lorentzen et al., 1991) (Branch et al., 1991) (Baker 
et al., 1995a) (Davidge et al., 1995b) (Davidge t al., 1996a). The majority of the studies that 
have investigated the effects of plasma on endothelial cell function have used human umbilical 
vein endothelial cells (HUVECs) (Lorentzen et al., 1991) (Branch et al., 1991) (Silver et al., 1996) 
because this type of cell is relatively easily isolated and the tissue is readily available. However, 
there are a number of important caveats to be considered when using human umbilical vein 
endothelial cells as representative of the endothelium per se. First, HUVECs are from large 
conduit vessels and therefore will not reflect the endothelium derived from the microvasculature. 
As pre-eclampsia is believed to be a disease with dysfunction of the microvascular endothelium, 
this type of endothelial cell may not prove to be the most appropriate. Second, HUVECs are 
fetally derived cells and pre-eclampsia involves dysfunction of the maternal endothelium. 
Several studies have also utilised bovine aortic microvascular endothelial cells (B-88) as a model 
of the human microvasculature, however, these are not without their limitations (Baker et at., 
1995b) (Davidge t al., 1995b) (Baker et al., 1996b) (Baker et al., 1996a) (Davidge et al., 1996a). 
Bovine cells, although microvascular, e from a different species and it has been demonstrated 
that microvascular endothelium derived from different organs displays distinctive tissue-specific 
245 
characteristics (Fajardo, 1989). Therefore, it must be questioned as to the relevance of findings 
that have utilised these cells to the in vivo situation. 
9.2 Aims: 
0 To ascertain whether human microvascular cells (from the uterus and systemic irculation) 
and human macrovascular cells (umbilical) cells were stimulated in a similar manner to B-88 
cells. 
9 To compare the abilities of VEGF, plasma from women with pre-eclampsia and plasma from 
normal pregnant women, to stimulate the different human endothelial cell types and B-88 
cells. 
" 
To investigate whether VEGF produces any of the observed alterations produced by plasma. 
" 
To investigate whether human cells (uterine) could be used to investigate further the sub- 
cellular mechanism ofaction of VEGF and plasma on myometrial vessels. 
9.3 Experimental design: 
9.3.1 Subjects: 
Plasma samples were obtained from 11 patients with pre-eclampsia asdescribed in Chapter 2.2. 
In addition, plasma was collected from 11 normal pregnant patients who had no complication of
pregnancy or underlying illness. After the initial experiments there was insufficient plasma from 
the original patients, therefore, in a further experiments to examine the effects of VEGF and 
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plasma; new plasma samples were collected from 12 further patients diagnosed as having pre- 
eclampsia nd 12 normal pregnant patients (Chapter 2.2) 
9.3.2 Cell culture: 
The addition of plasma: 
The four types of endothelial cell were grown as described inChapter 2.4, and passaged into 24 
well plates. B-88 cells were initially used as a positive control for endothelial activation, as 
preliminary data had confirmed that these cells were activated by plasma from women with pre- 
eclampsia (Chapter 3.3). Cells were made quiescent by culturing cells in serum depleted media 
as described in Chapter 2.4. After cells had been made quiescent for 24 hours medium was 
aspirated and fresh media added containing plasma from each subject at a final concentration f 
10%. A plasma concentration f 10% was utilised, as previous data, in the laboratory were this 
thesis was undertaken, had demonstrated that 2% plasma was unable to show differences 
between the two study groups of interest (Wellings et al., 1998). Each patient's plasma was 
studied in triplicate. Heparin was added to each well to give a final concentration of 10 Ulml. 
Twenty-four hours after addition of plasma, medium was collected as described in Chapter 2.5.3. 
Nitrite, 6-keto-prostaglandin Fla and LDH (Chapter 2.6) were then measured in the media. 
The addition of VEGF: 
After cells had been made quiescient (Chapter 2.5), they were stimulated for 24 hours with 
increasing concentrations f VEGF (0.01-1. OnM). Effects were studied in quadruplicate w lls. The 
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VEGF experiments were repeated at least twice and the results displayed are for a typical 
experiment. Heparin was added to each well to give a final concentration f 10 U/ml. In a further 
set of experiments it was determined inthe B-88 cell type whether the addition of an anti-VEGF 
antibody (10 ng/ml: R&D system, UK) could block the observed effect of VEGF on these 
endothelial cells. After stimulation, media were collected for determination of 6-keto prostaglandin 
F 1« and nitrite (stable metabolites ofprostacyclin a d nitric oxide). 
The addition of plasma from women with pre-eclampsia and from normal pregnant 
women with the addition of anti-VEGF antibody: 
In a further set of experiments, B-88 cells (as these were the only cells to be stimulated by 
plasma) were stimulated for 24 hours in serum free media containing 0.05% bovine albumin and 
10% plasma. The VEGF concentrations of the plasma samples used had been determined 
previously by radioimmunoassay (Chapter 2.1). After stimulation, media was collected and the 
concentrations of prostaglandin Fla, nitric oxide, lactate dehydrogenase (LDH) and cellular 
protein were determined. Experiments were repeated in the presence of anti-VEGF antibody 
(long/ml; R&D Systems: UK). 
9.4 Results: 
9.4.1: Patient data: 
Patient demographics are summarised in Tables 9.1 & 2, As anticipated, the pre-eclampsia 
patient group had blood pressures that were significantly higher than those of the normal pregnant 
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controls. In addition, significant proteinuria was only observed in the pre-eclampsia group. Table 
9.2 summarises the demographic data and the VEGF concentrations i  the cohorts of women with 
pre-eclampsia and the normotensive pregnant controls used in the set of experiments that 
examined the effect of the VEGF antibody. As anticipated, the plasma VEGF levels were 
significantly higher in the women with pre-eclampsia (5.2 Vs 3.9: P>0.01, Mann-Whitney-U test). 
9.4.2: Nitrite production in response to plasma and VEGF: 
Plasma: 
Nitrite production by the HUVEC and the HdMEC was undetectable in most wells, whereas there 
was a significant production of nitrite by both the decidual and B-88 cells (Table 9.3). In the 
decidual cells there was no significant difference in nitrite production by cell exposed to plasma 
from the women with pre-eclampsia when compared to the normal pregnant group, In contrast, 
production of nitrite by B-88 cells was significantly higher in the supernatants from cells exposed 
to plasma from women with pre-eclampsia when compared with that from the control pregnant 
group (Fig 9.3; P= 0.048, Mann-Whitney-U test). 
VEGF: 
In response to VEGF nitrite was undetectable in the media from HUVECs, and although 
production was detected in all other cells types, only HdMEC showed an increased production on 
stimulation with VEGF (P<0.05) (Fig 9.1). 
Fig 9.1 
Dose response of 6-ketoPGF 1a production by B88 (a) & HUVEC (b) 
cells stimulated with incremental concentrations of VEGF. Bars 
represent means +/- SEM. The effect of a monoclonal antibody for VEGF 
(10ng/ml) is represented by the grey bar 
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9.4.3: Prostacyclin production in response to plasma and VEGF: 
Plasma: 
Concentrations of prostacyclin production were markedly different according to cell type (Table 
9.3). Prostacyclin production was similar in response to stimulation by plasma from both normal 
pregnant and women with pre-eclampsia in the HUVEC, HdMEC, and decidual endothelial cell 
types at a concentration f plasma of 10%. In contrast, prostacyclin concentrations i  media from 
B88 cells in response to plasma from women with pre-eclampsia were significantly higher than in 
B-88 cells exposed to plasma from normal pregnant women (Fig 9.3; P= 0.046, Mann-Whitney-U 
test). 
VEGF., 
The production of prostacyclin was detected in all four endothelial cell types. However, only 
HUVEC and B-88 cell production increased with increasing concentrations of VEGF (Fig. 9.1a & 
9.1b, repeated measures ANOVA, P<0.05). Anti-VEGF antibody (10ng/ml) had the effect of 
inhibiting the prostacyclin production of B-88 stimulated cells back to the observed base line 
production (Figure 9.1a, Mann-Whitney 
-U, P< 0.05) 
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9.4.4: Correlation of plasma VEGF levels with prostacyclin and nitric oxide 
production: 
There was no significant correlation between plasma VEGF concentrations and nitric oxide 
production in the media from the stimulated B88 cell line when either plasma from women with pre 
eclampsia (r= 0.180, P>0.05, Spearmans Rank correlation) or normal pregnant controls were 
studied, (r= 0.223, P>0.05, Spearmans Rank correlation). However, in the pre-eclampsia group 
there was significant correlation between prostacyclin production and plasma VEGF levels, (Fig 
9.2, r- 0.64, P=0.02, Spearmans Rank correlation). This correlation was not present when the 
normal pregnant group was studied. (Fig 2. r 0.339, P >0.05 Spearmans Rank Correlation ). 
9.4.5: Effect of anti-VEGF antibody on plasma Induced endothelial cell 
prostacyclin and nitrite production: 
When B-88 endothelial cells were stimulated with plasma there was a significant Increase in the 
nitric oxide and prostacyclin production by cells that had been stimulated with plasma from women 
with pre-eclampsia as compared to normal pregnant women (Fig 9.3 P=0.01). When VEGF 
antibody was added to both groups' plasma, there was no effect on the nitrite production (Mann- 
Whitney-U P> 0.47). However, prostacyclin production by cells stimulated with plasma from 
women with pre-eclampsia was significantly inhibited (P= 0.01), and under these circumstances 
there was no significant differential effect of plasma from the two groups (P>0.05). 
Fig 9.2 
B88 6-ketoPGF1 a and nitric oxide production of cells stimulated with 
plasma from women with pre-eclampsia nd normotensive controls 
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9.5 Discussion: 
It is now well documented that plasma or serum from patients with pre-eclampsia contains 
factor(s) that are capable of altering endothelial cells (Lorentzen et al., 1991) (Branch et al., 1992) 
(Baker et al., 1995a) (Davidge et al., 1995a) (de Groot et al., 1995) (Davidge et al., 1996a) 
(Zammit et al., 1996). To date, most studies have investigated the effects of plasma on either the 
B-88 or freshly cultured human umbilical vein endothelial cells. This study confirmed that plasma 
from women with pre-eclampsia contains the putative circulating factor(s) believed to be 
associated with the pathogenesis of pre-eclampsia, because the plasma from patients with pre- 
eclampsia increased nitric oxide and prostacyclin production in the B-88 cells in comparison with 
the plasma from normal pregnant controls. This is consistent with other literature reports which 
have shown activation of these cells by plasma from women with pre-eclampsia or from 
fractionated plasma (see above). However, in this study there were no differences In secretion of 
the metabolites of nitric oxide or prostacyclin by human endothelial cell types, therefore the 
question must be asked as to what is the relevance of the B88 findings to the disease state. It 
may be that the B-88 cell line, which is of bovine origin, is a bioassay for the circulating factor and 
has little relevance to the mechanism of the disease. 
Gallery et al have isolated and cultured microvascular endothelial cells from the decidua and 
assessed the effects of serum from normal pregnant women and women with pre-eclampsia 
(Gallery et al., 1995). They found, using high concentrations of serum (20%), that there was 
increased prostcyclin release in the pre-eclampsia group. However, data presented In Chapter 
3.3 demonstrated that, under the conditions reported here at high plasma concentrations plasma 
from women with pre-eclampsia was cytotoxic to endothelial cells. In the study by Gallery et at, 
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markers of cellular viability were not measured to assess this possibility, and this may account for 
the differences observed. The study of Gallery et al also utilised serum and not plasma, which 
may add another confounding variable, as it is well known that cellular products are released into 
the serum on coagulation and these may produce in vitro alterations that are not relevant to the in 
vivo situation (Fox and DiCorleto, 1984). 
Nitric oxide concentrations in plasma-stimulated media collected from HdMEC cells were not 
detectable inany of the wells. This suggests that the microvascular endothelial cells derived from 
the skin behave differently with respect to the production ofnitric oxide, which may reflect different 
local control of vascular tone by the endothelium in different tissues. Indeed, it has been shown 
that microvascular endothelium derived from different organs displays distinctive tissue-specific 
characteristics (Fajardo, 1989). 
With regard to VEGF stimulation ofthese endothelial cells, nitric oxide was only detectable inthe 
HdMEC type. In this cell type VEGF caused a dose-dependent i crease in nitric oxide cell 
production. Analysis of the dose response by post hoc testing revealed that the concentrations 
required to produce an effect were relatively high (13.8nglml: 0.3nM). This finding that nitric oxide 
was stimulated by VEGF is consistent with other in vitro and in vivo data (Ahmed et al., 1997) 
(Horowitz et al., 1997) (Ni et al., 1997a) (Papapetropoulos et at., 1997) (Tsurumi et al., 1997) 
(Hood et al., 1998) (Murohara et al., 1998) (Tilton et al., 1999). Ahmed et al demonstrated that 
1Ong/ml VEGF produced 2.1nmol/ml nitric oxide; this Is in accord with the production i  this study 
(13.8ng/ml produced 1.5 nmol/ml). This study did not address question of which receptor system 
was involved in the increased production from HdME cells. However, in Chapter 8 It was 
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demonstrated that the effect of VEGF on myometrial resistance vessel endothelium was via the 
fit-1 receptor and this affected appeared to be mediated through nitric oxide. 
Although plasma from women with pre-eclampsia stimulated only B-88 endothelial cell 
prostacyclin production, VEGF stimulated significant production i  both B-88 cells and HUVECs. 
Further analysis of the data concluded that concentration f VEGF required to produce an effect in 
the HUVECs was (13.6ng/mI; 0.3nM) ten times that required in the B-88 (1.36ng/ml: 0.03nM). 
Why do these endothelial cell types respond differently to the stimulatory effects of plasma from 
women with pre-eclampsia? It is tempting to postulate that the circulating factor(s) described by 
Davidge t al activated specific receptors on endothelial cells that are present on B-88 cells but 
have been lost or down-regulated In the human endothelial cell types (Davidge et al., 1996a). If 
VEGF was one of the circulating factors then the differential effects of plasma might be explained 
by the fact that the concentration f VEGF in the plasma (0.52ng/ml) used to stimulate HOVE cells 
was too low, yet was sufficient to stimulate B-88. This is borne out by the fact that B-88 cells were 
stimulated with VEGF concentrations that were ten fold lower than that of HUVECs. 
This study has demonstrated that VEGF is capable of increasing the endothelial cell production of
prostacyclin and that VEGF antibody is capable of blocking this effect in a bovine cell line. lt has 
also shown that plasma VEGF concentrations correlate with the Increased production of 
prostacyclin induced by plasma from patients with pre-eclampsia. Davidge et al (1996) 
demonstrated that fractionated plasma produced two distinct components; a low molecular weight 
faction that increased prostacyclin and high molecular weight faction that Increased nitric oxide 
production. The low molecular weight fraction was in the range 42-62 Kda and this corresponds 
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to that of the VEGF family. The effects of VEGF on cell permeability are well documented 
(Ferrara et al., 1992) and appear to mediated through the eicosanoid messenger system (Fujii et 
al., 1997) (Murohara et al., 1998). Recently, Haller et al (1998) have added further circumstantial 
evidence to our hypothesis that VEGF may be one of the circulating factors In pre-eclampsia by 
their observation that plasma from women with pre-eclampsia increases the permeability of
cultured endothelial cells via the eicosanoid system (Haller et al., 1998). In sharp contrast this 
does not concur with the data obtained on myometrial resistance vessels which indicated that 
VEGF in this system may be increasing nitric oxide (Chapter 8). However, as stated previously B- 
88 cells may only serve as a bioassay and have no relevance In the in vivo situation. 
Furthermore, pre-eclampsia is ssociated with a decreased prostacyclin production in vivo. 
This study showed that the plasma VEGF concentrations correlate with increased production of 
prostacyclin only in the plasma from women with pre-eclampsia. However, if the two groups are 
combined there is a strong correlation ofincreasing prostacyclin production with Increasing VEGF 
levels. The fact that individually only the group with pre-eclampsia correlates may well represent 
the fact that VEGF has a critical concentration above which is has an effect or that there are 
insufficient umbers in the study groups to demonstrate a correlation. 
One further caveat to be considered is the finding that the effects of VEGF which were 
demonstrated occurred at concentrations above the reported circulating levels (Baker et al., 
1995b) (Sharkey et al., 1996). However, many cytokines have been demonstrated to enhance the 
effect of VEGF in vitro and this may explain the discrepancies in these levels. Further work Is 
required to fully elucidate the possible spectrum of cytokine interactions for this observed increase 
in prostacyclin. 
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It has also been reported that nitric oxide production was significantly increased in the media 
collected from endothelial cells (Baker et al., 1995a). Interestingly this study did not demonstrate 
any correlation between VEGF and nitric oxide production, although nitric oxide was expected to 
be involved in VEGF action. It is important tonote that VEGF has been reported to increase nitric 
oxide production from human umbilical vein endothelial cells (Hood et al., 1998). Our inability to 
demonstrate this probably related to the B88 cells utilised and the sensitivity of our assay. 
9.6 Summary: 
This study demonstrated that VEGF has a broadly comparable ffect to that of plasma from 
women with pregnancies complicated by pre-eclampsia on the production of prostacyclin in 
cultured B88 endothelial cells and the plasma effects of women with pre-eclampsia c n be 
inhibited by a VEGF antibody. All these observations are consistent with the original hypothesis 
that VEGF may be one of the circulating factors that causes the alteration i  endothelial function 
that is characteristic of this disease (Roberts et al., 1989). 
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Chapter Ten: General Discussion 
This chapter will be divided into sections; the first will deal with the strengths and weaknesses of 
this thesis. The second part will aim to place the results obtained in each individual chapter into 
the more general global context of the disease. It will also highlight where future work is possible 
and the techniques that could be applied to answer the hypotheses set up from the data. 
10.1: Strengthens and weakness: 
10.1.1: Myography: 
The anatomical inaccessibility of resistance vessels in mammals has proved to be the limiting 
factor in the study of their behaviour in vivo. In vivo animal experiments have produced large 
amounts of information on the accessible vascular beds, however, recent work has demonstrated 
that individual vascular beds within species behave very differently to each other. As such the 
study of animal models yields limited information, as extrapolation i to the human is potentially 
unreliable. Initial ex vivo studies in humans examined larger size arteries with inherent limitation. 
Wire myography has been used extensively in the investigation of small artery function. It is a 
relatively robust tool that produces consistent and reproducible r sults. However, it has well 
recognised limitations. The vessel geometry is significantly altered as it is held in a flat plane by 
two wires rather than in the more physiological cylindrical shape. Thus the endothelial surface is 
exposed to the wire pressure and the vessel wall is subject to distension at both ends, rather than 
the effects of pressure venly distributed along the entire endothelial surface. Chemical gents 
have to be applied to the external surface rather than through the lumen. The absence of flow 
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through the lumen is a further major limitation and has assumed appreciation In recent years as 
the importance of flow-mediated vasodilatory esponses have become Increasingly recognised 
(Mulvany and Aaljaer, 1990). In addition it is almost impossible to investigate the myogenic 
response using this system. A further constant criticism of this system is of the potential damage 
on the vessel by the introduction of wires down the lumen. In truth, the effect of this damage is 
minimal when other limitations are considered and the presence of the endothelium can be 
confirmed by histological examination. 
Clearly the comparison of myometrial vessels from pregnant and non-pregnant groups is 
compounded by an alteration in the uterine anatomy with pregnancy. This is particularly relevant 
in the third trimester, when the formation of the lower segment occurs. Therefore it was attempted 
to minimise the anatomical differences in the source of our vessels by taking biopsies from the 
isthmus in non-pregnant women, and from the upper part of the lower segment in pregnant 
women. However, it can not be determined from this study whether the vessels ampled were 
similar, with pregnancy being the only differentiating factor, or whether the vessels from the 
pregnant and non-pregnant group were in fact different In origin. 
Vasopressin: 
Although the hormone vasopressin may have a role in the physiological control of blood pressure 
through its actions on the Via receptor, this physiological effect is far from certain. However, as 
discussed previously evidence for its role the control of uterine circulation is increasing (Chapter 
3). Comparison of the potencies of the vasoconstrictors; vasopressin, U46619 and endothelin. 
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shows that vasopressin is the most effective vasoconstrictors in human myometrial resistance 
vessels and further adds evidence to support its role in the regulation of myometrial blood flow. 
It should also be noted that the initial aim of this project was to perform preliminary 
characterisation studies of the interaction of VEGF with the endothelium, using several bioassay 
techniques. Vasopressin provided asustained, repeatable contraction in the myometrial vessels 
under investigation, and was therefore chosen as the contractile agonist. Whilst other agents 
have been shown to be suitable subsequently, the choice of vasopressin was made on the 
observation ofprevious pilot studies and experimental work (Ashworth, 1998). This was felt to be 
acceptable initially, as this study started as an DM thesis, and with the limited time available, 
protocols were constructed from experimental work carried out prior to the commencement of this 
work. If this thesis was to be undertaken again it would be advantageous to repeat the pilot data 
and choose two vasoconstrictors to tudy as these may have produced iffering results. 
Sodium nitroDrusside: 
The observation was made that endothelium dependent relaxation from vessels from non- 
pregnant, pregnant women and women with pre-eclampsia showed no differences in non- 
endothelium-dependent r laxation when sodium nitroprusside was used. Sodium nitroprusside 
has been criticised as it leads to the production of nitrovasodilators other than nitric oxide 
(Feelisch and Kelm, 1991). Spermine NONOate isconsidered to be a purer donor, releasing NO 
on an almost equimolar basis (Ramamurthi and Lewis, 1997). It is possible that the assesement 
of nitric oxide synthesis in these vessels would have been better served by the utilization of a 
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guanylate cyclase inhibitor, blocking the action of nitric oxide via its second messenger, orby the 
use of a combination f nitric oxide synthesis inhibitors (McCarthy et al., 1993b), 
Heparin: 
The addition of heparin during vessel incubation with plasma could be criticised for its potential to 
interact with both the circulating factor(s) and the endothelium. However, its presence was 
required to prevent the formation of a fibrin clot which, when present, prevented further 
experimentation. Heparin was added in equal concentrations to both the control and pre- 
eclamptic groups in order to reduce the potential for experimental bias. 
10.1.2: Systemic Vs uterine: 
The use of omental vessels in the study of pregnancy and pre-eclampsia must be questioned as 
they may not be representative of the peripheral vascular system. It may be argued that it Is more 
pertinent to study vessels from organs that are know to undergo dramatic changes in blood flow 
with pregnancy; such organs include uterus, skin and kidney. However, these vessels are also 
not without their deficits, renal vessels which undergo a similar increase In blood flow as the 
uterus with pregnancy would be of most value (Dunlop, 1976) (Ezimokhai et al., 1981), however 
these are not available for in vitro study. Skin vessels are easily obtained, but whether gluteal 
biopsies, which are most commonly obtained, are representative of the whole skin surface 
remains to be elucidated. Therefore myometrial vessels may represent the best option to study 
vascular adaptation to human pregnancy; are situated juxtaposed to the developing placenta; re 
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an easily obtainable source of vessels which undergo dramatic blood flow changes during 
pregnancy, and show no variability depending on the site of biopsy (Svane et al., 1991). 
In this study myometrial vessels from non-pregnant women exposed to vasopressin a d U46619 
showed significant differences tothe normal pregnant controls. In a similar manner, pregnancy 
has also been shown to alter the vascular reactivity of guinea-pig uterine arteries to various 
vasoconstrictors (Weiner et al., 1989a) (Weiner et al., 1991) (Weiner et al., 1992b) (Weiner et al., 
1992a) (Jovanovic et al., 1995a). This thesis and other studies of human and animals have 
demonstrated that these effects are mediated through changes in endothelial function (Weiner et 
al., 1989a) (Jovanovic et al., 1995a). 
However, the effect that pregnancy has on systemic vessels of other species is far from 
conclusive. Isolated mesenteric resistance arteries from pregnant rats, assessed utilising wire 
myography, show attenuated responses to phenylephrine when compared to similar sized non- 
pregnant vessels (Davidge and McLaughlin, 1992). In a similar manner, isolated guinea pig aorta 
preparations also show blunted responses to both phenylephrine and norepinepherine i  pregnant 
animals (Harrison and Moore, 1989). Although, resistance vessels from guinea pig kidney and 
mesentery show no attenuated responses to the thromboxane memetic U46619, removal of the 
endothelium, from non-pregnant and pregnant vessels, caused enhanced responses of pregnant 
over non-pregnant vessels (Kim et al., 1994). This finding has also been demonstrated In larger 
guinea pig carotid vessels during pregnancy contracted to serotonin (Weiner et al., 1992b). 
Weiner et al hypothesed that although pregnancy caused no detectable alteration In 
vasoconstrictor agents responses, there was an alteration in vascular endothelium which led to 
increase basal release of endothelial derived substance relaxing factors. However, removal of the 
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endothelium from omental and subcutaneous resistance vessels does not cause altered 
responses with pregnancy (McCarthy et al., 1993b) (Ashworth, 1998). This would suggest that 
different organs adapt differently to pregnancy and might depend on their function during 
pregnancy. 
All vasodilators tudied showed significantly greater vasodilatation in omental arteries than 
myometrial rteries. The differences are unlikely to be artefactual consequences of the differing 
vessel wall thickness of tension, as relaxation is the parameter being measured, and is expressed 
as a percentage ofthe individual contraction from which relaxation is being induced. Therefore, it 
may be hypothesised that in myometrial vessels the reduced agonist-mediated responses are 
substituted by enhanced myogenic or flow-mediated responses. In support of this hypothesis, 
Kublickiene t al have demonstrated that in pregnant myometrial vessels the contribution of 
myogenic tone is greater than in omental vessels (Kublickiene et al., 1997). Also flow-mediated 
responses, which have only been studied in human skin resistance vessels, showed enhanced 
responses in pregnant vessels when compared to non-pregnant vessels (Cockell and Poston, 
1996). Whether these responses show the same pattern in the myometrial vessels remains to be 
elucidated. 
10.1.3: Cell culture Vs Myography: 
Comparison of the cell culture and the myography studies undertaken i  this thesis show striking 
similarities, but also striking contradictions. This thesis, in accord with other studies, show that 
plasma from women with pre-eclampsia is capable of altering endothelial cell function, both in the 
myography and cell culture system (Baker et al., 1995a) (Davidge et al., 1995b) (Ashworth et at., 
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1998). It also demonstrates that VEGF causes imilar endothelial terations in both myography 
and cell culture xperiments, and that inhibition of VEGF with a specific antibody was capable of 
returning plasma from women with pre-eclampsia toward the control group in both the myography 
and cell culture systems. 
The mechanisms for these changes in the two experimental systems appears to be contradictory. 
In the cell culture system, both VEGF and plasma increase cellular prostacyclin production, an 
effect which is inhibited by the addition of VEGF antibody. However, inthe myography s stem the 
effect appears to be mediated through an alteration in the nitric oxide pathway. This may 
represent the use of endothelial cells from a different species, as it has been shown that 
microvascular endothelium derived from different organs displays distinctive tissue-specific 
characteristics (Fajardo, 1989). When this project was initiated it was planned to utilise human 
microvascular endothelial cells, however, as Chapter 9 demonstrates this was not possible Is 
human microvascular cells were unresponsive to the effects of plasma. 
The majority of such studies (including this one) have utilised either bovine endothelial cells (B88) 
or human umbilical vein endothelial cells, however, neither of these represent the human pregnant 
microvascular endothelium where the pathology of this disease is postulated to occurs (Roberts et 
al., 1989). Therefore, the extrapolation of these in vitro results to the in vivo situation must be 
treated with caution. The results presented serve to demonstrate that plasma from women with 
pre-eclampsia c uses an acute in vitro effect on endothelial cell prostacyclin production and that 
this effect can be inhibited by anti-VEGF antibody. Further work is required to confirm that this 
observed in vitro effect is relevant to the In vivo situation. Studies of 'pre-eclampsia In a dish' may 
be fraught with danger due to inappropriate extrapolation i to the human system. 
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10.2: Maternal vascular adaptations to pregnancy and the role of VEGF: 
Evans et at (1997) have shown a positive and highly significant correlation between maternal 
serum levels of VEGF and hormones reflecting placental function (hCG, progesterone). They 
speculated that VEGF had a positive influence on trophoblast development and that it may also 
be involved in the initiation of the maternal cardiovascular adaptation to pregnancy (Evans et al., 
1997). Wheeler et al (1999) have also shown that VEGF measured at 16-20 weeks gestation 
correlates with placental nd fetal weight at birth, suggesting that VEGF is important in the utero- 
placental adaptations to pregnancy, during the second wave of trophoblast invasion (Wheeler et 
al., 1999). This thesis demonstrated that VEGF causes a vasodilatation i  non-pregnant 
myometrial vessels, whereas pregnant vessels how no response. This further enhanced the 
hypothesis that the vascular endothelium undergoes specific hanges in response to pregnancy. 
It is possible to speculate that VEGF may cause vasodilatation i  early pregnancy to enhance 
utero-placental blood flow and the early development of the placenta nd that as pregnancy 
progresses this effect is lost. It would be interesting to determine how VEGF causes 
vasodilatation in non-pregnant vessels and at what gestation this effect is lost. However, without 
an animal model this is not possible, unless technology advances to allow non-invasive 
experiments to be carried out on human myometrial vessels. One possible candidate animal to 
study would be the guinea pig, as it shares a similar placental development to the human 
placenta. It has also been recently shown that when pregnant guinea pigs are Injected with VEGF 
they develop a syndrome similar to pre-eclampsia, however, Injection Into non-pregnant animals 
does not produce these abnormalities (Hunter, 2000). Therefore, it would be Interesting and 
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potentially useful to ascertain whether guinea pig uterine artery display similar effects to human 
non-pregnant and pregnant myometrial rteries on exposure to VEGF. 
10.3 Maternal vascular adaptations to pre-eclampsia and the role of VEGF: 
Although this thesis does not appear to shed any light on the origin of this increased VEGF, It is 
clear from this thesis and the literature that VEGF is increased inpregnancies complicated by pre- 
eclampsia (Chapter 4) and that levels return to normal soon after delivery. This rapid return to 
normal would suggest that the fetal-maternal unit was implicated inthe increased levels observed. 
One methodological problem of this study and others that have examined the placenta s a 
possible site (Cooper et al., 1997) (Lyall et al., 1997b) (Chapter 5) is the differences in the 
gestational ges that placental biospies are obtained from each study group. Simmons et at 
(2000) have recently tried to address this discrepancy by the use of women with pre-eclampsia in 
the late third trimester and comparison with appropriate gestation matched controls. They 
demonstrated that placental VEGF immunostaining was significantly increased inwomen with pre- 
eclampsia; and that the increased VEGF expression positively correlated to the uterine artery 
resistance as assessed by Doppler ultrasound. From this they postulated that decreased 
uteroplacental blood supply causes a relative hypoxia within the placenta and increased 
production of VEGF (Simmons et al., 2000). Ranheim et at (2001) also using a more appropriate 
control group have recently demonstrated a non-significant i crease in the mRNA expression of
placentae from women with pre-eclampsia when compared to normotensive controls. One reason 
they may have failed to demonstrate any significant differences was the small numbers of 
placentae used and it may be useful to readdress this question with more appropriate numbers. 
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It has also been recently demonstrated that VEGF correlates with the increase In total peripheral 
resistance that occurs in this disease (Bosio et al., 2000). This thesis demonstrates that VEGF is 
capable of modulating vascular endothelial function in such a way as to enhance the response to 
the vasoconstrictor vasopressin a d inhibit the endothelium dependent relaxation to bradykinin I
myometrial vessels. In a manner that is similar to that in vessels from women with pre-eclampsia 
(Chapter 6) (Allen et al., 1989) (Ashworth et al., 1999) and to normal pregnant vessels incubated 
with plasma from women with pre-eclampsia (Ashworth et al., 1998). 
The contribution of the eicosanoids to the mechanism of the interaction between VEGF and the 
endothelium was examined by the addition of indomethacin to the organ bath. The inhibition of 
eicosinoids failed to alter the concentration response curves to vasopressin orbradykinin. These 
observations suggest that there is no preferential release of dilator or constrictor prostanoids in 
the vessels from normal pregnant woman, women with pre-eclampsia, or when vessels were 
incubated with VEGF. This Is consistent with the observations of Hayman (1999), who 
demonstrated that the addition of indomethacin to normal pregnant vessels, which had been 
exposed to plasma from women with pre-eclampsia, lso failed show alterations in their 
concentration response curves. Although these findings were consistent with previous work 
(McCarthy et at., 1994), they differ from other observations seen in myometrial vessels from 
women with established disease (Ashworth et at., 1999). However, In this thesis It has been 
demonstrated that results of Ashworth et at (1999) may be artifactual due to an increased 
relaxation in repeated concentration response curves (Chapter 3). 
The contribution of nitric oxide to the mechanism of resistance vessel relaxation; from non- 
pregnant women; and normal pregnant women; and women with pre-eclampsia in both 
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myometrial nd omental vessels; and the interaction between VEGF and the endothelium was 
studied by the addition of indomethacin a d L-NAME. It was observed that omental vessel 
relaxation in pregnancy and pre-eclampsia remained unaltered by the addition of indomethacin 
and L-NAME. Vessels obtained from the myometrium of non-pregnant and pregnant women 
showed dramatic differences, with an alteration in the contribution ofnitric oxide to the relaxation. 
Both vessels from non-pregnant women and women with pre-eclampsia show considerable 
dependence on nitric oxide mediated relaxation, whereas vessels from pregnant women showed 
no nitric oxide mediated relaxation. This would suggest that pregnancy is associated with an 
increase dependence on EDHF mediated relaxation, and that in pre-eclampsia this EDHF 
mediated relaxation is lost. 
McCarthy et al reported that in subcutaneous arteries, the inhibition of both cyclo-oxygenase and 
nitric oxide synthase attenuated, but did not abolish the endothelium-dependent r laxation to 
acetylcholine (McCarthy et al., 1994). Pascoal and Umans studied resistance arteries from the 
omentum and demonstrated, in a similar manner to this thesis, that vessels from normal pregnant 
women completely relaxed to acetycholine in an endothelium-dependent, but nitric oxide 
independent manner (Pascoal nd Umans, 1996). 
Although these results uggest the presence of EDHF, this 'compound' has yet to be identified, 
thus the importance of its role in physiology is speculative. However, as discussed previously 
recent experimental evidence supports a role for gap junction communication in the control of 
arterial function (Chapterl), and it seems that endothelial dependent relaxation, mediated through 
both nitric oxide and EDHF, partly relies on gap junctions (Javid et al., 1996) (Taylor et al., 1998). 
As such, the study of gap junctions in pregnancy and pregnancies complicated by pre-eclampsia 
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would be of interest and may have significant clinical Implications. These studies could Initially be 
carried out using the technique of myography with the use of gap junction inhibitors. The 
definitive investigation of EDHF would require electrophysiology to confirm the loss of the 
membrane hyperpolarisation with gap junction inhibition. 
This thesis showed that VEGF, in a similar manner to plasma from women with pre-eclampsia 
incubated with normal pregnant vessels, and vessels obtained from women with pre-eclampsia, 
caused a loss of endothelium-dependent r laxation. This loss of endothelium-dependent 
relaxation appeared to be associated with in increase in nitric oxide mediated relaxation. From 
this thesis it could be speculated that VEGF alters gap junction communication. It would be 
interesting to investigate this further by utilising vessel electrophysiology to establish whether 
VEGF inhibits hyperpolarisation on stimulation. If this was proven to be the case then this would 
then stimulate investigation f the mechanism of this response. 
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Summary: 
Pre-eclampsia is a multi-system disease characterised by maternal hypertension and proteinuria. 
This disease has been the leading cause of maternal death In the last decade. The disease is 
also responsible for considerable perinatal morbidity and mortality. There Is evidence to suggest 
that the maternal endothelium is pivotal in the pathophysiology. There is also increasing evidence 
to support the hypothesis that a placentally derived circulating factor causes alterations in 
endothelial function in pre-eclampsia. The evidence for this comes from cell culture experiments. 
These have demonstrated that endothelial cells cultured in the presence of plasma from women 
with pre-eclampsia produces increased amounts of the vasoactive compounds nitric oxide and 
prostacyclin. It has been demonstrated that normal myometrial vessels incubated with plasma 
from women with pre-eclampsia exhibit a reduction in endothelium dependent relaxation. 
However, the nature of this circulating factor remains to be elucidated. 
During pregnancy the placenta produces many cytokines that can pass into the maternal 
circulation. It is well documented that cytokines alter endothelial cell functions and as such are 
obvious candidates for the circulating factor. Vascular Endothelial Growth Factor (VEGF) is such 
a cytokine and there is much circumstantial evidence to support the hypothesis that placental- 
derived VEGF mediates the endothelial activation of pre-eclampsia. VEGF is produced by the 
placenta and unlike other cyokines contains a signal sequence that allows it to be secreted into 
the maternal circulation. In vitro levels of VEGF are dramatically increased within a few hours of 
exposure to hypoxia (Shweiki et al., 1992). VEGF exerts its biological activity by binding to one of 
-Pafkl I, va týrodý, e-kýýSe 11rASr, dol. two receptors: It-1 and KDR receptors. Different members of the VEGF family have different 
binding characteristics, this may have important implications for the control and functioning. 
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The thesis hypothesis was that placentally produced VEGF was important in the altered 
endothelial function observed in pre-eclampsia 
Plasma samples were obtained from primigrivid control normotensive women and primigravid 
women diagnosed with pre-eclampsia matched for age, gestation and race. Plasma VEGF levels 
were then measured using a radioimmunoassay v lidated for use in pregnancy plasma. Utilising 
this assay it was demonstrated in accord with other studies that levels of VEGF increase in 
women with pre-eclampsia when compared to normal pregnant controls. We also showed that 
the maternal serum concentrations of VEGF correlate with the observed increase in both diastolic 
and systolic blood pressure that occurs with this disease. 
Utilising myometrial resistance vessels of a diameter of 200-500µm from biopsies taken at the 
time of Caesarean section and the technique of wire myography we have confirmed the finding 
that these vessels from women pre-eclampsia exhibit a loss of endothelium dependent relaxation 
to bradykinin when contracted with vasopressin. It was also confirmed that normal pregnant 
myometrial vessels incubated with 2% plasma from women with pre-eclampsia for 16 hours 
exhibit a similar loss of endothelium dependent relaxation. These studies were thus extende to 
examine the Interaction of VEGF with the endothelium In this vascular bed. It was shown that 
myometrial vessels when incubated with VEGF exhibit a reduced endothelium-dependent 
relaxation to bradykinin, which Is analogous to that observed In vessels from women with pre- 
eclampsia nd normal vessels exposed to the plasma of women with pre-eclampsia. This 
response was concentration a d time dependent; requiring a minimum concentration f 0.5 µM 
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and an incubation time of 16 hours. The lengthy incubation time suggests that an alteration in 
cellular biochemistry may be required for VEGF to have its observed alteration in endothelial 
function. 
This myometrial vessel model of pre-eclampsia w s further utilised to characterise the endothelial 
interactions of VEGF and plasma from women with pre-eclampsia. The observed interaction of 
VEGF with the endothelium was abolished upon the addition of an anti-VEGF antibody (R&D, UK) 
to the media prior to incubation. Similarly the addition of anti-VEGF antibody to plasma from 
women with pre-eclampsia c used these vessels to return towards a normal relaxatory profile. 
The removal of VEGF from the plasma of women with pre-eclampsia utilising anti-VEGF antibody 
coated Dynal beads had no significant effect on the loss of endothelium dependent relaxation. 
These results would suggest that plasma borne factor causes the blood vessels to increase 
production ofVEGF which then affects the endothelial function of the vessel. 
VEGF functions through at least two receptors; the fit-I and KDR receptors. Therefore 
experiments were designed to elucidate which endothelial receptor VEGF was acting through. 
The effect of VEGF was unaffected by incubation with a specific anti-KDR receptor antibody. 
However, the addition of a specific anti-fit-1 receptor antibody to both plasma nd VEGF returned 
endothelial vessel function toward normal. This implies that plasma contains a factor that causes 
the release of VEGF from the blood vessel, which then acts through the fit-1 receptor to cause the 
observed alteration in endothelial function. 
It has been previously demonstrated that endothelial cells cultured In the presence of plasma 
showed increased production of the vasoactive compounds prostcyclin and nitric oxide when 
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compared to normal pregnant control plasma. Therefore to validate the myometrial vessel model 
results an endothelial cell culture model was utilised. Monlayer cultures of Bovine microvascular 
endothelial cells were prepared. Cells were then exposed to plasma from women with pre- 
eclampsia nd normal control plasma in the presence or absence of anti-VEGF antibody. The 
presence of anti-VEGF antibody significantly reduced the production of prostacyclin to a level 
comparable to that produced by normal pregnant plasma. The production of prostacyclin 
stimulated by normal pregnant plasma was unaffected by the antibody. These results 
demonstrate that VEGF may be pivitol to the pathogenesis of pre-eclampsia. 
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Appendix I: 
Dynabeads were coated with antibody according to manufacturers Instructions. Briefly a1 ml 
suspension ofthe tosylated Dynabeads (DM280) was aliquoted into a 1.5 mi eppendorff tube 
(Anachem-Scotiab; Luton, UK) ) this was placed in a Dynall MPC (Dynaiý Magnetic Particle 
Concentrator) for 2 minutes. Following removal of the supernatant the Dynabeads were then re- 
suspended in 740µl of phosphate buffered saline (PBS). 360µl of the antibody was then 
dissolved in a borate buffer (pH 9.5), mixed with the Dynabead® suspension (to give 30µg of 
antibody per 108 Dynabeads) in 1m PBS. This mixture was then incubated for 24 hours at 37°C 
with continuous slow tilt rotation. After incubation, the tube was placed in the Dynal-1 MPC for 2-3 
minutes and the supernatant removed. The coated Dynabeads were washed four times: twice in 
PBS/BSA (pH 7.4 for 5 minutes at 4°C), once in Tris/BSA (pH 8.0 for 4 hours at 37°C), and once 
in PBS/BSA (pH 7.4 for 5 minutes at 4°C). 
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Appendix 11 
Physiological Salt Solution: 
To make up I litre of PSS or potassium-replaced PSS: 
Compound 
PSS KPSS 
Weiht mm Weiht mm 
NaCl 6.954 119 0 0 
KCL 0.35 5.9 9.223 123 
CaCI2.2H20 0.368 2.5 0.368 2.5 
MgS04.71-120 0,289 0.289 
NaHCO 3 2.1 2.1 
KH2 P04 0.161 0.161 
EDTA 0.01 0.1 0.01 0.1 
Glucose 1.091 6.0 1.091 6.0 
The above compounds with the exception ofthe calcium chloride 
(CaCI 2), are dissolved in distilled water to make up I litre. The solution is then carbonated with 
5% C02 and 95% 02 for approximately 15 minutes. The CaCI 2 is then added to the solution. 
The solution requires re-carbonation prior to usage following any storage. The pHs of the 
solutions are 7.4. 
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Appendix III 
Transmural pressure (Pi) Wall tension 
(internal circumference/2t) 
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Appendix IV: 
Protein Extraction Buffer. 
NaCl 0.1 M 
Tris HCL 0.01M (pH 7.6) 
EDTA 0.001M (pH 8.0) 
Aprotinin lµglml 
PMSFI00µglml 
100µI Triton X100 
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Appendix V 
Griess solution #1: 
Napthylenediamine dihydrehloride 0.01g/ml 
Griess solution#2: 
Sulphanilamide 10g were dissolved in11.8 mis of 85% H3P04 and this was then made up to 
100mIs. 
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Appendix VI 
DC Protein Assay : 
Reagent A- alkaline copper tartrate solution 
Reagent B- dilute Folin reagent 
Reagent A'- Reagent A with Reagent S (20µl reagent S to Iml reagentA) 
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Appendix Vi 
Buffer Solution for Indomethacin: 
KH2PO4 o. 02M 
NaH2P04.2H20 0.12M 
pH balanced to 7.8 
